https://www.sagelyhealth.com/cancer-trialshttps://www.sagelyhealth.com/cancer-trials/nct02364557-nrg-br002-metastasis-directed-ablation-sbrt-surgery-fails-to2026-10-22https://www.sagelyhealth.com/cancer-trials/nct05963984-samuraciclib-fulvestrant-shows-higher-clinical-benefit-and-numerically-longer2026-10-22https://www.sagelyhealth.com/cancer-trials/nct03732820-olaparib-parp-inhibitor-abiraterone-cyp17-ar-pathway-inhibitor-extends2026-10-22https://www.sagelyhealth.com/cancer-trials/nct03783442-tislelizumab-antipd-1-chemo-extends-os-to-17-2mo2026-10-22https://www.sagelyhealth.com/cancer-trials/nct03599713-retifanlimab-pd-1-maic-suggests-lower-progression-risk-vs2026-10-22https://www.sagelyhealth.com/cancer-trials/nct04184050-mk-4002-bcmacd3-trispecific-t-cell-engager-drives-632026-10-22https://www.sagelyhealth.com/cancer-trials/nct04245839-liso-cel-cd19-car-t-delivers-100-cr-orr2026-10-22https://www.sagelyhealth.com/cancer-trials/nct04722848-ponatinib-bcr-abl-tki-blinatumomab-cd19xcd3-bite-improves-242026-10-22https://www.sagelyhealth.com/cancer-trials/nct04905316-canakinumab-il-1-blockade-ccrt-and-durvalumab-consolidation-hits2026-10-22https://www.sagelyhealth.com/cancer-trials/pembrolizumab-monotherapy-is-associated-with-longer-time-to-next2026-10-22https://www.sagelyhealth.com/cancer-trials/nct05800366-glofitamab-cd3cd20-pola-r-chp-cd79b-adc-anti-cd202026-10-22https://www.sagelyhealth.com/cancer-trials/nct05805501-tobemstomig-pd-1lag-3-tiragolumab-anti-tigit-axitinib-adds2026-10-22https://www.sagelyhealth.com/cancer-trials/nct07213804-sofetabart-mipitecan-fr-targeted-adc-posts-50-5-orr2026-10-22https://www.sagelyhealth.com/cancer-trials/nct03672539-cpx-351-liposomal-daunorubicin-cytarabine-cd33-targeted-gemtuzumab-ozogamicin2026-10-22https://www.sagelyhealth.com/cancer-trials/nct03899792-selpercatinib-selective-ret-inhibitor-posts-53-orr-with-22026-10-22https://www.sagelyhealth.com/cancer-trials/nct04514484-nivolumab-cabozantinib-shows-feasible-safety-and-prolonged-disease-stabilization2026-10-22https://www.sagelyhealth.com/cancer-trials/nct07847957-phase-1b-2-roginolisib-pi3k-delta-inhibitor-with-sequential2026-10-22https://www.sagelyhealth.com/cancer-trials/nct07869381-randomized-trial-compares-comprehensive-margin-assessment-with-standard-pathology2026-10-22https://www.sagelyhealth.com/cancer-trials/nct05306340-giredestrant-oral-serd-everolimus-improves-pfs-after-cdk4-62026-10-15https://www.sagelyhealth.com/cancer-trials/nct02264678-ceralasertib-atr-inhibitor-olaparib-parp-inhibitor-hits-37-82026-10-15https://www.sagelyhealth.com/cancer-trials/nct04179162-gembcg-intravesical-gemcitabine-bcg-immunostimulation-delivers-96-6mo-cr2026-10-15https://www.sagelyhealth.com/cancer-trials/nct02773849-tar-200-intravesical-gemcitabine-device-vs-nadofaragene-firadenovec-no2026-10-15https://www.sagelyhealth.com/cancer-trials/nct03462719-ibrutinib-btk-inhibitor-venetoclax-bcl-2-inhibitor-improves-long2026-10-15https://www.sagelyhealth.com/cancer-trials/nct00107289-single-131i-mibg-net-targeted-radiopharmaceutical-single-autologous-stem2026-10-15https://www.sagelyhealth.com/cancer-trials/nct03900598-safimaltib-jnj-67856633-malt1-inhibitor-posts-28-8-pooled2026-10-15https://www.sagelyhealth.com/cancer-trials/nct03618550-pembrolizumab-gvd-followed-by-autologous-transplantation-shows-91-five2026-10-15https://www.sagelyhealth.com/cancer-trials/nct03598608-favezelimab-antilag-3-pembrolizumab-pd-1-reports-83-orr2026-10-15https://www.sagelyhealth.com/cancer-trials/nct04495153-can-2409-valacyclovir-reports-14-3-month-median-os2026-10-15https://www.sagelyhealth.com/cancer-trials/nct04557150-forimtamig-gprc5dcd3-2-1-bispecific-posts-72-orr-at2026-10-15https://www.sagelyhealth.com/cancer-trials/nct05323656-setanaxib-pembrolizumab-misses-its-tumor-shrinkage-endpoint-but-shows2026-10-15https://www.sagelyhealth.com/cancer-trials/nct04008797-e7386-catenincbp-inhibitor-lenvatinib-delivers-36-7-orr-in2026-10-15https://www.sagelyhealth.com/cancer-trials/nct04543071-motixafortide-cxcr4-inhibitor-cemiplimab-pd-1-gem-nab-paclitaxel2026-10-15https://www.sagelyhealth.com/cancer-trials/nct06850623-act-ps101-focused-ultrasound-plus-mfolfirinox-shows-early-responses2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07562152-atebimetinib-deep-cyclic-mek-inhibitor-mgnp-links-weight-preservation2026-10-15https://www.sagelyhealth.com/cancer-trials/nct04365374-cesium-131-collagen-gammatile-brachytherapy-cuts-surgical-bed-recurrence2026-10-15https://www.sagelyhealth.com/cancer-trials/nct03946527-lanreotide-somatostatin-analog-shows-disease-stabilization-in-advanced-ppgl2026-10-15https://www.sagelyhealth.com/cancer-trials/nct04985604-tovorafenib-type-ii-raf-inhibitor-braf-craf-drives-432026-10-15https://www.sagelyhealth.com/cancer-trials/nct07852247-phase-1-cyberknife-sbrt-uses-synchrony-respiratory-motion-tracking2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07617337-phase-1-aqua07-allosteric-alk-inhibitor-macrocyclic-peptide-alone2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07813637-phase-1-janx013-psmacd28-costimulation-combines-with-janx007-psmacd32026-10-15https://www.sagelyhealth.com/cancer-trials/nct07832292-phase-2-jnj-101556143-uses-an-ar-brd4-induced2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07831772-remind-feasibility-study-tests-a-single-maintenance-imrt-fraction2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07664176-phase-1-nivolumab-plus-focused-ultrasound-and-microbubbles-tests2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07831369-phase-2-vista-combines-valproic-acid-irinotecan-and-simvastatin2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07452458-phase-3-nrg-cc017-tests-pulsed-radiation-plus-temozolomide2026-10-15https://www.sagelyhealth.com/cancer-trials/nct06357377-phase-1b-neo100-intranasal-perillyl-alcohol-evaluates-safety-and2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07851025-phase-3-trevi-oc-02-tests-fr-targeted-torvutatug2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07504588-phase-2-nrg-gy038-compares-sacituzumab-govitecan-plus-bevacizumab2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07776691-phase-3-rejoice-ovarian04-tests-cdh6-targeted-raludotatug-deruxtecan2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07844759-pilot-study-tests-single-fraction-stereotactic-radiation-plus-endocrine2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07401381-phase-1-letrozole-sie-study-compares-quarterly-injectable-and2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07619521-phase-1-2-selumetinib-plus-trastuzumab-deruxtecan-targets-kras2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07824960-phase-1b-2-avutometinib-plus-defactinib-adds-raf-mek2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07836049-phase-2-toripalimab-induction-and-post-chemoradiation-treatment-targets2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07673887-phase-3-asp2138-cldn18-2cd3-t-cell-engager-adds2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07516093-phase-3-daybreak-cll-306-compares-bexobrutideg-btk-degradation2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07819214-phase-2-epcoritamab-cd3cd20-consolidation-seeks-deeper-remissions-after2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07848295-phase-1-bms-986527-allogeneic-cd70-car-t-cell2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07625644-phase-3-brendell-lung01-tests-dll3-targeted-bl-m14d12026-10-15https://www.sagelyhealth.com/cancer-trials/nct07827612-phase-2-foray-tests-selective-fgfr3-inhibition-with-vepugratinib2026-10-15https://www.sagelyhealth.com/cancer-trials/nct06948084-phase-2-daratumumab-plus-teclistamab-is-compared-with-dpd2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07830225-phase-2-pilot-uses-ctdna-to-guide-checkpoint-inhibitor2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07750158-phase-3-stellar-316-tests-zanzalintinib-with-or-without2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07842965-phase-1-1b-champ-adds-ccr5-blockade-with-leronlimab2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07551596-phase-2-combat-tests-botensilimab-plus-balstilimab-for-ctdna2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07850973-phase-1-2-olaparib-intensifies-sequential-high-dose-chemotherapy2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07809906-phase-1-orm-1153-cd123-directed-degrader-antibody-conjugate2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07819136-phase-1-2-zinnia-tests-rec-7735-a-pik3ca2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07843550-phase-1-2-larotrectinib-plus-pembrolizumab-tests-trk-inhibition2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07832630-phase-2-saruparib-tests-parp1-inhibition-in-hrd-signature2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07811297-phase-1b-2a-catequentinib-tests-angiogenesis-blockade-alone-and2026-10-15https://www.sagelyhealth.com/cancer-trials/nct07836712-phase-2-add-it1-tests-propranolol-desloratadine-nutrient-repletion2026-10-15https://www.sagelyhealth.com/cancer-trials/nct03052608-ai-volumetric-brain-met-response-may-better-predict-pfs2026-10-08https://www.sagelyhealth.com/cancer-trials/nct04047862-ociperlimab-tigit-tislelizumab-pd-1-posts-55-orr-in2026-10-08https://www.sagelyhealth.com/cancer-trials/nct03726879-atezolizumab-pd-l1-trastuzumab-pertuzumab-chemo-misses-efs-dfs2026-10-08https://www.sagelyhealth.com/cancer-trials/nct05236036-tmz-induced-inflammatory-remodeling-exposes-a-rock-vulnerability-in2026-10-08https://www.sagelyhealth.com/cancer-trials/nct05002127-evorpacept-cd47-blocker-trp-lifts-orr-in-2l-3l2026-10-08https://www.sagelyhealth.com/cancer-trials/nct06566092-lifileucel-produces-confirmed-responses-in-2-of-3-treated2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07815665-phase-2-3-ivonescimab-pd-1vegf-bispecific-antibody-plus2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07822373-phase-2-enfortumab-vedotin-nectin-4-adc-mmae-tubulin2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07817173-thermaclear-heated-saline-intravesical-hyperthermia-gemcitabine-dna-synthesis-inhibi2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07828236-phase-1-lm-llo-tt-listeria-based-tetanus-toxoid2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07829185-phase-1-repurposed-pentamidine-mfolfirinox-in-pdac2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07804186-phase-3-darovasertib-pkc-inhibitor-plus-crizotinib-c-met2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07815574-phase-3-iscib1-gp100-trp-2-dna-vaccine-adds2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07812246-phase-2-zanubrutinib-btk-inhibitor-sonrotoclax-bcl-2-inhibitor2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07806773-phase-2a-tub-040-napi2b-targeted-topoisomerase-1-inhibitor2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07826949-phase-1-srn-101-intratumoral-aavifn-immuno-gene-therapy2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07824349-phase-1a-1b-jur-003-klk2cd3-bispecific-tcell-engager2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07816666-phase-3-torvutatug-samrotecan-fr-folr1-adc-with-exatecan2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07815704-phase-2-atorvastatin-hmgcoa-reductase-inhibitor-immunometabolism-addon-in2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07812636-early-phase-1-tirzepatide-dual-gip-glp-1-receptor2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07820358-phase-2-semaglutide-glp-1-receptor-agonist-lng-iud2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07811193-phase-2-vvd-133214-wrn-helicase-covalent-inhibitor-pembrolizumab2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07808151-phase-2-porustobart-ctla-4-antibody-pembrolizumab-pd-12026-10-08https://www.sagelyhealth.com/cancer-trials/nct07818018-phase-1b-2-intratumoral-2141-v11-cd40-agonist-added2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07781891-phase-2-lx-101-igf-1rtargeted-methotrexate-conjugate-in2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07814352-phase-1b-sx-682-cxcr1-2-chemokine-receptor-inhibitor2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07822919-phase-1-awt020-antipd-1il-2-fusion-protein-checkpoint2026-10-08https://www.sagelyhealth.com/cancer-trials/nct07839819-phase-1-2-pm54-oncogenic-transcription-inhibitor-irinotecan-doxorubicin2026-10-08https://www.sagelyhealth.com/cancer-trials/nct03036488-pembrolizumab-pd-1-neoadjuvant-chemo-cuts-recurrence-and-death2026-10-01https://www.sagelyhealth.com/cancer-trials/nct03301220-daratumumab-anti-cd38-cuts-progression-risk-in-japanese-high2026-10-01https://www.sagelyhealth.com/cancer-trials/nct03778229-savolitinib-met-tki-osimertinib-boosts-orr-to-49-when2026-10-01https://www.sagelyhealth.com/cancer-trials/nct04259944-pegasus-ctdna-mrd-assay-guides-adjuvant-capoxfolfiri-escalation-but2026-10-01https://www.sagelyhealth.com/cancer-trials/nct04260126-pds0101-hpv16-targeted-immunotherapy-pembrolizumab-drives-34-orr-and2026-10-01https://www.sagelyhealth.com/cancer-trials/nct03643276-blinatumomab-cd19xcd3-bite-replaces-2-chemo-blocks-and-improves2026-10-01https://www.sagelyhealth.com/cancer-trials/nct01333709-adjuvant-chemo-shows-no-clear-added-benefit-after-folfirinox2026-10-01https://www.sagelyhealth.com/cancer-trials/mosunetuzumab-cd20xcd3-bispecific-response-adapted-polatuzumab-vedotin-cd79b-adc2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07803653-phase-1-fh-steap1-il-18-car-t-tests2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07801664-phase-2-adt-gnrh-antagonist-agonist-ultra-hypofractionated-sbrt2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07796490-phase-1-2-onabotulinumtoxina-botox-neuromuscular-blocker-snare-mediated2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07796763-phase-2-trastuzumab-rezetecan-shr-a1811-her2-directed-topoisomerase2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07799220-phase-2-boson-tests-zanubrutinib-obinutuzumab-sonrotoclax-in-frontline2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07477418-phase-1b-2-prismtamp-tests-arterial-gemcitabine-chemotherapy-microperfusion2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07227831-phase-2-therabionic-p1-amplitudemodulated-rf-electromagnetic-field-tumorfrequency2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07339059-phase-2-sacituzumab-govitecan-trop2-directed-sn-38-adc2026-10-01https://www.sagelyhealth.com/cancer-trials/nct07783594-phase-2-epcoritamab-cd3cd20-bispecific-tcell-engager-vs-watchful2026-10-01https://www.sagelyhealth.com/cancer-trials/osimertinib-egfr-tki-sustains-8-year-os-benefit-after2026-09-24https://www.sagelyhealth.com/cancer-trials/a-tumor-informed-ctdna-mrd-assay-flags-post-surgery2026-09-24https://www.sagelyhealth.com/cancer-trials/nct03328104-everolimus-mtor-inhibitor-nectar-salvage-delivers-75-orr-in2026-09-24https://www.sagelyhealth.com/cancer-trials/pembrolizumab-pd-1-chemotherapy-sustains-5-year-os-benefit2026-09-24https://www.sagelyhealth.com/cancer-trials/nct04195750-improving-hrqol-correlates-with-longer-pfs-os-in-litespark2026-09-24https://www.sagelyhealth.com/cancer-trials/nct04987203-tivozanib-vegfr-tki-beats-tivozanib-nivolumab-in-post-ici-22026-09-24https://www.sagelyhealth.com/cancer-trials/nct05536141-casdatifan-hif-2-inhibitor-monotherapy-in-late-line-ccrcc2026-09-24https://www.sagelyhealth.com/cancer-trials/nct03740165-pembrolizumab-pd-1-chemo-maintenance-pembrolizumab-olaparib-parp-extends2026-09-24https://www.sagelyhealth.com/cancer-trials/nct05469893-teclistamab-bcmaxcd3-bispecific-drives-78-cr-and-92-22026-09-24https://www.sagelyhealth.com/cancer-trials/nct03766178-camrelizumab-pd-1-nimotuzumab-egfr-mab-delivers-32-62026-09-24https://www.sagelyhealth.com/cancer-trials/nct07805954-phase-3-zoldonrasib-rmc-9805-kras-g12d-ras-on2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07723651-phase-2-18f-fluorthanatrace-ftt-parp1-targeted-pet-tracer2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07768436-phase-2-ddcmf-chemo-alkylator-antifolate-thymidylate-synthase-inhibitor2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07703436-phase-2-safusidenib-erbumine-mutant-idh1-inhibitor-in-post2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07778602-early-phase-1-avutometinib-dual-raf-mek-inhibitor-defactinib2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07773987-phase-2-pembrolizumab-pd-1-inhibitor-plus-hypofractionated-rt2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07807163-phase-2-ficerafusp-alfa-bca101-egfrtgf-bifunctional-antibody-pembrolizumab2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07796126-phase-2-toripalimab-pd-1-cd279-antibody-priming-before2026-09-24https://www.sagelyhealth.com/cancer-trials/nct07767500-phase-2-elekta-unity-mr-linac-mr-guided-sbrt2026-09-24https://www.sagelyhealth.com/cancer-trials/nct05379985-daraxonrasib-rmc-6236-ras-on-tri-complex-inhibitor-delivers2026-09-17https://www.sagelyhealth.com/cancer-trials/nct03800134-durvalumab-pd-l1-neoadjuvant-chemo-lifts-pcr-across-lobectomy2026-09-17https://www.sagelyhealth.com/cancer-trials/nct04214262-atezolizumab-pd-l1-sbrt-fails-to-improve-osand-adds2026-09-17https://www.sagelyhealth.com/cancer-trials/nct02159495-cd123-car-t-delivers-27-cr-cri-in-post2026-09-17https://www.sagelyhealth.com/cancer-trials/nct03598608-favezelimab-lag-3-mab-pembrolizumab-pd-1-posts-292026-09-17https://www.sagelyhealth.com/cancer-trials/nct03008408-ribociclib-cdk4-6-everolimus-mtor-letrozole-aromatase-lifts-orr2026-09-17https://www.sagelyhealth.com/cancer-trials/nct04895735-pemetrexed-antifolate-chemo-pembrolizumab-pd-1-delivers-37-52026-09-17https://www.sagelyhealth.com/cancer-trials/nct06026410-fti-darlifarnib-cabozantinib-shows-3350-orr-in-pretreated-ccrcc2026-09-17https://www.sagelyhealth.com/cancer-trials/nct04634539-l-glutamine-gem-nab-p-reaches-22-month-mos2026-09-17https://www.sagelyhealth.com/cancer-trials/nct03956056-personalized-neoantigen-vaccines-elicit-t-cell-responses-in-resected2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07783581-phase-2-ospri-tests-pembrolizumab-pd1-inhibitor-with-proton2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07793578-phase-1b-2-capivasertib-akt-pkb-inhibitor-plus-immune2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07762586-phase-2-lumber-nac-compares-neoadjuvant-platinum-chemotherapy-dna2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07786428-phase-2-detente-1-tests-pembrolizumab-pd1-inhibitor-with2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07791498-phase-2-teclistamab-bcmacd3-tcellredirecting-bispecific-antibody-in-r2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07187869-phase-1-cabozantinib-multi-kinase-met-axl-vegfr2-inhibitor2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07793435-phase-1-2-adi-212-psma-targeted-v1-car2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07718737-phase-2-3-amt-116-cd44v9-targeted-topoisomerase-i2026-09-17https://www.sagelyhealth.com/cancer-trials/nct05976555-phase-1-bcmadntgfrii-armored-car-t-bcma-car-tgf2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07758673-phase-1-baffr-car-t-baff-rtargeted-car-t2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07793253-phase-2-daraxonrasib-pan-ras-on-tri-complex-inhibitor2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07718854-phase-2-sacituzumab-tirumotecan-mk-2870-trop2-adc-pembrolizumab2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07702032-phase-3-petosemtamab-egfrlgr5-bispecific-antibody-vs-cetuximab-in2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07058012-phase-2-cemiplimab-pd-1-antibody-trial-adds-fianlimab2026-09-17https://www.sagelyhealth.com/cancer-trials/nct07765446-phase-2-sir2501-sarm1-inhibitor-aims-to-prevent-paclitaxel2026-09-17https://www.sagelyhealth.com/cancer-trials/nct05168566-sutetinib-irreversible-egfr-tki-drives-70-8-orr-and2026-09-10https://www.sagelyhealth.com/cancer-trials/nct02201992-crizotinib-alk-tki-fails-to-improve-dfs-as-adjuvant2026-09-10https://www.sagelyhealth.com/cancer-trials/nct04866017-ociperlimab-tigit-tislelizumab-pd-1-with-ccrt-shows-numerically2026-09-10https://www.sagelyhealth.com/cancer-trials/nct02032823-olaparib-parp-inhibitor-sustains-os-idfs-gains-at-62026-09-10https://www.sagelyhealth.com/cancer-trials/nct01302834-imaging-detected-extranodal-extension-iene-upstages-hpv-opc-but2026-09-10https://www.sagelyhealth.com/cancer-trials/nct02533271-scrt-55gy-capox-total-neoadjuvant-therapy-improves-5-year2026-09-10https://www.sagelyhealth.com/cancer-trials/nct03069469-vimseltinib-csf1r-switch-control-inhibitor-delivers-64-orr-in2026-09-10https://www.sagelyhealth.com/cancer-trials/nct03646123-bv-cd30-directed-adc-nivolumab-pd-1-limited-chemo2026-09-10https://www.sagelyhealth.com/cancer-trials/nct04663347-epcoritamab-cd3cd20-r2-drives-95-orr-in-frontline-follicular2026-09-10https://www.sagelyhealth.com/cancer-trials/nct05301842-stride-durvalumab-tremelimumab-vegfr-fgfr-tki-lenvatinib-tace-extends2026-09-10https://www.sagelyhealth.com/cancer-trials/nct06169124-darolutamide-androgen-receptor-inhibitor-leuprolide-exemestane-shows-low-orr2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07777822-phase-3-zoldonrasib-rmc-9805-kras-g12d-selective-ras2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07541170-phase-3-divarasib-kras-g12c-inhibitor-vs-pd-12026-09-10https://www.sagelyhealth.com/cancer-trials/nct07784959-phase-1b-nxp900-src-family-kinase-inhibitor-plus-lorlatinib2026-09-10https://www.sagelyhealth.com/cancer-trials/nct06768489-phase-1b-jnj-79635322-bcmagprc5dcd3-tcellredirecting-trispecific-antibody-combos2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07589634-phase-2-ramantamig-bcmagprc5dcd3-trispecific-mab-with-il-6r2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07637578-phase-2-elranatamab-bcmacd3-bispecific-with-il-6r-blockade2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07728188-phase-3-etentamig-abbv-383-bcmacd3-bispecific-tcell-engager2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07759102-phase-1-orca-q-naive-t-celldepleted-allogeneic-hsct2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07727668-feasibility-early-phase-1-iberdomide-cc-220-cereblon-e32026-09-10https://www.sagelyhealth.com/cancer-trials/nct07609940-phase-4-linvoseltamab-bcmacd3-bispecific-with-prophylactic-tocilizumab-il2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07769502-phase-2-telisotuzumab-adizutecan-abbv-400-c-met-hgfr2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07769372-mr-guided-focal-sbrt-uses-mri-target-localization-to2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07768189-phase-3-crb-701-nectin-4targeted-adc-mmae-tubulin2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07753824-phase-2-ivonescimab-pd-1vegf-bispecific-antibody-plus-intraperitoneal2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07772882-phase-1-arginine-supplementation-metabolic-immunomodulator-with-pembrolizumab-pd2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07776613-phase-2-romosozumab-sclerostin-directed-monoclonal-antibody-as-bone2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07778316-phase-3-tarlatamab-amgen-dll3cd3-bispecific-tcell-engager-compares2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07581002-phase-2-3-pivekimab-sunirine-cd123-targeted-adc-ign2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07731789-phase-2-tafasitamab-cd19-cytolytic-mab-rituximab-cd20-mab2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07734038-phase-2-venetoclax-bcl-2-inhibitor-zanubrutinib-btk-inhibitor2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07780838-phase-2a-pemigatinib-fgfr1-2-3-inhibitor-alternated-with2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07780565-phase-1b-monzosertib-cdc7-kinase-inhibitor-tests-azoledrug-interaction2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07737769-phase-1-arsenic-trioxide-p53-reactivating-agent-with-fludarabine2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07791446-trinav-pressure-enabled-infusion-catheter-pressure-modulated-delivery-for2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07661459-phase-2-oat-ici-tests-cox-inhibition-h1-antihistamine2026-09-10https://www.sagelyhealth.com/cancer-trials/nct07703878-phase-1-gs-1206-small-molecule-inhibitor-tests-undisclosed2026-09-10https://www.sagelyhealth.com/cancer-trials/nct02446405-enzalutamide-ar-inhibitor-testosterone-suppression-extends-8-year-os2026-09-03https://www.sagelyhealth.com/cancer-trials/nct04663347-epcoritamab-cd3cd20-bispecific-r-chop-drives-85-cr-and2026-09-03https://www.sagelyhealth.com/cancer-trials/nct03467373-glofitamab-cd20cd3-bispecific-g-r-chop-drives-83-92026-09-03https://www.sagelyhealth.com/cancer-trials/nct04266249-thp-taxane-trastuzumab-pertuzumab-posts-43-8-pcr-in2026-09-03https://www.sagelyhealth.com/cancer-trials/pt34-pn-pt2-lvi-model-flags-4-higher-post2026-09-03https://www.sagelyhealth.com/cancer-trials/nct04183166-tg4050-individualized-mva-neoantigen-vaccine-shows-0-16-per2026-09-03https://www.sagelyhealth.com/cancer-trials/nct01949129-mrd-0-01-before-or-day-100-post-hsct2026-09-03https://www.sagelyhealth.com/cancer-trials/nct04185883-sotorasib-kras-g12c-inhibitor-panitumumab-egfr-mab-folfiri-drives2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07444541-phase-1b-2-ano31905-cldn18-2cd3-bispecific-chemo-in2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07765836-phase-2-vilastobart-tumor-activated-fc-enhanced-anti-ctla2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07748611-phase-2-smart-panc-tests-smad4-guided-neoadjuvant-chemo2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07745361-phase-2-mrt-2359-gspt1-molecular-glue-degrader-apalutamide2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07756593-phase-1b-sipuleucelt-n803-trial-tests-pap-vaccine-plus2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07751159-phase-2-balance-rt-compares-hdr-brachytherapy-boost-vs2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07743190-phase-2-pembrolizumab-pd1-inhibitor-with-anthracycline-sparing-neoadjuvant2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07723209-phase-2-partial-breast-irradiation-ebrt-trial-tests-localized2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07136428-phase-1b-2-asciminib-allosteric-bcr-abl-inhibitor-trastuzumab2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07723469-phase-3-srg-514-ketorolac-cox-1-2-inhibitor2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07762703-phase-1b-2-breakvax-personalized-neoantigen-vaccine-pd-12026-09-03https://www.sagelyhealth.com/cancer-trials/nct07365241-phase-3-abbv-706-sez6-targeted-topo-1-adc2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07736937-phase-1b-2-tub-040-napi2b-targeted-topoisomerase-i2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07720180-phase-2-ovafit-til-cd137-4-1bb-selected-autologous2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07755436-phase-1-arr-002-dual-target-muc16-napi2b-adc2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07489495-phase-3-belzutifan-hif-2-inhibitor-zanzalintinib-multi-kinase2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07716735-phase-1-2-mercaptopurine-6mp-purine-antagonist-dna-synthesis2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07748988-phase-1-casdatifan-selective-hif-2-transcription-factor-inhibitor2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07718672-phase-2-sbrt-hot-spot-dose-painting-radiotherapy-to2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07762716-phase-1b-2-breakvax-personalized-vaccine-pd-1-ctla2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07766187-phase-2-durvalumab-pd-l1-inhibitor-plus-histotripsy-non2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07740941-phase-2-nasa-tests-pembrolizumab-pd1-blockade-vs-ipilimumab2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07720115-phase-2-s-531011-ccr8-directed-monoclonal-antibody-plus2026-09-03https://www.sagelyhealth.com/cancer-trials/nct07728942-phase-1-slr-108-ptk7-targeted-antibodyradionuclide-conjugate-for2026-09-03https://www.sagelyhealth.com/cancer-trials/nivolumab-ipilimumab-based-regimens-lift-5-year-survival-in2026-08-27https://www.sagelyhealth.com/cancer-trials/nct04025879-nivolumab-pd-1-blockade-chemo-ctdna-clearance-flags-higher2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03143153-nivolumab-pd-1-chemo-or-nivolumab-ipilimumab-ctla-42026-08-27https://www.sagelyhealth.com/cancer-trials/mfolfox6-bevacizumab-atezolizumab-pd-l1-extends-pfs-vs-atezolizumab2026-08-27https://www.sagelyhealth.com/cancer-trials/nct02967692-spartalizumab-pd-1-dabrafenib-trametinib-extends-os-vs-braf2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03732820-olaparib-parp-inhibitor-abiraterone-shows-brca2-driven-benefit-in2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03367702-nrg-gu005-5-fraction-sbrt-improves-bowel-qol-but2026-08-27https://www.sagelyhealth.com/cancer-trials/nct04736199-darolutamide-ar-antagonist-adt-cuts-rpfs-risk-across-high2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03574324-tpf-induction-docetaxel-cisplatin-5-fu-fails-to-beat-22026-08-27https://www.sagelyhealth.com/cancer-trials/nct01969838-ruxolitinib-jak1-2-inhibitor-loses-svr35-tss50-ground-when2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03937219-cabozantinib-vegfr-met-axl-tki-nivolumab-ipilimumab-extends-pfsbut2026-08-27https://www.sagelyhealth.com/cancer-trials/nct04586231-belzutifan-hif-2-inhibitor-lenvatinib-vegfr-tki-extends-pfs2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03907488-nivolumab-pd-1-avd-delivers-2-year-pfs-782026-08-27https://www.sagelyhealth.com/cancer-trials/nct06169124-darolutamide-ar-antagonist-leuprolide-exemestane-misses-orr-bar-but2026-08-27https://www.sagelyhealth.com/cancer-trials/ono-4578-ep4-pge2-axis-antagonist-nivolumab-oxaliplatin-chemo2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03972488-177lu-dotatate-sstr-targeted-prrt-extends-pfs-14-months2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03390504-erdafitinib-fgfr14-inhibitor-extends-os-vs-chemo-in-fgfr3altered2026-08-27https://www.sagelyhealth.com/cancer-trials/nct04971226-asciminib-stamp-inhibitor-bcr-abl1-myristoyl-pocket-beats-flumatinib2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07700979-phase-3-cadonilimab-pd-1ctla-4-bispecific-antibody-capox2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07707674-phase-1-xnw28012-tissue-factortargeted-topo1-inhibitor-adc-in2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07405151-phase-1-2-ifinatamab-deruxtecan-b7-h3-topo-i2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07218666-phase-2-zanzalintinib-met-vegfr2-axl-mer-tki-in2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07714551-phase-2-zanzalintinib-met-vegfr-axl-mer-inhibitor-in2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07743138-phase-2-ivonescimab-pd-1vegf-bispecific-antibody-in-previously2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07732413-phase-1b-nlg802-indoximod-prodrug-ido-tdo-pathway-immunometabolic2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07723534-phase-2-zolbetuximab-cldn18-2-directed-monoclonal-antibody-capox2026-08-27https://www.sagelyhealth.com/cancer-trials/nct07749586-phase-1-2-arv-6723-oral-protac-hpk1-degrader2026-08-27https://www.sagelyhealth.com/cancer-trials/nct03761108-linvoseltamab-bcmacd3-bispecific-shows-sustained-hrqol-gains-pain-fatigue2026-08-20https://www.sagelyhealth.com/cancer-trials/nct04094688-high-dose-vitamin-d3-cholecalciferol-add-on-fails-to2026-08-20https://www.sagelyhealth.com/cancer-trials/nct04513925-tiragolumab-antitigit-atezolizumab-fails-to-beat-durvalumab-for-pfs2026-08-20https://www.sagelyhealth.com/cancer-trials/nct04663347-epcoritamab-cd3cd20-bispecific-br-delivers-96-cr-and-832026-08-20https://www.sagelyhealth.com/cancer-trials/nct07719361-phase-1-fx-111-aron-degrader-targets-transcriptionally-active2026-08-20https://www.sagelyhealth.com/cancer-trials/nct07727473-early-phase-1-semaglutide-glp-1-receptor-agonist-neoadjuvant2026-08-20https://www.sagelyhealth.com/cancer-trials/nct07735624-phase-2-botensilimab-ctla-4-antibody-balstilimab-pd-12026-08-20https://www.sagelyhealth.com/cancer-trials/nct07729046-phase-2-neratinib-pan-her-egfr-her2-her4-tki2026-08-20https://www.sagelyhealth.com/cancer-trials/nct07737795-phase-2-ok-1-sheta2-grp78-hsc70-mortalin-inhibitor2026-08-20https://www.sagelyhealth.com/cancer-trials/nct07634471-phase-2-3-mk-1045-cd19cd3-bispecific-antibody-plus2026-08-20https://www.sagelyhealth.com/cancer-trials/nct07708961-phase-2-wsd0922-fu-egfr-egfrviii-inhibitor-plus-adjuvant2026-08-20https://www.sagelyhealth.com/cancer-trials/nct07732634-phase-2-rimo-301-hafnium-based-mof-radiosensitizer-pembrolizumab2026-08-20https://www.sagelyhealth.com/cancer-trials/nct07332507-phase-1b-teclistamab-bcmacd3-bispecific-tcell-engager-in-relapsed2026-08-20https://www.sagelyhealth.com/cancer-trials/nct06741644-phase-1-2-cs2009-pd-1-vegfa-ctla-42026-08-20https://www.sagelyhealth.com/cancer-trials/nct01265849-multikine-leukocyte-interleukin-injection-ciz-neoadjuvant-immune-conditioning-cuts2026-08-13https://www.sagelyhealth.com/cancer-trials/lipi-strongly-stratifies-survival-in-es-sclc-but-does2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03523312-maximal-ablative-rt-67-5gy-15fx-or-75gy-25fx2026-08-13https://www.sagelyhealth.com/cancer-trials/nct02162732-precision-guided-shh-blockade-vismodegib-hdac-inhibition-vorinostat-accompanies2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03145181-teclistamab-bcmacd3-bispecific-drives-76-9-orr-and-252026-08-13https://www.sagelyhealth.com/cancer-trials/nct03761108-linvoseltamab-bcmacd3-bispecific-maintains-6374-orr-in-frail-rrmm2026-08-13https://www.sagelyhealth.com/cancer-trials/nct01863550-indefinite-lenalidomide-imid-maintenance-fails-to-improve-os-vs2026-08-13https://www.sagelyhealth.com/cancer-trials/nct02081378-asciminib-bcr-abl1-stamp-inhibitor-delivers-durable-molecular-responses2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03013998-venetoclax-bcl-2-inhibitor-azacitidine-28-day-induction-trends2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04195945-cpx-351-liposomal-daunorubicin-cytarabine-vs-clag-m-high2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03112174-ibrutinib-btk-inhibitor-venetoclax-bcl-2-inhibitor-delivers-952026-08-13https://www.sagelyhealth.com/cancer-trials/nct04245839-liso-cel-cd19-car-t-sustains-68-3-year2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03625037-epcoritamab-cd3cd20-bispecific-exposureresponse-supports-48mg-qwq2wq4w-with-lower2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04395677-taletrectinib-next-gen-ros1-tki-linked-to-better-pfs2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04746924-ociperlimab-antitigit-tislelizumab-antipd1-fails-to-beat-pembrolizumab-os2026-08-13https://www.sagelyhealth.com/cancer-trials/nct05583188-pef-irreversible-electroporation-ablation-perioperative-chemoio-delivers-75-pcr2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03164616-trident-ml-signature-flags-kras-stk11-mutant-egfr-fgfr32026-08-13https://www.sagelyhealth.com/cancer-trials/nct03709719-blinatumomab-cd19cd3-bite-consolidation-cuts-relapse-in-high-risk2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04964934-camizestrant-oral-serd-cdk4-6i-doubles-pfs-when-ctdna2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03493854-ph-fdc-sc-pertuzumab-trastuzumab-dual-her2-blockade-matches2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03036488-pembrolizumab-pd-1-keynote-522-neoadjuvant-regimen-gbrca-trends2026-08-13https://www.sagelyhealth.com/cancer-trials/pld-pegylated-liposomal-doxorubicin-immunogenic-anthracycline-pembrolizumab-pd-12026-08-13https://www.sagelyhealth.com/cancer-trials/nct03907488-nivolumab-pd-1-avd-lifts-3-year-pfs-in2026-08-13https://www.sagelyhealth.com/cancer-trials/nct06444880-panitumumab-based-egfr-blockade-drives-53-9-orr-in2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04071223-cabozantinib-vegfr-met-axl-tki-radium-223-bone-seeking2026-08-13https://www.sagelyhealth.com/cancer-trials/nct05345444-rtire-ire-focal-ablation-reduced-dose-rt-yields-1002026-08-13https://www.sagelyhealth.com/cancer-trials/nct03395197-talazoparib-parp-inhibitor-enzalutamide-ar-antagonist-shows-early-rpfs2026-08-13https://www.sagelyhealth.com/cancer-trials/pola-anti-cd79b-adc-r-chp-delivers-93-orr2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04077723-englumafusp-alfa-cd194-1bbl-costimulator-glofitamab-cd20cd3-drives-562026-08-13https://www.sagelyhealth.com/cancer-trials/nct04452591-cretostimogene-grenadenorepvec-rbe2fselective-oncolytic-virus-drives-75-cr-with2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04700124-enfortumab-vedotin-nectin-4-adc-pembrolizumab-pd-1-lifts2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04940052-dabrafenib-trametinib-braf-mek-cuts-progression-risk-in-braf2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03181100-atezolizumab-pd-l1-mapk-targeted-therapy-links-atc-long2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03639935-rucaparib-parp-inhibitor-nivolumab-pd-1-maintenance-misses-primary2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03724851-vactosertib-tgfbr1-alk5-inhibitor-pembrolizumab-drives-12-6-orr2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04111172-ad5-f35-gucy2c-padre-adenoviral-vaccine-swapping-ad35-fiber2026-08-13https://www.sagelyhealth.com/cancer-trials/nct03177382-doublet-long-course-tnt-capecitabine-oxaliplatin-improves-dfs-and2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04904588-standard-dose-ptcy-enables-mismatched-donor-hct-but-carries2026-08-13https://www.sagelyhealth.com/cancer-trials/nct04083976-erdafitinib-pan-fgfr-tki-drives-56-orr-in-fgfr2026-08-13https://www.sagelyhealth.com/cancer-trials/nct06741644-cs2009-pd-1-vegf-ctla-4-trispecific-posts-182026-08-13https://www.sagelyhealth.com/cancer-trials/nct07564141-phase-3-rinatabart-sesutecan-rina-s-fr-adc-delivering2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07690189-phase-1-ntb-928-frcd3-bispecific-t-cell-engager2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07672782-phase-2-tisotumab-vedotin-tissue-factortargeted-mmae-adc-in2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07725380-phase-1-2-domatinostat-class-i-hdac-inhibitor-sirolimus2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07659678-phase-2-64cu-dota-ecl1i-ccr2-targeted-pet-radiotracer2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07667400-phase-1-2-sx-682-cxcr1-2-inhibitor-plus2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07339176-phase-1-2-n17350-intratumoral-elane-pathway-therapeutic-elastase2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07686068-phase-1-2a-vbc106-fr-msln-targeted-topo1-inhibitor2026-08-13https://www.sagelyhealth.com/cancer-trials/nct07439653-phase-1-2-torl-5-700-adc-target-moa2026-08-13https://www.sagelyhealth.com/cancer-trials/nct05707273-memory-enriched-cd19-car-t-delivers-84-18-mo2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03817320-ixazomib-mln9708-proteasome-inhibitor-salvage-chemo-delivers-67-cr2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05388123-low-dose-vemurafenib-braf-v600e-inhibitor-rituximab-drives-732026-08-06https://www.sagelyhealth.com/cancer-trials/nct04965493-pirtobrutinib-non-covalent-btk-inhibitor-venetoclax-rituximab-lifts-pfs2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04843904-save-obinutuzumab-venetoclax-bcl-2-inhibitor-compresses-the-52026-08-06https://www.sagelyhealth.com/cancer-trials/nct03824483-boven-zanubrutinib-btk-inhibitor-venetoclax-bcl2-inhibitor-obinutuzumab-anti2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03194932-venetoclax-bcl-2-inhibitor-high-dose-cytarabine-drives-572026-08-06https://www.sagelyhealth.com/cancer-trials/nct04971226-asciminib-deepens-frontline-molecular-responses-in-east-asian-cml2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03018288-pembrolizumab-hsppc-96-misses-1-year-os-endpoint-in2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03652545-wt1-prame-survivin-trivalent-taat-cells-show-tolerable-safety2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02454634-idh1-vac-idh1r132h-peptide-vaccine-links-immune-response-to2026-08-06https://www.sagelyhealth.com/cancer-trials/nct01341652-ptvg-hp-pap-dna-vaccine-signals-os-benefit-in2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02446405-enzalutamide-ar-inhibitor-benefit-in-mhspc-concentrates-in-apic2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02799602-darolutamide-ar-antagonist-triplet-delays-mcrpc-hr-0-362026-08-06https://www.sagelyhealth.com/cancer-trials/nct04141709-ablative-mdt-psma-petguided-sbrt-prolongs-time-to-psa2026-08-06https://www.sagelyhealth.com/cancer-trials/pembrolizumab-pd-1-blockade-ai-derived-itil-tumor-content2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03570437-cediranib-vegfr-tki-weekly-paclitaxel-lifts-early-disease-control2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03981796-niraparib-parp-inhibitor-dostarlimab-pd-1-maintenance-cuts-pfs2026-08-06https://www.sagelyhealth.com/cancer-trials/neoadjuvant-pd-1-checkpoint-blockade-is-associated-with-longer2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04454489-pembrolizumab-pd-1-quadshot-rt-14-8gy-4fx-delivers2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04414540-metformin-ampk-modulation-pembrolizumab-pd-1-posts-50-orr2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04585750-rezatapopt-p53-y220c-reactivator-drives-46-orr-in-heavily2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03531645-fulvestrant-abemaciclib-enables-cytoreduction-in-unresectable-lgsoc2026-08-06https://www.sagelyhealth.com/cancer-trials/kras-mutant-mesonephric-like-ovarian-adenocarcinoma-shows-17-52026-08-06https://www.sagelyhealth.com/cancer-trials/nct03434379-atezolizumab-pd-l1-bevacizumab-vegf-in-hcc-on-target2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05239728-pembrolizumab-belzutifan-hif-2-improves-adjuvant-dfs-in-high2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03203473-omnivore-supports-nivolumab-stop-early-responders-not-salvage-ipilimumab2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05536141-casdatifan-hif-2-inhibitor-drives-3135-orr-with-122026-08-06https://www.sagelyhealth.com/cancer-trials/nct03777657-tislelizumab-pd-1-capox-vs-capox-folfox-chemo-backbone2026-08-06https://www.sagelyhealth.com/cancer-trials/nct06324357-zongertinib-t-dxd-shows-early-responses-in-trastuzumab-pretreated2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05184712-ivonescimab-pd-1vegf-bispecific-pemetrexed-carboplatin-extends-os-after2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02075840-alectinib-alk-tki-shows-bigger-pfs-edge-in-low2026-08-06https://www.sagelyhealth.com/cancer-trials/nct06241807-camrelizumab-pd-1-chemo-delivers-33-pcr-in-resectable2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03915951-encorafenib-binimetinib-braf-mek-inhibition-validates-foundationone-liquid-tissue2026-08-06https://www.sagelyhealth.com/cancer-trials/baseline-ppis-correlate-with-sharply-worse-durvalumab-outcomes-in2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04472598-navitoclax-bcl-2-bcl-xl-inhibitor-ruxolitinib-doubles-week2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02113982-tagraxofusp-cd123-directed-cytotoxin-in-bpdcn-delivers-71-902026-08-06https://www.sagelyhealth.com/cancer-trials/nct05218499-brigimadlin-mdm2p53-antagonist-misses-pfs-endpoint-vs-doxorubicin-in2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03875235-durvalumab-pd-l1-gemcis-extends-4-year-survival-in2026-08-06https://www.sagelyhealth.com/cancer-trials/nct01775072-kras-mutant-biliary-tract-cancer-predicts-shorter-pfs-on2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05740566-tarlatamab-dll3cd3-bite-maic-suggests-os-edge-vs-paclitaxel2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04223856-enfortumab-vedotin-nectin-4-adc-pembrolizumab-pd-1-sustains2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05519241-ppm-plz4-targeted-paclitaxel-micelles-shows-early-complete-remissions2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03049189-177lu-lu-edotreotide-sstr2-targeted-prrt-beats-everolimus-on2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03926338-toripalimab-pd-1-celecoxib-cox-2-lifts-pcr-to2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03840239-capeox-sandwich-tnt-fluoropyrimidine-oxaliplatin-rt-drives-46-92026-08-06https://www.sagelyhealth.com/cancer-trials/nct04191499-inavolisib-pi3k-inhibitor-p110-degrader-more-than-doubles-pfs2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03742102-durvalumab-pd-l1-trastuzumab-deruxtecan-her2-adc-delivers-622026-08-06https://www.sagelyhealth.com/cancer-trials/nct04539938-tucatinib-t-dxd-posts-51-orr-in-pretreated-her22026-08-06https://www.sagelyhealth.com/cancer-trials/nct06072612-bria-imt-sv-br-1-gm-whole-cell-vaccine2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02437318-alpelisib-pi3k-benefit-tracks-with-fgfr1-2-alterations-and2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03716180-abbreviated-thp-paclitaxel-trastuzumab-pertuzumab-drives-99-5-year2026-08-06https://www.sagelyhealth.com/cancer-trials/her2-ultralow-rescoring-finds-45-prevalence-inside-her2-02026-08-06https://www.sagelyhealth.com/cancer-trials/concurrent-boost-sib-during-whole-breast-rt-matches-sequential2026-08-06https://www.sagelyhealth.com/cancer-trials/mammaprint-h2-70-gene-signature-flags-anthracycline-benefit-in2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02810743-subito-olaparib-parp-inhibitor-matches-iact-alkylator-auto-sct2026-08-06https://www.sagelyhealth.com/cancer-trials/nct00053898-nrg-nsabp-b-35-tamoxifen-vs-anastrozole-suggests-close2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02166463-brentuximab-vedotin-cd30-adc-avepc-lifts-pfs-in-pediatric2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04663347-epcoritamab-cd3cd20-r2-delivers-higher-cr-os-vs-realworld2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03625037-epcoritamab-cd3cd20-bispecific-hits-early-mrd-negativity-in-r2026-08-06https://www.sagelyhealth.com/cancer-trials/nct02947347-ibrutinib-btk-inhibitor-rituximab-extends-pfs-but-adds-toxicity2026-08-06https://www.sagelyhealth.com/cancer-trials/nct00695786-r2-based-frontline-fl-flipi24-flags-high-risk-patients2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05660967-epcoritamab-cd3cd20-bispecific-delivers-57-6-cr-as-chemo2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03533283-glofitamab-cd20xcd3-polatuzumab-vedotin-cd79b-adc-blunts-high-risk2026-08-06https://www.sagelyhealth.com/cancer-trials/nct03761108-linvoseltamab-bcmacd3-tops-elranatamab-on-orr-cr-in-unanchored2026-08-06https://www.sagelyhealth.com/cancer-trials/nct05455320-talquetamab-gprc5dcd3-daratumumab-pomalidomide-sharply-improves-24-mo-pfs2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07715734-phase-2-cemiplimab-pd-1-checkpoint-inhibitor-with-standardized2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07720167-phase-2-cemiplimab-pd-1-inhibitor-plus-platinum-doublet2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07723248-phase-3-rinzimetostat-oric-944-eed-prc2-inhibitor-darolutamide2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07200830-phase-3-177lu-vipivotide-tetraxetan-psma-targeted-beta-emitting2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07721259-phase-2-stemvac-dna-vaccine-targets-cdh3-cd105-yb2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07698613-phase-2-asp-1929-egfr-targeted-photoimmunotherapy-cetuximabir700-conjugate2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07698899-phase-1-177lu-dtpa-omburtamab-compartmental-radioimmunotherapy-targets-b72026-08-06https://www.sagelyhealth.com/cancer-trials/nct07715903-phase-1-carfilzomib-selective-proteasome-inhibitor-via-hepatic-artery2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07700160-phase-1-2a-vbc108-cldn18-2cdh17-bispecific-topo1-inhibitor2026-08-06https://www.sagelyhealth.com/cancer-trials/nct07705035-phase-1a-1b-dbc-664-undisclosed-moa-target-first2026-08-06https://www.sagelyhealth.com/cancer-trials/nct04819100-selpercatinib-ret-inhibitor-slashes-recurrence-risk-in-resected-ret2026-07-16https://www.sagelyhealth.com/cancer-trials/nct05668988-sunvozertinib-egfr-exon20ins-tki-extends-pfs-vs-carbo-pem2026-07-16https://www.sagelyhealth.com/cancer-trials/nct02595944-nivolumab-pd-1-inhibitor-fails-to-improve-dfs-vs2026-07-16https://www.sagelyhealth.com/cancer-trials/nct05256290-silevertinib-bdtx-1535-a-covalent-4th-gen-egfr-tki2026-07-16https://www.sagelyhealth.com/cancer-trials/nct03656536-pemigatinib-fgfr13-inhibitor-improves-pfs-and-orr-vs-gem2026-07-16https://www.sagelyhealth.com/cancer-trials/nct06298968-gemcis-lenvatinib-adebrelimab-vegfr-fgfr-pd-l1-hits-462026-07-16https://www.sagelyhealth.com/cancer-trials/nct03141177-cabozantinib-vegfr-met-axl-tki-nivolumab-pd-1-sustains2026-07-16https://www.sagelyhealth.com/cancer-trials/hc-7366-gcn2-activator-isr-metabolic-stress-agonism-belzutifan2026-07-16https://www.sagelyhealth.com/cancer-trials/nct03686124-prame-directed-tcr-t-anzu-cel-ima203cd8-hits-502026-07-16https://www.sagelyhealth.com/cancer-trials/nct03652064-d-vrd-doubles-sustained-mrd-negativity-vs-vrd-in2026-07-16https://www.sagelyhealth.com/cancer-trials/nct02426086-imetelstat-telomerase-inhibitor-doubles-mos-vs-realworld-bat-after2026-07-16https://www.sagelyhealth.com/cancer-trials/nct03750539-hypofractionated-pelvic-rt-37-5gy-15fx-weekly-cisplatin-shows2026-07-16https://www.sagelyhealth.com/cancer-trials/nct06265727-crb-701-sys6002-nectin-4targeted-mmae-adc-shows-early2026-07-16https://www.sagelyhealth.com/cancer-trials/nct03609593-br-induction-bcl2-inhibitor-venetoclax-cd20-rituximab-consolidation-delivers2026-07-16https://www.sagelyhealth.com/cancer-trials/nct02631044-liso-cel-cd19-car-t-delivers-38-5-year2026-07-16https://www.sagelyhealth.com/cancer-trials/nct03712605-pembrolizumab-pd-1-cuts-mcc-specific-relapse-events-in2026-07-16https://www.sagelyhealth.com/cancer-trials/nct04164901-vorasidenib-dual-mutant-idh1-2-inhibitor-cuts-seizure-rates-22026-07-16https://www.sagelyhealth.com/cancer-trials/nct03897881-intismeran-autogene-pembrolizumab-sustains-5-year-rfs-dmfs-benefit-22026-07-16https://www.sagelyhealth.com/cancer-trials/nct05091567-lurbinectedin-dna-binding-transcription-inhibitor-atezolizumab-extends-qtwist-vs2026-07-16https://www.sagelyhealth.com/cancer-trials/nct05599984-abbv-706-sez6-targeted-top1i-adc-posts-52-orr2026-07-16https://www.sagelyhealth.com/cancer-trials/nct05301842-tremelimumab-ctla-4-durvalumab-pd-l1-lenvatinib-vegfr-tki2026-07-16https://www.sagelyhealth.com/cancer-trials/nct05489237-velzatinib-idrx-42-selective-kit-inhibitor-drives-61-orr2026-07-16https://www.sagelyhealth.com/cancer-trials/nct05804045-pimicotinib-csf1r-inhibitor-sustains-76-orr-and-improves-knee2026-07-16https://www.sagelyhealth.com/cancer-trials/nct05735184-ziftomenib-menin-inhibitor-venetoclax-azacitidine-drives-46-crc-and2026-07-16https://www.sagelyhealth.com/cancer-trials/nct03553004-niraparib-parp-inhibitor-delivers-4-4-mo-mpfs-in2026-07-16https://www.sagelyhealth.com/cancer-trials/nct04607421-ec-encorafenib-braf-inhibitor-cetuximab-egfr-mab-folfiri-cuts-22026-07-16https://www.sagelyhealth.com/cancer-trials/nct04089631-ctdna-mrd-guided-act-capecitabineoxaliplatin-cuts-3-year-recurrence-22026-07-16https://www.sagelyhealth.com/cancer-trials/nct04008030-nivolumab-ipilimumab-pd-1-ctla-4-improves-long-term-22026-07-16https://www.sagelyhealth.com/cancer-trials/nct04365374-cesium-131-tile-brachytherapy-tbrt-slashes-surgical-bed-recurrence2026-07-16https://www.sagelyhealth.com/cancer-trials/nct04971226-asciminib-abl-myristoyl-pocket-stamp-inhibitor-sustains-deeper-molecular2026-07-16https://www.sagelyhealth.com/cancer-trials/nct04561362-zelenectide-pevedotin-bt8009-nectin-4targeted-bdc-pembrolizumab-hits-50-32026-07-16https://www.sagelyhealth.com/cancer-trials/nct06656390-alk201-fgfr2b-adc-posts-24-orr-in-refractory-solid2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07383441-phase-3-mo-03-live-biotherapeutic-butyrateproducing-clostridium-butyricum2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07662928-phase-2-epcoritamab-cd3cd20-bispecific-tcell-engager-plus-daepochr2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07473128-phase-3-trilaciclib-cdk4-cdk6-inhibitor-tests-myeloprotection-in2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07660094-phase-3-can-2409-hsv-tk-adenoviral-gene-therapy2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07388524-phase-3-atezolizumab-pd-l1-inhibitor-hyaluronidase-for-sc2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07393282-phase-3-linvoseltamab-bcmacd3-bispecific-antibody-versus-daratumumab-anti2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07671339-phase-1-eli-002-7p-kras-targeted-amphiphile-peptide2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07661095-phase-1-crd3874-si-allosteric-sting-agonist-tmem173-in2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07667335-phase-1b-2-quemliclustat-cd73-adenosine-pathway-inhibitor-with2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07661420-phase-1-211atmabg-targeted-alpha-radiotherapy-net-norepinephrine-transporteravid2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07662031-phase-2-tovecimig-dll4vegf-bispecific-antibody-plus-folfiri-in2026-07-16https://www.sagelyhealth.com/cancer-trials/nct06622057-phase-3-d07001-oral-gemcitabine-deoxycytidine-antimetabolite-capecitabine-in2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07601243-phase-1-gs-2426-mat2a-smallmolecule-inhibitor-in-mtapdeleted2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07671768-phase-1-mr-guided-sbrt-adaptive-mr-guided-radiotherapy2026-07-16https://www.sagelyhealth.com/cancer-trials/nct07671534-phase-2-gemcitabine-mitomycin-c-cytotoxics-with-thalidomide-anti2026-07-16https://www.sagelyhealth.com/cancer-trials/nct02964078-pembrolizumab-pd-1-high-dose-il-2-t-cellactivating2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03635892-cabonivo-cabozantinib-vegfr-met-axl-tki-nivolumab-pd-12026-07-08https://www.sagelyhealth.com/cancer-trials/nct03829111-cbm588-clostridium-butyricum-live-biotherapeutic-icb-combos-drives-big2026-07-08https://www.sagelyhealth.com/cancer-trials/nct00715442-sunitinib-vegfr-tki-response-in-mccrcc-tracks-with-pro2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03141177-cabozantinib-vegfr-met-axl-tki-nivolumab-pd-1-doubles2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03138512-ai-quantified-high-branching-tumor-vasculature-h-e-stratifies2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04071223-radium-223-bone-seeking-alpha-emitter-cabozantinib-vegfr-met2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04586231-belzutifan-hif-2-inhibitor-lenvatinib-holds-hrqol-steady-vs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04987203-tivozanib-vegfr-tki-beats-tivozanib-nivolumab-in-post-ici2026-07-08https://www.sagelyhealth.com/cancer-trials/nct01343043-lete-cel-ny-eso-1-tcr-t-and-afami2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03896503-sacituzumab-govitecan-trop2sn-38-top1-adc-berzosertib-atr-inhibitor2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03574324-tpf-induction-docetaxel-cisplatin-5-fu-fails-to-beat2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03016819-catequentinib-al3818-multitarget-rtk-inhibitor-delivers-26-8-orr2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05377996-emiltatug-ledadotin-b7-h4-adc-reaches-40-orr-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03360890-pembrolizumab-pd-1-docetaxel-doxorubicin-delivers-modest-responses-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04969835-ava6000-fap-released-doxorubicin-posts-90-disease-control-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05669664-darolutamide-leuprolide-yields-40-pr-rate-in-ar-salivary2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06118086-rem-422-myb-mrna-degrader-hits-42-orr-at2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04895735-pemetrexed-pembrolizumab-antifolate-chemo-pd-1-posts-75-clinical2026-07-08https://www.sagelyhealth.com/cancer-trials/nct01665794-darakpd-anti-cd38-mab-proteasome-inhibitor-imid-delivers-382026-07-08https://www.sagelyhealth.com/cancer-trials/nct04318327-durcabtagene-autoleucel-phe885-a-rapid-manufactured-bcma-car-t2026-07-08https://www.sagelyhealth.com/cancer-trials/daratumumab-cd38-mab-boosts-depth-of-response-across-age2026-07-08https://www.sagelyhealth.com/cancer-trials/isa-sc-on-body-injector-vrd-cuts-infusion-reactions2026-07-08https://www.sagelyhealth.com/cancer-trials/nct02252172-daratumumab-cd38-mab-rd-extends-pfs-to-61-9mo2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04181827-ciltacabtagene-autoleucel-cilta-cel-bcma-car-t-delivers-durable2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04091126-belantamab-mafodotin-bcma-adc-vrd-in-dreamm-9-delivers2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04586426-talquetamab-gprc5dcd3-teclistamab-bcmacd3-lands-on-q2w-rp2r-with2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03471260-aza-ven-ivosidenib-idh1-inhibitor-drives-95-orr-and2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06656494-mesutoclax-icp-248-a-selective-bcl-2-inhibitor-drives2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03661307-quizartinib-flt3-inhibitor-decitabine-venetoclax-drives-89-cr-cri2026-07-08https://www.sagelyhealth.com/cancer-trials/revumenib-menin-inhibitor-kmt2a-npm1-program-maintenance-post-allosct2026-07-08https://www.sagelyhealth.com/cancer-trials/dose-dense-minihyper-cvd-inotuzumab-cd22-adc-blinatumomab-cd192026-07-08https://www.sagelyhealth.com/cancer-trials/nct03263572-blinatumomab-cd19-bite-ponatinib-bcr-abl1-tki-drives-832026-07-08https://www.sagelyhealth.com/cancer-trials/nct03876769-tisagenlecleucel-cd19-car-t-delivers-64-5-year-dfs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04260022-olverembatinib-bcr-abl1-tki-blinatumomab-cd19-bite-delivers-early2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04277637-sonrotoclax-bcl2-inhibitor-zanubrutinib-btk-inhibitor-drives-99-pb2026-07-08https://www.sagelyhealth.com/cancer-trials/liso-cel-cd19-car-t-delivers-84-orr-552026-07-08https://www.sagelyhealth.com/cancer-trials/pirtobrutinib-reaches-93-orr-and-93-24-month-pfs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03375320-cabozantinib-multi-kinase-vegfr-met-axl-inhibitor-cuts-progression2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03049189-lu-177-edotreotide-preserves-qol-better-than-everolimus-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05636618-212pb-vmt-net-shows-39-orr-with-low-early2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04039607-nivolumab-ipilimumab-pd-1-ctla-4-sustains-os-benefit2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05717400-early-sofosbuvir-based-daas-atezolizumab-bevacizumab-boosts-circulating-t2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05797805-tegavivint-tbl1nuclear-catenin-degradation-shows-22-orr-in-wnt2026-07-08https://www.sagelyhealth.com/cancer-trials/liso-cel-cd19-car-t-delivers-88-orr-802026-07-08https://www.sagelyhealth.com/cancer-trials/nct05123482-puxitatug-samrotecan-b7-h4-adc-posts-48-orr-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03526432-atezolizumab-pd-l1-bevacizumab-vegf-posts-33-9-orr2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03981796-dostarlimab-pd-1-carboplatin-paclitaxel-shows-57-9-42026-07-08https://www.sagelyhealth.com/cancer-trials/nct03914612-pembrolizumab-pd-1-carboplatin-paclitaxel-sustains-48-mo-os2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04774419-dostarlimab-pd-1-pelvic-imrt-in-mmr-d-endometrial2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05574101-cemiplimab-pd-1-response-adapted-definitive-rt-delivers-862026-07-08https://www.sagelyhealth.com/cancer-trials/nct03969004-cemiplimab-pd-1-cuts-recurrence-risk-in-high-risk2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06568172-neoadjuvant-antipd-1-immunotherapy-drives-54-pcr-and-improves2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03212404-cosibelimab-pd-l1-delivers-50-orr-in-unresectable-locally2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03971461-lu-177-dotatate-prrt-sstr2-targeted-hits-69-pfs2026-07-08https://www.sagelyhealth.com/cancer-trials/rms13-nct01871766-response-adapted-metastasis-rt-shows-soft-tissue2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03930953-golcadomide-cc-99282-celmod-rituximab-drives-97-orr-782026-07-08https://www.sagelyhealth.com/cancer-trials/nct04245839-liso-cel-cd19-car-t-drives-89-ctdna-mrd2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06563479-fmiso-pet-hypoxia-imaging-guides-30gy-chemoradiation-with-972026-07-08https://www.sagelyhealth.com/cancer-trials/nct05491512-ict-carboplatin-paclitaxel-cetuximab-fmiso-pet-hypoxia-clearance-enables2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05108870-hb200-hpv16-e6-e7-viral-immunotherapy-carbo-pac-drives2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03854799-avelumab-pd-l1-neoadjuvant-chemoradiotherapy-delivers-74-7-42026-07-08https://www.sagelyhealth.com/cancer-trials/nct06281405-toripalimab-pd-1-capox-itnt-with-scrt-lifts-complete2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04902443-pom-nivo-imid-pd-1-blockade-hits-100-response2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05041127-cetuximab-anti-egfr-mab-delivers-8-recist-prs-but2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04595747-rogaratinib-pan-fgfr14-inhibitor-posts-41-7-orr-and2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05208047-bezuclastinib-selective-type-1-kit-tki-sunitinib-type-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct05489237-velzatinib-idrx-42-broad-spectrum-kit-pdgfra-tki-drives2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05320198-disc-0974-anti-hemojuvelin-hepcidin-lowering-drives-5071-anemia2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05451810-epcore-nhl-6-sc-epcoritamab-cd3cd20-enables-outpatient-r2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06045247-epcoritamab-cd20cd3-bispecific-r-minicvp-posts-86-cr-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06091865-odronextamab-cd20xcd3-bispecific-chop-drives-85-cr-in-high2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05585320-atebimetinib-mek-deep-cyclic-inhibitor-mgnp-delivers-42-orr2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05257993-nesuparib-jpi-547-dual-tnks-parp-inhibitor-gemabraxane-hits2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05832892-surufatinib-vegfr-fgfr1-csf1r-tki-kn046-pd-l1-ctla2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05685602-emavusertib-ca-4948-irak4-nf-b-inhibitor-gem-nab2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06203821-np137-antinetrin-1-emt-inhibitor-mfolfirinox-delivers-10-92026-07-08https://www.sagelyhealth.com/cancer-trials/nct03323489-claude-opus-4-1-ca-eda-flags-prior-neurotoxic2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04431258-ibrilatazar-abtl0812-autophagy-inducer-fails-itt-pfs-but-trends2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04548752-olaparib-pd-1-blockade-pembrolizumab-misses-pfs-bar-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06710132-precemtabart-tocentecan-m9140-anti-ceacam5-top1-adc-posts-212026-07-08https://www.sagelyhealth.com/cancer-trials/nct04263948-multidom-telemonitoring-circadian-rhythm-epro-cuts-emergency-admissions-to2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05083780-hcq-autophagy-inhibitor-cpc-akt-emt-modulating-repurposed-agent2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05599984-abbv-706-sez6-targeted-topo-1-adc-posts-522026-07-08https://www.sagelyhealth.com/cancer-trials/nct05680922-lb2102-dll3-targeted-dntgfbr2-armored-autologous-car-t-shows2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06077500-obrixtamig-dll3cd3-adds-73-orr-to-1l-es-sclc2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03288350-avelumab-antipd-l1-modified-dcf-perioperative-chemo-delivers-612026-07-08https://www.sagelyhealth.com/cancer-trials/nct04159974-durvalumab-pd-l1-cross-boosts-mpr-to-54-in2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06137144-azd3470-mta-cooperative-prmt5-inhibitor-hits-80-orr-502026-07-08https://www.sagelyhealth.com/cancer-trials/nct06288360-camrelizumab-pd-1-cisplatin-nab-paclitaxel-hits-100-orr2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06277791-adebrelimab-antipd-l1-cisplatin-docetaxel-delivers-64-path-response2026-07-08https://www.sagelyhealth.com/cancer-trials/gemcitabine-nab-sirolimus-albumin-bound-mtor-inhibitor-delivers-302026-07-08https://www.sagelyhealth.com/cancer-trials/nct02122913-larotrectinib-trk-inhibitor-delivers-69-orr-and-19-mo2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03037385-pralsetinib-selective-ret-inhibitor-drives-92-orr-in-pretreated2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03669432-thyro-rt-finds-no-significant-lrr-benefit-from-adjuvant2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03682536-luspatercept-tgf-superfamily-ligand-trap-extends-transfusion-independence-vs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05341739-preoperative-single-fraction-srs-16gy-for-resectable-brain-mets2026-07-08https://www.sagelyhealth.com/cancer-trials/asciminib-stamp-inhibitor-abl-myristoyl-pocket-delivers-rapid-mr22026-07-08https://www.sagelyhealth.com/cancer-trials/chemo-checkpoint-inhibitor-pd-1-pd-l1-extends-os2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05775159-rilvegostomig-pd-1tigit-bispecific-gem-cis-posts-16-82026-07-08https://www.sagelyhealth.com/cancer-trials/nct01900743-regorafenib-multi-kinase-vegfr-tki-shows-numerically-longer-os2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05327530-ave-sg-trop2-adc-extends-pfs-across-visceral-liver-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct04561362-zelenectide-pevedotin-bt8009-nectin-4targeted-bdc-pembrolizumab-hits-50-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct02603432-avelumab-pd-l1-1l-maintenance-extends-os-regardless-of-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct02812420-durvalumab-pd-l1-tremelimumab-ctla-4-neoadjuvant-combo-hits-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct06225596-zelenectide-pevedotin-bt8009-nectin4-bdc-pembrolizumab-delivers-5558-orr-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct06238479-ly4101174-nectin-4targeted-exatecan-adc-shows-18-orr-post-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct06465069-ly4052031-nectin-4-topo1-adc-delivers-48-orr-in-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct05382442-ivonescimab-pd-1vegf-bispecific-mfolfox6-posts-70-8-orr-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct04886804-zongertinib-selective-irreversible-her2-tki-drives-45-orr-with-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct03698461-abfolfox-pd-l1-vegf-folfox-drives-immune-activated-crlm-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct03715933-ozekibart-inbrx-109-dr5-agonist-folfiri-delivers-23-orr-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct04111172-ad5-f35-gucy2c-padre-gucy2c-directed-adenoviral-vaccine-drives-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct05198934-sotorasib-kras-g12c-inhibitor-panitumumab-egfr-mab-links-early-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct05848739-st316-catenin-bcl9-antagonist-reaches-46-7-orr-with-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct06084481-telisotuzumab-adizutecan-temab-a-abbv-400-c-mettargeted-topo-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct06699836-leronlimab-ccr5-mab-tas-102-bev-shows-early-ctdna-22026-07-08https://www.sagelyhealth.com/cancer-trials/nct03594422-olverembatinib-hqp1351-hits-p38cd36-lipid-scavenging-axis-delivers-232026-07-08https://www.sagelyhealth.com/cancer-trials/nct05877599-nt-175-tp53-r175hhla-a-02-01-etcr-tgfr22026-07-08https://www.sagelyhealth.com/cancer-trials/nct05892718-hcb101-sirpigg4-fc-cd47-checkpoint-blocker-shows-early-monotherapy2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06026410-darlifarnib-ko-2806-fti-rheb-mtorc1-adagrasib-drives-672026-07-08https://www.sagelyhealth.com/cancer-trials/nct06792552-sim0505-anti-cdh6-topo-i-adc-drives-37-prs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03935893-tilscore-guided-til-therapy-produces-33-orr-in-checkpoint2026-07-08https://www.sagelyhealth.com/cancer-trials/larotrectinib-trk-inhibitor-delivers-65-orr-and-42-mo2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03425279-mecbotamab-vedotin-cab-axl-adc-delivers-17-6-mo2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03401788-belzutifan-hif-2-inhibitor-delivers-6-year-surgery-sparing2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04157985-stop-vs-continue-pd-1-pd-l1-at-12026-07-08https://www.sagelyhealth.com/cancer-trials/nct04469764-abemaciclib-cdk4-6-inhibitor-hormonal-therapy-posts-17-52026-07-08https://www.sagelyhealth.com/cancer-trials/nct05010031-atm-mutant-tumors-4gy2-palliative-rt-delivers-83-6mo2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05118789-zidesamtinib-nvl-520-a-ros1-selective-trk-sparing-tki2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05023486-np-g2-044-fascin-inhibitor-antipd-1-drives-502026-07-08https://www.sagelyhealth.com/cancer-trials/nct05378425-ntx1088-anti-pvr-cd155-pembrolizumab-drives-17-confirmed-prs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct04977453-efdelikofusp-alfa-cd80il-2v2-immunocytokine-pembrolizumab-shows-40-orr2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05768932-bal0891-dual-ttk-plk1-spindle-checkpoint-inhibitor-sets-1602026-07-08https://www.sagelyhealth.com/cancer-trials/nct05359445-ima401-magea4-8-tcer-posts-33-orr-in-hnscc2026-07-08https://www.sagelyhealth.com/cancer-trials/nct05492682-pepticrad-1-cd40l-ox40l-oncolytic-ad-ny-eso-12026-07-08https://www.sagelyhealth.com/cancer-trials/nct06253130-eik1003-parp1-selective-inhibitor-weekly-paclitaxel-shows-23-orr2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06256055-ucmym802-armored-msln-car-t-mrna-electroporated-laco-stim2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06150664-ctx-8371-pd-1pd-l1-bispecific-cd80-cd28enabling-shows2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06233942-bg-c9074-b7-h4targeting-topo-i-adc-shows-282026-07-08https://www.sagelyhealth.com/cancer-trials/nct06784193-op-3136-oral-kat6a-b-inhibitor-shows-early-tumor2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06751329-dm002-antimuc1-her3-bsadc-topoi-payload-shows-20-prs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06515990-dm005-egfr-c-met-bispecific-topo-i-adc-shows2026-07-08https://www.sagelyhealth.com/cancer-trials/eftilagimod-alfa-soluble-lag-3-mhc-class-ii-apc2026-07-08https://www.sagelyhealth.com/cancer-trials/nct06725758-odm-212-pan-tead-yaptaz-pathway-inhibitor-posts-272026-07-08https://www.sagelyhealth.com/cancer-trials/nct06271837-t-dxd-delivers-58-orr-and-15-7-month2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07647068-phase-2-autologous-til-adoptive-cell-therapy-il2-tcell2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07654426-phase-2-dexrazoxane-top2-cardioprotectant-vs-liposomal-doxorubicin-anthracycline2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07650240-phase-2-177lu-lu-psma-617-radioligand-psma-targeted2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07652242-phase-1-iti-5000-sarna-vaccine-targets-herv-k2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07647328-phase-3b-camizestrant-oral-serd-ribociclib-cdk4-6-inhibitor2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07654257-phase-2-apbi-multicatheter-hdr-brachytherapy-local-radiation-single2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07655284-phase-3-stent-x-compares-ureteral-stent-device-vs2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07578649-phase-3-pf-08634404-pd-1vegf-bispecific-antibody-plus2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07650266-phase-2-cemiplimab-pd-1-inhibitor-fianlimab-lag-32026-07-08https://www.sagelyhealth.com/cancer-trials/nct07657312-phase-2-infliximab-tnf-inhibitor-prophylaxis-with-bcmacd3-gprc5dcd32026-07-08https://www.sagelyhealth.com/cancer-trials/nct07650656-phase-2-indocyanine-green-nir-fluorescent-dye-tracer-fluorescence2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07650357-phase-1-clsp-5282-kras-g12vhla-a03-01-t2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07647679-phase-1-lattice-radiotherapy-spatially-fractionated-imrt-adds-vertex2026-07-08https://www.sagelyhealth.com/cancer-trials/nct07658196-phase-1-acm-cpg-tlr9-agonist-polymer-lipid-nanoparticle2026-07-08https://www.sagelyhealth.com/cancer-trials/nct03897881-intismeran-autogene-pembrolizumab-sustains-5-year-rfs-dmfs-benefit2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06295159-ipilimumab-ctla-4-nivolumabrelatlimab-pd-1-lag-3-drives2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03470922-nivolumab-relatlimab-pd-1-lag-3-adds-10-absolute2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03467516-til-adoptive-cell-therapy-autologous-delivers-22-orr-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03543969-adaptive-encorafenib-binimetinib-braf-mek-nivolumab-cuts-grade-32026-06-25https://www.sagelyhealth.com/cancer-trials/nct04123470-recent-anti-ctla-4-ipilimumab-linked-to-il-6high2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04262466-brenetafusp-pramecd3-immtac-shows-17-orr-at-160g-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05529316-botensilimab-fcenhanced-antictla4-balstilimab-antipd1-delivers-22-orr-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05267626-imneskibart-au-007-il-2cd25-decoy-antibody-low-dose2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05912244-io102-io103-pd-l1-ido-peptide-vaccine-nivolumabrelatlimab-pd2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06060613-obx-115-acz-inducible-mbil15armored-til-drives-67-orr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03554083-atezolizumab-tiragolumab-pd-l1-tigit-shows-index-node-pcr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05382442-ivonescimab-pd-1vegf-bispecific-mfolfox6-posts-70-8-orr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04008030-nivolumab-ipilimumab-pd-1-ctla-4-improves-long-term2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06262581-tislelizumab-pd-1-neoadjuvant-drives-78-6-pcr-ctdna2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06106308-onvansertib-plk1-inhibitor-folfiri-bev-lifts-orr-to-722026-06-25https://www.sagelyhealth.com/cancer-trials/nct03698461-abfolfox-pd-l1-vegf-folfox-drives-immune-activated-crlm2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03715933-ozekibart-inbrx-109-dr5-agonist-folfiri-delivers-23-orr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04111172-ad5-f35-gucy2c-padre-gucy2c-directed-adenoviral-vaccine-drives2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04886804-zongertinib-selective-irreversible-her2-tki-drives-45-orr-with2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05198934-sotorasib-kras-g12c-inhibitor-panitumumab-egfr-mab-links-early2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05848739-st316-catenin-bcl9-antagonist-reaches-46-7-orr-with2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06084481-telisotuzumab-adizutecan-temab-a-abbv-400-c-mettargeted-topo2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06699836-leronlimab-ccr5-mab-tas-102-bev-shows-early-ctdna2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04089631-ctdna-mrd-guided-act-capecitabineoxaliplatin-cuts-3-year-recurrence2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04607421-ec-encorafenib-braf-inhibitor-cetuximab-egfr-mab-folfiri-cuts2026-06-25https://www.sagelyhealth.com/cancer-trials/nct01150045-lycopene-tomato-carotenoid-intake-linked-to-40-lower-recurrence2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03641976-bevacizumab-folfoxiri-vegf-blockade-triplet-chemo-misses-pfs-bar2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03721653-atezotribe-ctdna-ctf-non-responders-show-larger-pfs-gain2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04008030-nivolumab-ipilimumab-pd-1-ctla-4-pfs-benefit-holds2026-06-25https://www.sagelyhealth.com/cancer-trials/nct01991873-panitumumab-egfr-mab-maintenance-benefit-holds-regardless-of-baseline2026-06-25https://www.sagelyhealth.com/cancer-trials/nct02394795-panitumumab-egfr-mab-drives-ctdna-highlow-conversions-that-track2026-06-25https://www.sagelyhealth.com/cancer-trials/zanzalintinib-multi-kinase-tam-met-vegfr-inhibitor-atezolizumab-pd2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03929666-zanidatamab-dual-her2-bispecific-ecd2-4-chemo-in-1l2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04592913-durvalumab-pd-l1-blockade-perioperative-flot-boosts-efs-across2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03777657-tislelizumab-pd-1-chemo-adds-2-6-months-qtwist2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05277168-shr-a1904-garetatug-rezetecan-cldn18-2-adc-posts-252026-06-25https://www.sagelyhealth.com/cancer-trials/nct05772546-avatrombopag-tpo-r-agonist-sharply-improves-platelet-recovery-and2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05152147-zanidatamab-dual-her2-bispecific-pd-1-tislelizumab-delivers-os2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06256328-ono-4578-ep4-antagonist-nivolumab-oxaliplatin-fluoropyrimidine-extends-pfs2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03615326-pembrolizumab-trastuzumab-pd-1-her2-sustains-os-gain-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05327530-ave-sg-trop2-adc-extends-pfs-across-visceral-liver2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06465069-ly4052031-nectin-4-topo1-adc-delivers-48-orr-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03924895-enfortumab-vedotin-nectin-4-adc-pembrolizumab-pd-1-delivers2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04917809-erdafitinib-pan-fgfr-inhibitor-delivers-55-cr-chemoablation-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04561362-zelenectide-pevedotin-bt8009-nectin-4targeted-bdc-pembrolizumab-hits-502026-06-25https://www.sagelyhealth.com/cancer-trials/nct02603432-avelumab-pd-l1-1l-maintenance-extends-os-regardless-of2026-06-25https://www.sagelyhealth.com/cancer-trials/nct02812420-durvalumab-pd-l1-tremelimumab-ctla-4-neoadjuvant-combo-hits2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06225596-zelenectide-pevedotin-bt8009-nectin4-bdc-pembrolizumab-delivers-5558-orr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06238479-ly4101174-nectin-4targeted-exatecan-adc-shows-18-orr-post2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03022825-nogapendekin-alfa-inbakicept-pmln-il15-superagonist-bcg-tops-pembrolizumab2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03549715-durvalumab-pd-l1-ddmvac-hits-49-pcr-in-neoadjuvant2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04164901-vorasidenib-dual-mutant-idh1-2-inhibitor-delivers-50-month2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04164901-vorasidenib-dual-mutant-idh1-2-inhibitor-cuts-seizure-rates2026-06-25https://www.sagelyhealth.com/cancer-trials/nct02287428-neovax-personalized-neoantigen-long-peptide-vaccine-poly-iclc-plus2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04552886-doc1021-dubodencel-dc-vaccine-expands-memory-t-cells-with2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05168423-cartegfril13r2-egfr-il13r2-bivalent-cart-shows-12-0mo-mos2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05768919-liposomal-curcumin-lc-rt-tmz-hits-rp2d-350mg-m22026-06-25https://www.sagelyhealth.com/cancer-trials/nct04478279-lucicebtide-st101-c-ebp-antagonist-shows-early-survival-signal2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05342883-gammatile-cs-131-brachytherapy-stupp-cuts-rapid-early-progression2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04516447-azenosertib-wee1-inhibitor-weekly-paclitaxel-delivers-39-orr-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05257408-relacorilant-glucocorticoid-receptor-antagonist-nab-paclitaxel-extends-os-by2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06303505-tub-040-napi2b-exatecan-adc-delivers-61-corr-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct01970722-sbs5-clock-like-mutational-signature-flags-longer-pfs-after2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03579394-delayed-interval-debulking-6-cycle-nac-shows-no-dfs2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04274426-mirvetuximab-soravtansine-fr-adc-carboplatin-fails-to-improve-pfs2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06028932-sacituzumab-govitecan-trop2-adc-delivering-sn-38-posts-352026-06-25https://www.sagelyhealth.com/cancer-trials/nct06395519-etx-19477-oral-parg-inhibitor-posts-29-pr-rate2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04752826-bi-1808-tnfr2-igg1-mab-treg-depleting-pembrolizumab-delivers2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06459973-yl205-napi2b-targeted-topo1-adc-posts-46-5-orr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct01436968-can-2409-hsvtk-adenoviral-gene-therapy-valacyclovir-improves-dfs2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03767244-apalutamide-androgen-receptor-inhibitor-perioperative-adt-improves-5-year2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04821622-talazoparib-parp-inhibitor-enzalutamide-ar-inhibitor-boosts-3-year2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06318273-abbv-969-psma-steap1-dual-targeting-top1i-adc-drives2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03561220-comppare-proton-therapy-vs-imrt-photon-shows-no-22026-06-25https://www.sagelyhealth.com/cancer-trials/nct03767244-apalutamide-ar-antagonist-adt-periop-boosts-pcr-mrd-and2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04821622-talazoparib-parp-inhibitor-enzalutamide-ar-inhibitor-halves-rpfs-risk2026-06-25https://www.sagelyhealth.com/cancer-trials/nct00268476-mmai-digital-pathology-ai-biomarker-predicts-abiraterone-benefit-cyp172026-06-25https://www.sagelyhealth.com/cancer-trials/nct02555189-enzalutamide-ribociclib-cdk4-6-misses-psa50-bar-but-extends2026-06-25https://www.sagelyhealth.com/cancer-trials/nct01949337-enzalutamide-era-mcrpc-ctdna-ar-enhancer-ar-copy-gains2026-06-25https://www.sagelyhealth.com/cancer-trials/st-doxpca-ai-virtual-spatial-transcriptomics-identifies-an-os2026-06-25https://www.sagelyhealth.com/cancer-trials/nct02975934-rucaparib-parp-inhibitor-extends-rpfs-in-brca-mutant-mcrpc2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04221542-xaluritamig-steap1cd3-t-cell-engager-abiraterone-posts-58-psa502026-06-25https://www.sagelyhealth.com/cancer-trials/nct04709276-cabazitaxel-carbo-nivolumab-ipilimumab-pd-1-ctla-4-hits2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04455750-enzalutamide-parp-inhibitor-rucaparib-adds-psa-dropsbut-no-clear2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04691804-fuzuloparib-parp-inhibitor-abiraterone-extends-rpfs-in-1l-mcrpc2026-06-25https://www.sagelyhealth.com/cancer-trials/a-dream-alliance-a032101-intermittent-adt-arpi-interruption-delivers2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04736199-darolutamide-ar-antagonist-adt-drives-deep-psa-suppression-across2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06100705-bat-supraphysiologic-testosterone-sipuleucelt-drives-100-pa2024-elispot-responses2026-06-25https://www.sagelyhealth.com/cancer-trials/nct06241846-yl201-b7-h3targeted-adc-posts-33-orr-and-112026-06-25https://www.sagelyhealth.com/cancer-trials/nct06549465-conv01-ac-225-psmamab-alpha-radioconjugate-drives-45-psa502026-06-25https://www.sagelyhealth.com/cancer-trials/nct00309985-st-doxpca-h-e-biomarker-identifies-mhspc-patients-most2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03589339-nbtxr3-hafnium-oxide-radioenhancer-sbrt-reirradiation-followed-by-antipd2026-06-25https://www.sagelyhealth.com/cancer-trials/pembrolizumab-pd-1-definitive-rt-improves-2-year-pfs2026-06-25https://www.sagelyhealth.com/cancer-trials/nct05784688-tosposertib-tgfri-vegfr2-inhibitor-pembrolizumab-drives-75-orr-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04429542-ficerafusp-alfa-egfrtgf-trap-pembrolizumab-drives-deeper-shrinkage-and2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03040999-pembrolizumab-pd-1-definitive-crt-improves-5-year-efs2026-06-25https://www.sagelyhealth.com/cancer-trials/nct03769506-asp-1929-egfrir700-photoimmunotherapy-lifts-os-to-15-7mo2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04291105-vv1-vsvifnnis-intratumoral-oncolytic-virus-pd1-blockade-cemiplimab-hits2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04862650-metronomic-carboplatin-paclitaxel-pd-1-blocker-cemiplimab-delivers-422026-06-25https://www.sagelyhealth.com/cancer-trials/nct05376553-cemiplimab-pd-1-cisplatin-docetaxel-induction-delivers-83-orr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04375384-cetuximab-egfr-igg1-after-pd-1-failure-delivers-332026-06-25https://www.sagelyhealth.com/cancer-trials/nct07645326-phase-2-adt-arpi-androgen-receptor-signaling-inhibition-with2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07635238-phase-2-mr-guided-sbrt-uses-mr-linac-image2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07639086-phase-2-sacituzumab-tirumotecan-trop2-directed-adc-topoisomerase-i2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07635524-phase-2-61cu-nu101-psma-targeted-pet-radiotracer-psma2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07644598-phase-2-microboost-sbrt-focal-sib-dna-damage-via2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07567846-phase-1-2-gdc-1261-trial-in-prostate-cancer2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07645469-phase-1-fh-wt1-e50-wt1-targeted-tcrt-plus2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07634536-phase-2-automated-vmat-based-tmli-conditioning-refines-marrow2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07572006-phase-1-jnj-95804306-no-disclosed-moa-target-in2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07638982-phase-1-axatilimab-csf1r-blocking-monoclonal-antibody-conditions-macrophages2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07640737-phase-2-aur103-calcium-oral-cd47-antagonist-tests-innate2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07635056-phase-1-ciml-nk-allogeneic-nk-cell-immunotherapy-il2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07633756-phase-1b-rec-617-selective-cdk7-inhibitor-transcription-cell2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07489287-phase-1-gb-5267-il-18armored-anti-muc16-car2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07634094-phase-2-pembrolizumab-pd-1-antibody-plus-tlr3-agonist2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07634601-phase-2-elacestrant-oral-serd-estrogen-receptor-degrader-everolimus2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07643012-phase-1-2-mrguided-adaptive-imrt-mrlinacbased-pelvic-radiation2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07644559-phase-2-vs-7375-oral-kras-g12d-on-off2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07645651-phase-1b-samuraciclib-trial-tests-cdk7-inhibitor-transcription-cell2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07564401-phase-1-2-dji136-lb2102-dll3-targeted-autologous-cart2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07566052-phase-3-setidegrasib-asp3082-kras-g12dtargeted-protein-degrader-vs2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07639242-phase-2-olomorasib-kras-g12c-covalent-inhibitor-pembrolizumab-pd12026-06-25https://www.sagelyhealth.com/cancer-trials/nct07489066-phase-2-pf-08634404-trial-tests-pd-1vegf-bispecific2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07227402-phase-3-belzutifan-hif-2-inhibitor-zanzalintinib-met-vegfr2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07492641-phase-3-bgb-43395-cdk4-selective-inhibitor-plus-letrozole2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07527858-phase-2-denikitug-gs-1811-trial-tests-ccr8-targeted2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07644585-pilot-early-feasibility-conformalflash-ultra-highdose-rate-proton-therapy2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07321912-phase-2-eflornithine-dfmo-ornithine-decarboxylase-inhibitor-added-maintenance2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07086768-phase-1-bsi-082-anti-sirp-macrophage-checkpoint-antibody2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07644039-phase-1-2-pm54-pembrolizumab-tests-tubulin-microtubule-inhibition2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07636785-phase-1-2-vmd-102-selective-pkc-protein-kinase2026-06-25https://www.sagelyhealth.com/cancer-trials/nct07638371-phase-1-msktcr5-cd8-armored-kras-hras-nras-g12d2026-06-25https://www.sagelyhealth.com/cancer-trials/nct04538742-t-dxd-her2-adc-durvalumab-pd-l1-delivers-832026-06-18https://www.sagelyhealth.com/cancer-trials/nct04784715-t-dxd-her2-adc-pertuzumab-crs-deepen-slowly-82026-06-18https://www.sagelyhealth.com/cancer-trials/nct04961996-giredestrant-oral-serd-full-er-antagonist-cuts-recurrence-risk2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05132582-tucatinib-her2-tki-trastuzumab-pertuzumab-extends-pfs-as-1l2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05325632-intratumoral-dc1-type-1-dendritic-cell-immunotherapy-dual-her22026-06-18https://www.sagelyhealth.com/cancer-trials/nct05374512-dato-dxd-trop2-adc-extends-pfs2-tfst-tsst-vs2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05382286-sacituzumab-govitecan-trop2-adc-pembrolizumab-extends-pfs-vs-chemo2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05593094-zn-a-1041-bbb-permeable-her2-tki-t-dxd2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05501886-gedatolisib-pan-pi3k-mtorc1-2-inhibitor-fulvestrant-palbociclib-doubles2026-06-18https://www.sagelyhealth.com/cancer-trials/nct01452399-cavity-shave-margins-csm-cut-positive-margins-re-excisions2026-06-18https://www.sagelyhealth.com/cancer-trials/nct03747120-pembrolizumab-pd-1-added-to-neoadjuvant-thp-trends-toward2026-06-18https://www.sagelyhealth.com/cancer-trials/nct03742102-durvalumab-pd-l1-paclitaxel-posts-56-orr-in-1l2026-06-18https://www.sagelyhealth.com/cancer-trials/nct00005970-her2-targeted-trastuzumab-shows-on-time-benefit-but-late2026-06-18https://www.sagelyhealth.com/cancer-trials/nct04443348-low-dose-rt-9gy-pembrolizumab-boosts-early-t-cell2026-06-18https://www.sagelyhealth.com/cancer-trials/nct04454528-rtpembrolizumab-pd-1-preop-window-yields-higher-major-pathologic2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05382299-sacituzumab-govitecan-trop2-adc-delivering-sn-38-extends-pfs2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05548127-vepdegestrant-protac-er-degrader-abemaciclib-delivers-30-6-orr2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05563220-elacestrant-oral-serd-capivasertib-akt-inhibitor-posts-11-32026-06-18https://www.sagelyhealth.com/cancer-trials/nct05768139-tersolisib-ly4064809-stx-478-mutant-selective-pi3k-inhibitor-shows2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05840211-sacituzumab-govitecan-trop2-adc-trends-toward-longer-pfs-vs2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05280067-zeta-bc-003-p21-pathway-intratumoral-biomaterial-drives-ct2026-06-18https://www.sagelyhealth.com/cancer-trials/nct06120283-bgb-43395-selective-cdk4-inhibitor-letrozole-shows-high-early2026-06-18https://www.sagelyhealth.com/cancer-trials/nct06206837-vepdegestrant-protac-er-degrader-atirmociclib-selective-cdk4-inhibitor-delivers2026-06-18https://www.sagelyhealth.com/cancer-trials/nct06465368-atirmociclib-selective-cdk4-inhibitor-letrozole-drives-88-ki-672026-06-18https://www.sagelyhealth.com/cancer-trials/nct03591276-pld-pembrolizumab-anthracycline-pd-1-delivers-33-orr-in2026-06-18https://www.sagelyhealth.com/cancer-trials/nct04546009-giredestrant-oral-serd-er-degrader-palbociclib-misses-1l-pfs2026-06-18https://www.sagelyhealth.com/cancer-trials/nct04964934-camizestrant-oral-serd-complete-er-antagonist-switch-at-emergent2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05132582-tucatinib-trastuzumab-pertuzumab-extends-her2-mbc-maintenance-pfs-but2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05382299-sacituzumab-govitecan-trop2-directed-adc-delivering-sn-38-extends2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05306340-giredestrant-oral-serd-full-er-antagonist-everolimus-extends-pfs22026-06-18https://www.sagelyhealth.com/cancer-trials/nct07619365-phase-2-trastuzumab-deruxtecan-her2-adc-topoisomerase-i-payload2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07391774-phase-3-rxfine-low-ribociclib-cdk4-6-inhibitor-guided2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07604571-phase-1-1b-iev407-trial-tests-an-undisclosed-target2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07629089-phase-1b-vorasidenib-dual-mutant-idh1-idh2-inhibitor-plus2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07620548-phase-2-cemiplimab-pd-1-inhibitor-litt-ablation-vs2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07554339-phase-3-calderasib-mk-1084-kras-g12c-inhibitor-durvalumab2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07619599-phase-1-64cu-dota-pembrolizumab-pet-radiotracer-targets-pd2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07619339-phase-1-tepotinib-ivonescimab-trial-tests-met-inhibitor-plus2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07306832-phase-1b-pivekimab-sunirine-cd123-targeted-antibodydrug-conjugate-in2026-06-18https://www.sagelyhealth.com/cancer-trials/nct06917911-phase-2-venetoclax-bcl-2-inhibitor-vs-gemtuzumab-ozogamicin2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07617363-phase-1-atrn-119-atr-kinase-inhibitor-plus-decitabine2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07428616-phase-2-zanzalintinib-c-met-hgfr-and-vegfr-inhibitor2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07628894-phase-1-circadian-optimized-light-therapy-colt-supports-til2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07343934-phase-1-hucart19-il18-edhfr-cd19-car-t-secreting2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07518186-phase-3-jnj-79635322-bcma-gprc5dcd3-trispecific-antibody-vs2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07624513-phase-3-isatuximab-anti-cd38-mab-iberdomide-crbn-e32026-06-18https://www.sagelyhealth.com/cancer-trials/nct07555938-phase-3-cevostamab-fcrh5cd3-bispecific-antibody-plus-pd-in2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07277231-phase-3-sonrotoclax-bgb-11417-bcl2-inhibitor-plus-zanubrutinib2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07621718-phase-3-zoldonrasib-rmc-9805-kras-g12d-selective-ras2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07619417-early-feasibility-aliya-pef-system-irreversible-electroporation-non-thermal2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07619313-phase-1-1b-ab801-axl-receptor-tyrosine-kinase-inhibitor2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07059845-phase-2-mirvetuximab-soravtansine-fr-targeted-adc-dm4-tubulin2026-06-18https://www.sagelyhealth.com/cancer-trials/nct06796907-phase-1-2-mocertatug-rezetecan-b7-h4targeted-topoisomerase-i2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07156227-phase-1-camonsertib-atr-kinase-inhibitor-plus-sbrt-re2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07631000-phase-2-cadonilimab-pd-1ctla-4-bispecific-antibody-plus2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07629960-phase-1-2-blu-924-sar449336-pan-kras-inhibitor2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07630168-phase-2-timed-trial-tests-pd1-pdl1-checkpoint-blockade2026-06-18https://www.sagelyhealth.com/cancer-trials/nct06656390-phase-1-2-alk201-fgfr2b-targeting-adc-top1-inhibitor2026-06-18https://www.sagelyhealth.com/cancer-trials/nct07438782-phase-1-gsk5533524-antibodydrug-conjugate-adc-targeting-an-undisclosed2026-06-18https://www.sagelyhealth.com/cancer-trials/nct05099172-sevabertinib-her2-tki-sustains-6775-orr-in-her2-mutant2026-06-11https://www.sagelyhealth.com/cancer-trials/nct05384626-neladalkib-next-gen-alk-tki-trk-sparing-posts-312026-06-11https://www.sagelyhealth.com/cancer-trials/nct05265091-lunbotinib-a400-ep0031-selective-ret-inhibitor-posts-8187-orr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct05789082-divarasib-kras-g12c-inhibitor-pembrolizumab-drives-73-orr-and2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06706076-bh-30643-omniegfr-mutantselective-macrocyclic-tki-shows-59-orr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06361927-ssgj-707-pf-08634404-pd-1vegf-bispecific-delivers-672026-06-11https://www.sagelyhealth.com/cancer-trials/nct06293690-lattice-sf-sbrt-toripalimab-chemo-drives-95-mpr-in2026-06-11https://www.sagelyhealth.com/cancer-trials/nct02773238-flare-rt-pet-spect-guided-risk-adaptive-rt-boosts2026-06-11https://www.sagelyhealth.com/cancer-trials/pembrolizumab-pd-1-platinum-doublet-chemo-shows-larger-os2026-06-11https://www.sagelyhealth.com/cancer-trials/nct02595944-nivolumab-pd-1-adjuvant-therapy-fails-to-extend-dfs2026-06-11https://www.sagelyhealth.com/cancer-trials/nct02193282-adjuvant-erlotinib-egfr-tki-fails-to-improve-os-after2026-06-11https://www.sagelyhealth.com/cancer-trials/nct03516981-pembrolizumab-lenvatinib-vegfr-fgfr-tki-hits-biomarker-gated-orr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct03520686-nogapendekin-alfa-inbakicept-nai-il-15r-agonist-boosts-pfs2026-06-11https://www.sagelyhealth.com/cancer-trials/nct03800134-durvalumab-antipd-l1-reshapes-the-tme-and-deepens-efs2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04222972-pralsetinib-ret-tki-doubles-pfs-vs-platinum-soc-in2026-06-11https://www.sagelyhealth.com/cancer-trials/nct03539536-telisotuzumab-vedotin-c-met-adc-shows-similar-activity-with2026-06-11https://www.sagelyhealth.com/cancer-trials/nct00946712-baseline-ct-qvt-vascular-tortuosity-score-predicts-os-benefit2026-06-11https://www.sagelyhealth.com/cancer-trials/nct02737501-brigatinib-alk-tki-ai-mri-radiomics-predicts-longer-ipfs2026-06-11https://www.sagelyhealth.com/cancer-trials/nct01336634-dabrafenib-trametinib-braf-mek-inhibition-shows-longer-pfs-os2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04389632-sigvotatug-vedotin-itgb6-vedotin-adc-pembrolizumab-drives-50-corr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04077463-amivantamab-egfr-met-lazertinib-egfr-tki-delivers-41-02026-06-11https://www.sagelyhealth.com/cancer-trials/nct04538664-amivantamab-egfr-met-bispecific-carbo-pem-doubles-pfs-vs2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04780568-osimertinib-tegavivint-catenin-tbl1-transcription-inhibitor-posts-73-orr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04047862-ociperlimab-antitigit-tislelizumab-antipd1-enriches-responses-in-pdl1-tigit2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04956640-olomorasib-kras-g12c-inhibitor-pembrolizumab-drives-5867-orr-in2026-06-11https://www.sagelyhealth.com/cancer-trials/nct05256290-silevertinib-bdtx-1535-4th-gen-covalent-egfr-tki-posts2026-06-11https://www.sagelyhealth.com/cancer-trials/nct05410145-elisrasib-d3s-001-gdp-bound-kras-g12c-inhibitor-drives-22026-06-11https://www.sagelyhealth.com/cancer-trials/nct05541822-vabametkib-abn401-a-selective-type-i-c-met-tki2026-06-11https://www.sagelyhealth.com/cancer-trials/nct05553834-alirocumab-pcsk9-inhibitor-cemiplimab-antipd-1-shows-biomarker-enriched2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06043817-pfl-721-mutant-selective-egfr-her2-exon-20-tki2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06008093-tremelimumab-ctla-4-durvalumab-pd-l1-chemo-extends-response2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04956640-olomorasib-kras-g12c-inhibitor-pembrolizumab-maintains-7277-orr-despite2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06228326-kb707-inhaled-hsv-1-il-12-il-2-immunotherapy2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06385925-tsn1611-kras-g12d-on-off-inhibitor-posts-50-orr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct05950139-alkvac-peptide-vaccine-alk-resistancemutation-neoantigens-elicits-tcell-responses2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06667544-rnk08954-oral-kras-g12d-inhibitor-posts-38-5-orr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06712316-pumitamig-pd-l1vegf-a-bispecific-chemo-drives-70-orr2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06905197-dzd6008-4th-gen-egfr-tki-posts-60-orr-at2026-06-11https://www.sagelyhealth.com/cancer-trials/nct06115642-hlx43-antipd-l1-adc-drives-31-orr-in-heavily2026-06-11https://www.sagelyhealth.com/cancer-trials/nct03052608-lorlatinib-alk-tki-reaches-55-7-year-pfs-in2026-06-11https://www.sagelyhealth.com/cancer-trials/encorafenib-binimetinib-braf-mek-hits-61-orr-in-chinese2026-06-11https://www.sagelyhealth.com/cancer-trials/nct04258137-cope-ctdna-profiling-raises-genotyping-to-97-but-does2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07612293-phase-2-stagemtc-evaluates-thyroid-lobectomy-no-drug-target2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07611110-phase-3-azd2265-fpi-2265-actinium-225-psma-targeted2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07609225-phase-1-flt-thymidine-analog-pet-tracer-vs-cse2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07608718-phase-2-zanzalintinib-c-met-vegfr-tyrosine-kinase-inhibitor2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07610525-phase-2-better-trial-tests-pembrolizumab-pd-1-blockade2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07612254-phase-1-2-repeat-tests-accelerated-partial-breast-re2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07612215-phase-2-elacestrant-serd-trastuzumab-pertuzumab-her2-mabs-in2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07546500-phase-3-azenosertib-wee1-inhibitor-vs-chemotherapy-in-cyclin2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07614022-phase-1-lp-118-dual-bcl-2-bcl-xl2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07605949-phase-2-revumenib-menin-inhibitor-triplet-with-azacitidine-venetoclax2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07608627-phase-1-64cu-dota-a2dm-pet-psca-targeted-immunopet2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07609472-phase-2-fg001-upar-targeted-near-infrared-fluorescent-imaging2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07612007-phase-2b-hrx215-darizmetinib-mkk4-inhibitor-to-accelerate-liver2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07417488-phase-1-ad5-f35-hgucy2c-padre-lm-gucy2c-vaccines2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07578571-phase-1-im-1617-undisclosed-rtktargeting-adc-with-top12026-06-11https://www.sagelyhealth.com/cancer-trials/nct07612189-phase-1-neok002-egfrmuc1-bispecific-adc-with-topoisomerase-12026-06-11https://www.sagelyhealth.com/cancer-trials/nct07607678-phase-1-bi-3819026-anti-layn-antibody-ezabenlimab-pd2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07612488-phase-1-cs231295-aurora-bselective-multi-kinase-inhibitor-in2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07612176-phase-1-neok001-b7-h3ror1-bispecific-adc-targets-dual2026-06-11https://www.sagelyhealth.com/cancer-trials/nct07605962-phase-1-2-ui-102-cholesteryl-pullulan-nanoparticle-tlr72026-06-11https://www.sagelyhealth.com/cancer-trials/nct03742102-dato-dxd-trop2-adc-durvalumab-pd-l1-drives-802026-06-04https://www.sagelyhealth.com/cancer-trials/nct03272477-trastuzumab-pertuzumab-dual-her2-blockade-with-endocrine-therapy-matches2026-06-04https://www.sagelyhealth.com/cancer-trials/nct06040541-zoldonrasib-rmc-9805-ras-on-kras-g12d-inhibitor-drives2026-06-04https://www.sagelyhealth.com/cancer-trials/nct05410145-elisrasib-d3s-001-gdp-bound-kras-g12c-inhibitor-posts2026-06-04https://www.sagelyhealth.com/cancer-trials/preop-dsc-mri-perfusion-cbv-cbf-predicts-poorer-survival2026-06-04https://www.sagelyhealth.com/cancer-trials/nct03070392-tebentafusp-gp100cd3-immtac-doubles-5-year-os-to-162026-06-04https://www.sagelyhealth.com/cancer-trials/nct04913220-pegenzileukin-sar444245-non-il2-il2r-agonist-pd1-cemiplimab-hits2026-06-04https://www.sagelyhealth.com/cancer-trials/imnn-001-intraperitoneal-il-12-plasmid-gene-therapy-carbo2026-06-04https://www.sagelyhealth.com/cancer-trials/nct03141684-atezolizumab-pdl1-in-asps-shows-low-late-toxicity-beyond2026-06-04https://www.sagelyhealth.com/cancer-trials/lenvatinib-vegfr-fgfr-tki-pembrolizumab-pd-1-improves-os2026-06-04https://www.sagelyhealth.com/cancer-trials/nct04857164-pembrolizumab-pd-1-nab-paclitaxel-albumin-bound-taxane-platinum2026-06-04https://www.sagelyhealth.com/cancer-trials/nct04533451-pembrolizumab-pd-1-carboplatin-pemetrexed-shows-manageable-grade3-toxicity2026-06-04https://www.sagelyhealth.com/cancer-trials/nct03288545-ev-103-enfortumab-vedotin-nectin-4-adc-pembrolizumab-pd2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07566156-phase-3-ev-309-tests-enfortumab-vedotin-nectin-42026-06-04https://www.sagelyhealth.com/cancer-trials/nct07365995-phase-3-bnt324-db-1311-b7-h3targeted-topoisomerase-ipayload2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07493512-phase-1b-xaluritamig-amg-509-steap1cd3-bispecific-tcell-engager2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07593079-pilot-randomized-study-uses-bicalutamide-androgen-receptor-inhibitor-to2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07319195-early-phase-1-mitazalimab-cd40-agonist-nivolumab-pd-12026-06-04https://www.sagelyhealth.com/cancer-trials/nct07596212-phase-2-bupropion-xl-norepinephrinedopamine-reuptake-inhibitor-to-improve2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07591649-phase-1-2-adaptnk-adaptive-cmv-induced-nk-cell2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07594015-phase-2-pembrolizumab-pd-1-inhibitor-lenvatinib-multi-kinase2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07604285-phase-1-2-mt-125-non-muscle-myosin-ii2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07593092-phase-1-xmab541-cldn6cd3-tcellengaging-bispecific-xmab808-b7h3cd28-costimulatory2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07365319-phase-2-3-eik1001-tlr7-8-agonist-pembrolizumab-chemo2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07603856-phase-2-nivolumab-pd1-inhibitor-hypofractionated-ablative-rt-vs2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07594522-phase-2-ivonescimab-pd-1vegf-bispecific-antibody-consolidation-after2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07531095-phase-1b-tarlatamab-dll3cd3-tcell-engager-zl1310-dll3-topoi2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07604233-phase-1-2-asciminib-stamp-bcr-abl1-inhibitor-with2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07601100-phase-1b-2-isatuximab-iberdomide-cereblon-e3-ligase-modulator2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07595874-phase-2-botensilimab-fcenhanced-antictla4-balstilimab-pd1-antibody-in2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07451054-phase-1-cart-45-anti-cd45-car-t-cd452026-06-04https://www.sagelyhealth.com/cancer-trials/nct07594067-phase-1-tcr1188-abc-kras-g12v-tcr-ilt4-lilrb22026-06-04https://www.sagelyhealth.com/cancer-trials/nct07603375-phase-2-flot-docetaxel-microtubule-inhibitor-consolidation-after-crt2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07594548-phase-1-1b-futibatinib-fgfr14-inhibitor-paclitaxel-ramucirumab-vegfr22026-06-04https://www.sagelyhealth.com/cancer-trials/nct07602842-phase-1-2-idp-001-egfrcdcp1-bispecific-adc-proximity2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07594431-phase-2-lattice-radiotherapy-spatially-fractionated-sbrt-vs-dose2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07594626-phase-1b-2-navlimetostat-bms-986504-prmt5-inhibitor-pemetrexed2026-06-04https://www.sagelyhealth.com/cancer-trials/nct07525141-phase-1-jnj-1761981-er-intratumoral-extended-release-cisplatin2026-06-04https://www.sagelyhealth.com/cancer-trials/nct03414684-carboplatin-nivolumab-pd-1-misses-primary-pfs-endpoint-in2026-05-27https://www.sagelyhealth.com/cancer-trials/nct02945579-sabr-definitive-breast-rt-endocrine-therapy-hits-53-pcr2026-05-27https://www.sagelyhealth.com/cancer-trials/nct03477513-ml-guided-pprt-dose-escalated-rt-boost-doubles-pfs2026-05-27https://www.sagelyhealth.com/cancer-trials/nct04015700-gnos-pv01-personalized-neoantigen-dna-vaccine-drives-t-cell2026-05-27https://www.sagelyhealth.com/cancer-trials/nct04726397-mr-linac-adaptive-gbm-rt-shows-flair-fhr-omission2026-05-27https://www.sagelyhealth.com/cancer-trials/nct03607370-prolonging-ncrttme-interval-to-12-weeks-fails-to-boost2026-05-27https://www.sagelyhealth.com/cancer-trials/nct02106312-doremy-36gy-preop-radiotherapy-rt-in-myxoid-liposarcoma-preserves2026-05-27https://www.sagelyhealth.com/cancer-trials/nct03173248-ivosidenib-mutant-idh1-inhibitor-azacitidine-drives-a-74-month2026-05-27https://www.sagelyhealth.com/cancer-trials/nct05038124-preop-sbrt-2730gy-3fx-or-1824gy-1fx-before-fixation2026-05-27https://www.sagelyhealth.com/cancer-trials/nct04972097-nanoknife-focal-irreversible-electroporation-ire-shows-no-new-failures2026-05-27https://www.sagelyhealth.com/cancer-trials/sabr-26gy1-or-42gy-3fx-delivers-100-7-year2026-05-27https://www.sagelyhealth.com/cancer-trials/nct05877430-cjrb-101-live-leuconostoc-mesenteroides-biotherapeutic-pd-1-blockade2026-05-27https://www.sagelyhealth.com/cancer-trials/nct04482309-t-dxd-her2-adc-drives-4558-orr-in-pretreated2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07053436-phase-2-linvoseltamab-bcmacd3-bispecific-tcell-engager-vs-isakrd2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07581704-phase-1b-sirolimus-mtor-inhibitor-pre-conditioning-plus-bcmacd32026-05-27https://www.sagelyhealth.com/cancer-trials/nct07479979-phase-1b-2-selinexor-xpo1-sine-inhibitor-plus-carfilzomib2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07590934-phase-1b-2-azd9574-parp1-inhibitor-azd2265-fpi-22652026-05-27https://www.sagelyhealth.com/cancer-trials/nct07581184-phase-1b-aky-2519-b7-h3targeted-actinium-225-alpha2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07579195-phase-1-2-reinforce-tests-enfortumab-vedotin-nectin-42026-05-27https://www.sagelyhealth.com/cancer-trials/nct06822010-phase-2-gemcitabine-jelmyto-mitomycin-dna-crosslinker-chemoablation-in2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07581405-phase-2-olanzapine-dopamine-d2-5-ht2a-antagonist-to2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07554521-phase-2-tislelizumab-pd-1-inhibitor-plus-platinum-fluoropyrimidine2026-05-27https://www.sagelyhealth.com/cancer-trials/nct06549751-phase-1-mt-601-multitaa-specific-adoptive-t-cells2026-05-27https://www.sagelyhealth.com/cancer-trials/nct06937996-n-a-nanoknife-irreversible-electroporation-cell-membrane-nanopore-ablation2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07579221-phase-1-2-navlimetostat-prmt5-inhibitor-pumitamig-pd-l1vegf2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07590583-pilot-endorse-study-evaluates-response-guided-systems-medicine-report2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07220135-phase-2-neothera-tests-her2-dual-antibody-blockade-trastuzumab2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07054190-phase-2-inavolisib-pi3k-inhibitor-ribociclib-cdk4-6-inhibitor2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07582003-phase-1-s-adenosylmethionine-same-methyl-donor-supplement-to2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07580339-phase-1b-dcsz11-cd93-directed-monoclonal-antibody-adds-tumor2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07578025-phase-2-zanzalintinib-xl092-multi-kinase-vegfr2-met-axl2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07578077-phase-1-2-golcadomide-celmod-cereblon-e3-ligase-modulator2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07583810-phase-2-nemtabrutinib-non-covalent-btk-inhibitor-plus-rituximab2026-05-27https://www.sagelyhealth.com/cancer-trials/nct06724237-phase-3-ptcl-stat-tests-high-dose-chemotherapy-dna2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07588698-phase-2-epcoritamab-cd20cd3-bispecific-antibody-plus-r-chop2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07342478-phase-3-rocbrutinib-lp-168-dual-covalent-reversible-btk2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07582159-phase-2-avt-triplet-tafasitamab-cd19-mab-acalabrutinib-btk2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07583303-phase-1-bsb-2002-mutant-npm1targeted-tcr-t-therapy2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07012044-phase-1-astx727-oral-decitabine-cedazuridine-dna-hypomethylating-agent2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07586618-phase-1-4a10-alt-101-tests-anti-cd127-il2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07566377-phase-2-cord-blood-transplantation-allogeneic-hematopoietic-stem-cell2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07582172-phase-2-tmli-conditioning-fludarabine-melphalan-imrt-marrow-lymphoid2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07584226-phase-1-rly-8161-trial-tests-an-nras-selective2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07586046-phase-1-yttrium-90-beta-emitting-glass-microspheres-radioembolization2026-05-27https://www.sagelyhealth.com/cancer-trials/nct07587879-phase-1-2a-pmc2129g12-intratumoral-mrna-lnp-encodes-epcamcd32026-05-27https://www.sagelyhealth.com/cancer-trials/nct06819735-phase-1-2-dt-7012-anti-ccr8-monoclonal-antibody2026-05-27https://www.sagelyhealth.com/cancer-trials/nct02276443-artemis-ac-neoadjuvant-chemo-links-immune-hot-cold-contexture2026-05-21https://www.sagelyhealth.com/cancer-trials/psma-pet-ct-guided-srt-field-adt-tailoring-delivers2026-05-21https://www.sagelyhealth.com/cancer-trials/nct03757221-daratumumab-cd38-ixazomib-oral-proteasome-inhibitor-sans-dexamethasone-delivers2026-05-21https://www.sagelyhealth.com/cancer-trials/amivantamab-egfrmet-bispecific-delivers-32-orr-in-metex14-nsclcincluding2026-05-21https://www.sagelyhealth.com/cancer-trials/lazertinib-3rd-gen-egfr-tki-matches-osimertinib-in-1l2026-05-21https://www.sagelyhealth.com/cancer-trials/cemiplimab-pd-1-monotherapy-doubles-os-vs-chemo-in2026-05-21https://www.sagelyhealth.com/cancer-trials/nct04429542-bca101-egfr-tgf-bifunctional-antibody-pembrolizumab-drives-54-orr2026-05-21https://www.sagelyhealth.com/cancer-trials/trastuzumab-deruxtecan-her2-adc-drives-67-recist-responses-in2026-05-21https://www.sagelyhealth.com/cancer-trials/nct04900623-react-1-0-hpv-ctdna-ttmv-hpv-dna-response2026-05-21https://www.sagelyhealth.com/cancer-trials/nct06159842-ala-pdt-20-aminolevulinic-acid-blue-light-delivers-1002026-05-21https://www.sagelyhealth.com/cancer-trials/nct05379985-daraxonrasib-rmc-6236-ras-on-multiselective-inhibitor-delivers-352026-05-21https://www.sagelyhealth.com/cancer-trials/nct03504397-zolbetuximab-anti-cldn18-2-mab-chemo-extends-pfs-to2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07574489-phase-2-3-prostate-sbrt-trial-tests-focal-dil2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07574541-phase-2-triadeno-psa-muc1-brachyury-ad5-vaccine-n2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07570979-phase-1-inr731-trial-tests-oral-investigational-agent-in2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07564232-phase-1-lnk001-dual-enpp3-caix-and-gated-car2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07567014-phase-2-emapalumab-ifn-neutralizing-antibody-to-prevent-bsab2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07539311-phase-2-rinatabart-sesutecan-rinas-fr-targeted-antibodydrug-conjugate2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07566364-phase-2-mosunetuzumab-cd20cd3-bispecific-antibody-tcell-engager-for2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07566585-phase-1-bsb-2002-mutant-npm1targeted-tcr-t-cellular2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07572136-phase-1-tslpr-cart-anti-tslpr-crlf2-car-t2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07565220-phase-1-thiotepa-based-conditioning-de-escalated-cyclophosphamide-dna2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07573111-phase-1-quail-100-lgna-100-attenuated-live-bacterial2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07572929-pragmatic-mrd-guided-maintenance-after-allo-hct-no-single2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07569263-phase-1-8r-70car-cd70-car-t-cxcr2-il2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07563738-phase-1-2-odm-212-pan-tead-hippo-yaptead2026-05-21https://www.sagelyhealth.com/cancer-trials/nct07563829-phase-1-npx372-b7-h7cd3-tcellengaging-bispecific-antibody-in2026-05-21https://www.sagelyhealth.com/cancer-trials/nct02861573-pembrolizumab-pd-1-lenvatinib-vegfr-fgfr-multikinase-posts-362026-05-14https://www.sagelyhealth.com/cancer-trials/abirateroneenzalutamide-ar-pathway-inhibition-adt-early-psa-0-2ng2026-05-14https://www.sagelyhealth.com/cancer-trials/nct06604442-18f-flotufolastat-rhpsma-7-3-psma-pet-lowers-bladder2026-05-14https://www.sagelyhealth.com/cancer-trials/nct05208944-thio-telomere-targeting-nucleoside-analog-sequential-cemiplimab-pd-12026-05-14https://www.sagelyhealth.com/cancer-trials/nct03916419-ctfe-tumor-naive-ctdna-burden-metric-predicts-os-pfs2026-05-14https://www.sagelyhealth.com/cancer-trials/nct04487080-amivantamab-egfr-met-bispecific-lazertinib-egfr-tki-suppresses-met2026-05-14https://www.sagelyhealth.com/cancer-trials/nct04619797-tiragolumab-antitigit-atezolizumab-pdl1-chemo-misses-pfs-os-vs2026-05-14https://www.sagelyhealth.com/cancer-trials/nct02855203-pembrolizumab-pd-1-radiotherapy-mdt-trends-toward-longer-pfs2026-05-14https://www.sagelyhealth.com/cancer-trials/nct03740529-pirtobrutinib-non-covalent-btk-inhibitor-drives-82-5-orr2026-05-14https://www.sagelyhealth.com/cancer-trials/nct01941641-folfoxiri-triplet-chemo-capecitabine-rt-delivers-20-5-pcr2026-05-14https://www.sagelyhealth.com/cancer-trials/nct03136185-bomedemstat-lsd1-inhibitor-shrinks-spleen-and-improves-fibrosis-markers2026-05-14https://www.sagelyhealth.com/cancer-trials/nct05745233-intraperitoneal-nivolumab-pd-1-blockade-yields-78-ascites-control2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07553390-phase-1b-trick-nk-trop2-targeted-car-nk-il2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07558733-phase-1b-2-piktor-serabelisib-pi3k-inhibitor-sapanisertib-dual2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07552181-phase-2-mo-03-live-biotherapeutic-microbiome-modulator-plus2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07560865-phase-1-ft536-mica-b-directed-car-nk-mica2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07492316-phase-1-rna-lp-vaccine-cmv-pp65lamp-mrna-autologous2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07562152-phase-3-atebimetinib-mek1-2-inhibitor-plus-modified-gnp2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07551583-phase-2-nivolumab-pd-1-checkpoint-inhibitor-plus-avd2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07551635-phase-2-fhd-286-smarca4-2-brg1-brm-atpase2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07560826-phase-2-methotrexate-dihydrofolate-reductase-inhibitor-optimizes-hdmtx-discharge2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07557056-phase-2-nemtabrutinib-reversible-non-covalent-btk-inhibitor-venetoclax2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07227311-phase-2-dreamm-15-belantamab-mafodotin-bcma-targeting-mmaf2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07552558-phase-1-2-ficerafusp-alfa-egfrtgf-bifunctional-antibody-with2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07455032-phase-2-cadi-05-polytlr-agonist-heatkilled-mycobacterium-indicus2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07558096-pilot-randomized-trial-of-avive-amnion-softtissue-barrier-to2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07416552-phase-1-cea-prit-2-0-pretargeted-alpha-therapy2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07493538-phase-2-treosulfan-fludarabine-conditioning-plus-ptcy-alkylator-based2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07456046-phase-1-d3s-003-dual-state-kras-g12d-inhibitor2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07488923-phase-1-ml261-dll3-targeted-car-t-with-card11pik3r32026-05-14https://www.sagelyhealth.com/cancer-trials/nct07519655-phase-1-pf-08046033-gpnmb-targeted-antibody-drug-conjugate2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07524322-phase-1-1b-rgt-490-mutant-selective-pi3k-inhibitor2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07229313-phase-1-kivu-107-ptk7-targeted-antibody-drug-conjugate2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07414836-phase-1a-1b-bg-c0979-adam9-targeted-adc-with2026-05-14https://www.sagelyhealth.com/cancer-trials/nct07488676-phase-1b-2-asp546c-cldn18-2-targeted-adc-with2026-05-14https://www.sagelyhealth.com/cancer-trials/nct04395677-taletrectinib-cns-penetrant-ros1-tki-posts-90-orr-and2026-05-07https://www.sagelyhealth.com/cancer-trials/nct05767359-cilta-cel-bcma-car-t-drives-100-mrd-1062026-05-07https://www.sagelyhealth.com/cancer-trials/nct05322590-bxq-350-saposin-c-nanovesicle-sphingolipid-homeostasis-modulator-mfolfox7-22026-05-07https://www.sagelyhealth.com/cancer-trials/nct00502684-perioperative-propranolol-blocker-etodolac-cox-2-inhibitor-shows-manageable2026-05-07https://www.sagelyhealth.com/cancer-trials/nct04379596-t-dxd-her2-adc-rilvegostomig-pd-1tigit-fluoropyrimidine-delivers2026-05-07https://www.sagelyhealth.com/cancer-trials/nct02706353-sotigalimab-intratumoral-cd40-agonist-pembrolizumab-delivers-50-orr-and2026-05-07https://www.sagelyhealth.com/cancer-trials/nct03748641-niraparib-parp-inhibitor-abiraterone-cyp17-inhibitor-drives-38-62026-05-07https://www.sagelyhealth.com/cancer-trials/cabazitaxel-microtubule-inhibitor-taxane-based-cabascore-stratifies-mcrpc-survival2026-05-07https://www.sagelyhealth.com/cancer-trials/nct03643549-bortezomib-26s-proteasome-nf-b-inhibition-sequential-temozolomide-extends2026-05-07https://www.sagelyhealth.com/cancer-trials/nct04948333-asciminib-stamp-abl-myristoyl-pocket-inhibitor-posts-39-week2026-05-07https://www.sagelyhealth.com/cancer-trials/therasphere-y-90-glass-microspheres-sirt-delivers-21-82026-05-07https://www.sagelyhealth.com/cancer-trials/short-course-blinatumomab-cd19cd3-bite-clears-mrd-in-b2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07544992-phase-1-egfr-il13r2-pool-car-t-cells-target2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07541781-phase-1b-sitagliptin-dpp-4-inhibitor-bevacizumab-anti-vegf2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07539441-phase-1-2-mirdametinib-mek1-2-inhibitor-tests-mapk2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07549958-phase-1b-pitavastatin-hmgcoa-reductase-inhibitor-plus-gemcitabine-nabpaclitaxel2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07545811-phase-1-janx014-psma-directed-cd3-t-cell-engager2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07548164-phase-2-nanoknife-ire-non-thermal-ablation-boost-vs2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07550517-phase-2-lutetium-lu-177-vipivotide-tetraxetan-psma-targeted2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07545954-phase-1b-dsp-0390-ebp-cholesterol-biosynthesis-inhibitor-plus2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07476287-phase-2-pf-08634404-pd1vegf-bispecific-antibody-with-platinum2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07538804-phase-1-2-ans02-trial-tests-a-4thgeneration-egfr2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07543172-phase-2-cimavaxegf-antiegf-vaccine-plus-kras-g12c-inhibitors2026-05-07https://www.sagelyhealth.com/cancer-trials/nct05208944-phase-2-ateganosine-thio-telomere-targeting-nucleoside-sequenced-with2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07475806-phase-2-enfortumab-vedotin-nectin-4-adc-pembrolizumab-pd2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07214532-phase-2-signateratm-ctdna-mrd-surveillance-to-time-cdk42026-05-07https://www.sagelyhealth.com/cancer-trials/nct07405801-phase-2-inavolisib-pi3k-inhibitor-ribociclib-cdk4-6-inhibitor2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07339384-phase-3-signatera-ctdna-mrd-assay-tumor-informed-personalized2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07549412-phase-3-precemtabart-tocentecan-ceacam5-adc-delivering-top1-inhibitor2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07550088-phase-2-balstilimab-pd-1-mab-botensilimab-fcenhanced-ctla42026-05-07https://www.sagelyhealth.com/cancer-trials/nct07147231-phase-1-2-pidnarulex-rna-pol-i-inhibitor-g2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07075185-phase-1-kln-1010-anti-bcma-car-gene-therapy2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07096778-phase-2-inobrodib-ccs1477-p300-cbp-bromodomain-inhibitor-with2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07426757-phase-1-pf-07994525-trial-in-r-r-multiple2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07544654-phase-3-obrixtamig-dll3cd3-bispecific-tcell-engager-plus-platinum2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07165132-phase-1-ryz401-actinium-225-sstr2-targeted-alpha-radiopharmaceutical2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07392892-phase-2-3-pf-08634404-pd-1vegf-bispecific-antibody2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07406633-phase-2-kqb198-imatinib-tests-egfr-targeted-protein-degrader2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07436364-pilot-definity-perflutren-lipid-microspheres-ceus-microbubble-perfusion-pressure2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07549022-phase-2-bms-986504-mta-cooperative-prmt5-inhibitor-for2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07192471-phase-1-kk2223-in-r-r-t-cell-nhl2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07548450-phase-2-mosunetuzumab-cd20cd3-bispecific-antibody-pirtobrutinib-noncovalent-btk2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07223814-phase-3-bleximenib-jnj-75276617-meninkmt2a-interaction-inhibitor-added2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07548983-phase-1-ruxolitinib-jak1-2-inhibitor-plus-azacitidine-dna2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07549464-phase-1-plm-102-flt3-inhibitor-next-generation-tyrosine2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07549451-phase-2-imetelstat-telomerase-inhibitor-in-mds-mpn-overlap2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07540572-phase-1-ide574-dual-kat6-kat7-lysine-acetyltransferase-inhibitor2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07544589-phase-1-disp-10-dv-10-oncolytic-adenovirus-bcma2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07439094-phase-1-2a-ckd-703-trial-tests-c-mettargeting2026-05-07https://www.sagelyhealth.com/cancer-trials/nct07541573-phase-1a-1b-gtb-5550-b7-h3targeted-trike-nk2026-05-07https://www.sagelyhealth.com/cancer-trials/nct03743298-dc-ata-personal-dendritic-cell-vaccine-pd-1-lag2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05533697-mrna-4359-pd-l1-ido1-mrna-immunotherapy-pembrolizumab-drives2026-04-30https://www.sagelyhealth.com/cancer-trials/nct02706353-sotigalimab-intratumoral-cd40-agonist-pembrolizumab-drives-50-orr-and2026-04-30https://www.sagelyhealth.com/cancer-trials/nct03141684-atezolizumab-pd-l1-delivers-37-month-dor-in-asps2026-04-30https://www.sagelyhealth.com/cancer-trials/nct00801489-flag-go-cd33-adc-lifts-5-year-os-to2026-04-30https://www.sagelyhealth.com/cancer-trials/nct03786081-tisotumab-vedotin-tissue-factor-adc-triplet-with-pembrolizumab-carbo2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04181827-cilta-cel-bcma-car-t-drives-71-30mo-pfs2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04910568-cevostamab-fcrh5cd3-bispecific-pom-dex-drives-8688-orr-and2026-04-30https://www.sagelyhealth.com/cancer-trials/nct03710603-d-vrd-daratumumab-anti-cd38-drives-65-sustained-mrd2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04524871-muzastotug-adg126-masked-anti-ctla-4-atezolizumab-bevacizumab-lifts2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04658147-perioperative-nivolumab-relatlimab-pd-1-lag-3-is-surgery2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04334759-durvalumab-pd-l1-platinum-pemetrexed-biomarker-signals-bap1-ddr2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04535713-metronomic-gemcitabine-doxorubicin-docetaxel-pd-1-nivolumab-posts-572026-04-30https://www.sagelyhealth.com/cancer-trials/nct04886804-zongertinib-her2-selective-irreversible-tki-hits-76-orr-and2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06332170-risvutatug-rezetecan-b7-h3-top1i-adc-adebrelimab-pd-l12026-04-30https://www.sagelyhealth.com/cancer-trials/nct04395677-taletrectinib-cns-penetrant-ros1-tki-delivers-55-8-orr2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06881784-daraxonrasib-rmc-6236-ras-on-tri-complex-inhibitor-moves2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05742607-iph5201-anti-cd39-durvalumab-pd-l1-platinum-chemo-posts2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06716138-ans03-type-ii-ros1-trk-tki-shows-54-52026-04-30https://www.sagelyhealth.com/cancer-trials/nct04750954-peposertib-m3814-dna-pk-inhibition-sensitizes-lu-177-dotatate2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05636618-212pb-vmt-net-sstr2-targeted-alpha-therapy-shows-392026-04-30https://www.sagelyhealth.com/cancer-trials/nct06555744-zw191-fr-targeted-adc-posts-52-unconfirmed-orr-in2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05257408-relacorilant-glucocorticoid-receptor-antagonist-nab-paclitaxel-cuts-death-risk2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05116189-pembrolizumab-pd-1-weekly-paclitaxel-extends-os-in-platinum2026-04-30https://www.sagelyhealth.com/cancer-trials/nct03643549-bortezomib-proteasome-inhibitor-nf-b-mgmt-suppression-temozolomide-shows2026-04-30https://www.sagelyhealth.com/cancer-trials/pax5-rearranged-pax5r-b-all-shows-mrd-driven-risk2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05714072-ruxolitinib-abemaciclib-cdk4-6-shows-44-svr35-in-rux2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05859750-cadonilimab-ak104-pd-1-ctla-4-bispecific-gem-nab2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06179069-zl-1310-dll3-targeted-topo-i-adc-drives-582026-04-30https://www.sagelyhealth.com/cancer-trials/nct06459869-ng-350a-cd40-agonist-oncolytic-adenoviral-vector-long-course2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04180371-bt5528-epha2-targeted-bicycle-drug-conjugate-delivering-mmae-nivolumab2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05405595-adg126-masked-anti-ctla-4-pembrolizumab-fruquintinib-drives-25502026-04-30https://www.sagelyhealth.com/cancer-trials/nct01910610-folfiricetuximab-egfr-mab-sequencing-fails-to-beat-bevacizumab-strategy2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05322590-bxq-350-saposin-c-nanovesicle-sphingolipid-homeostasis-modulator-mfolfox72026-04-30https://www.sagelyhealth.com/cancer-trials/nct04137289-bi-905711-trailr2-cdh17-bispecific-shows-biomarker-apoptosis-but2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06268015-botensilimab-fc-enhanced-anti-ctla-4-balstilimab-antipd-12026-04-30https://www.sagelyhealth.com/cancer-trials/marrow-ablative-high-dose-chemo-auhcr-plus-re-irradiation2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06885281-zl-1310-dll3-targeted-topo-i-adc-drives-482026-04-30https://www.sagelyhealth.com/cancer-trials/nct04855656-zedoresertib-wee1-lunresertib-pkmyt1-shows-early-tumor-shrinkage-in2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05410145-elisrasib-d3s-001-gdp-bound-kras-g12c-inhibitor-drives2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05381909-bgb-24714-smac-mimetic-iap-antagonist-shows-no-mtd2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05791448-au409-transcription-regulator-tata-box-modulation-shows-11-pr2026-04-30https://www.sagelyhealth.com/cancer-trials/nct05568680-synkir-110-mesothelin-kir-car-dap12-shows-early-tumor2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06171750-tolododekin-alfa-ank-101-anchored-il-12-drives-cd82026-04-30https://www.sagelyhealth.com/cancer-trials/nct06270706-pln-101095-dual-v8-v1-integrin-tgf-activation-blocker2026-04-30https://www.sagelyhealth.com/cancer-trials/nct06463340-sgr-3515-wee1-myt1-dual-inhibitor-shows-manageable-g32026-04-30https://www.sagelyhealth.com/cancer-trials/nct06719362-m3t01-anti-fasl-shows-60-stable-disease-and-clean2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07529405-phase-2-vg712-anti-cd3-immunotoxin-diphtheria-toxin-fusion2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07522073-phase-3-incb161734-kras-g12dselective-inhibitor-plus-chemo-in2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07527169-phase-2-zanzalintinib-c-met-vegfr-tyrosine-kinase-inhibitor2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07527325-phase-2-fianlimab-cemiplimab-tests-dual-lag-3-pd2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07528352-phase-1b-rebel-tests-ebrt-then-epcoritamab-glofitamab-cd20cd32026-04-30https://www.sagelyhealth.com/cancer-trials/nct07530172-phase-2-yttrium-90-tare-beta-radiation-embolization-versus2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07535437-phase-1-2-ivonescimab-pd-1vegf-a-bispecific-with2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07535463-phase-1-2-ivonescimab-pd-1vegf-a-bispecific-antibody2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07528638-pilot-feasibility-study-uses-ionm-for-nerve-identification-during2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07524855-phase-1-hld-0117-oral-riptac-with-no-disclosed2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07529717-phase-1-2-azd8359-steap2-targeted-cd8-guided-t2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07521657-phase-2-mirdametinib-mek1-2-inhibitor-with-radiotherapy-in2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07533942-phase-2-jzp3507-onc206-dopamine-receptor-d2-antagonist-small2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07535112-phase-1-bay-3771249-kras-g12d-selective-inhibitor-egfr2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07530536-phase-1-rtms-targets-motor-network-rebalancing-via-theta2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07532525-phase-1-pomalidomide-imid-cereblon-modulator-to-boost-cd192026-04-30https://www.sagelyhealth.com/cancer-trials/nct07524530-phase-2-haploidentical-hsct-using-cyclophosphamide-busulfan-or-fludarabine2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07469891-phase-1-prt12396-mutant-selective-jak2v617f-inhibitor-allosteric-jh22026-04-30https://www.sagelyhealth.com/cancer-trials/nct07532902-phase-1a-1b-bms-986504-mta-cooperative-prmt5-inhibitor2026-04-30https://www.sagelyhealth.com/cancer-trials/nct07524348-phase-1-e303-nectin-4targeting-antibody-drug-conjugate-in2026-04-30https://www.sagelyhealth.com/cancer-trials/nct04644237-trastuzumab-deruxtecan-her2-adc-posts-5056-orr-in-her22025-09-12https://www.sagelyhealth.com/cancer-trials/nct06017258-cd371-savvy-il-18-armored-car-t-clears-32025-09-12https://www.sagelyhealth.com/cancer-trials/nct03083873-lifileucel-ln-145-autologous-til-posts-11-orr-and2025-09-12https://www.sagelyhealth.com/cancer-trials/nct04238819-abemaciclib-cdk4-6-temozolomide-irinotecan-delivers-durable-cr-in2025-09-12https://www.sagelyhealth.com/cancer-trials/folfoxiri-bevacizumab-vegf-extends-pfs-vs-doublets-in-unresectable2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07146230-phase-ii-randomized-durvalumab-monalizumab-nkg2a-vs-durva-oleclumab2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07145177-phase-ib-177lu-psma-617-liver-directed-therapy-for2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07142967-phase-ib-elekta-unity-mr-linac-salvage-sbrt-short2025-09-12https://www.sagelyhealth.com/cancer-trials/nct06315257-phase-i-pbi-11-hpv16-18-dna-vaccine-ta2025-09-12https://www.sagelyhealth.com/cancer-trials/nct06169280-phase-i-nsc-crad-s-pk7-oncolytic-adenovirus-nac2025-09-12https://www.sagelyhealth.com/cancer-trials/nct06953960-phase-1-2-abbv-453-bcl-2-inhibitor-daratumumab2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07049926-phase-1b-2-zanzalintinib-c-met-vegfr-tki-belzutifan2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07128680-phase-i-nivolumab-ipilimumab-exl01-live-biotherapeutic-in-mrcc2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07139977-phase-ii-enfortumab-vedotin-nectin-4-adc-in-recurrent2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07126158-phase-ii-adaptive-sbrt-defactinib-fak-avutometinib-raf-mek2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07137494-phase-i-mb-cart19-1-cd19-car-t-for2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07011576-phase-ii-fruquintinib-vegfr-folfiri-in-second-line-mcrc2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07139951-phase-ii-p-hipec-with-cisplatin-paclitaxel-during-gastrectomy2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07148947-phase-ii-pacritinib-jak2-flt3-inhibitor-bridge-in-accelerated2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07144384-phase-i-ud-expanded-nk-vs-tgf-imprinted-nk2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07141706-phase-1a-1b-db-1317-adam9-directed-topo-i2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07021066-phase-i-bl-m05d1-cldn18-2-directed-topo-i2025-09-12https://www.sagelyhealth.com/cancer-trials/nct06535607-phase-ii-evolve-02-volrustomig-medi5752-pd-1-ctla2025-09-12https://www.sagelyhealth.com/cancer-trials/nct07148050-phase-i-sc-car-gpc3xil15-21-pediatric-aya-car2025-09-12https://www.sagelyhealth.com/cancer-trials/nct06946225-phase-ib-ima203-prame-tcr-t-mrna-4203-prame2025-09-12https://www.sagelyhealth.com/cancer-trials/nct02405221-hpv16-l2-e7-e6-vaccine-ta-cin-thigh-injection2025-09-05https://www.sagelyhealth.com/cancer-trials/nct03220646-abemaciclib-cdk4-6-hits-68-pfs6-in-recurrent-grade2025-09-05https://www.sagelyhealth.com/cancer-trials/nct05026983-encorafenib-binimetinib-braf-mek-produces-rapid-lmd-response-and2025-09-05https://www.sagelyhealth.com/cancer-trials/nct03325634-sbrt-ablative-radiotherapy-yields-95-1-yr-local-control2025-09-05https://www.sagelyhealth.com/cancer-trials/nct04390737-haihes-hh2853-ezh1-2-dual-achieves-31-orr-162025-09-05https://www.sagelyhealth.com/cancer-trials/nct07136077-phase-2-fruquintinib-vegfr-inhibitor-and-tislelizumab-pd-12025-09-05https://www.sagelyhealth.com/cancer-trials/nct07137390-phase-ib-ii-regorafenib-multikinase-inhibitor-plus-lorigerlimab-pd2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07128355-phase-1b-botensilimab-ctla-4-mab-balstilimab-pd-12025-09-05https://www.sagelyhealth.com/cancer-trials/nct07128641-phase-ii-odronextamab-bispecific-cd20-cd3-antibody-for-follicular2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07137481-phase-ii-study-ic9-cd5car-il-15-nk-cells2025-09-05https://www.sagelyhealth.com/cancer-trials/nct06802523-phase-i-trial-of-lintuzumab-ac-225-a-cd332025-09-05https://www.sagelyhealth.com/cancer-trials/nct07130695-phase-2-olutasidenib-idh1-inhibitor-aml-maintenance-trial2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07133425-phase-2-sar445877-pd-1-il-15-fusion-protein2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07137871-phase-i-trial-of-avasopasem-a-superoxide-dismutase-mimetic2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07103018-phase-1-study-of-ktx2001-nsd2-inhibitor-with-darolutamide2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07093554-phase-ib-talquetamab-bispecific-targeting-gprc5d-cd3-and-cilta2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07132918-phase-2-hearts-trial-mrgart-mri-guided-adaptive-radiotherapy2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07132190-phase-ii-trial-of-linac-stereotactic-radiation-delivering-precise2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07118202-phase-1-therabionic-p1-device-electromagnetic-modulation-therapy-for2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07104331-phase-ii-nab-sirolimus-trial-nanoparticle-albumin-bound-mtor2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07132645-phase-i-trial-of-68ga-ga-fapi-04-a2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07133997-phase-1-1b-trial-venetoclax-bcl-2-inhibitor-in2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07136571-phase-i-trial-bland-particles-embolization-with-arterial-occlusion2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07030959-phase-i-study-of-aube00-an-oral-kras-targeting2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07136779-phase-1-2a-vbc101-egfr-and-cmet-targeted-bispecific2025-09-05https://www.sagelyhealth.com/cancer-trials/nct07109726-phase-1-2-ter-2013-undisclosed-target-trial-in2025-09-05https://www.sagelyhealth.com/cancer-trials/nct03676192-ct-p16-bevacizumab-biosimilar-anti-vegf-matches-reference-bevacizumab2025-08-29https://www.sagelyhealth.com/cancer-trials/nct06241352-atorvastatin-hmg-coa-chemotherapy-shows-70-3-tumor-marker2025-08-29https://www.sagelyhealth.com/cancer-trials/eli-002-2p-mkras-amphiphile-links-strong-t-cell2025-08-29https://www.sagelyhealth.com/cancer-trials/nct05789589-azeliragon-rage-srs-posts-100-8-wk-per-patient2025-08-29https://www.sagelyhealth.com/cancer-trials/nct03685890-melphalan-ilp-regional-alkylator-cd8-phenotype-predicts-cr-in2025-08-29https://www.sagelyhealth.com/cancer-trials/nct04002947-ultrasensitive-ctdna-mrd-outperforms-pet-for-defining-remission-in2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07060807-phase-3-patritumab-deruxtecan-study-of-her3-directed-adc2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07114679-pilot-sbir-trial-mbi-guided-biopsy-using-radiotracer-uptake2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07122713-phase-1-pilot-study-of-breast-radiation-ionizing-dna2025-08-29https://www.sagelyhealth.com/cancer-trials/nct06679101-phase-3-belantamab-mafodotin-trial-bcma-targeting-adc-in2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07116616-phase-1-2-mrna-2808-mrna-gene-therapy-vaccine2025-08-29https://www.sagelyhealth.com/cancer-trials/nct06973096-phase-1-cart-egfr-il13r2-cells-targeting-egfr-and2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07024615-phase-1b-study-of-asp2138-a-cldn18-2-directed2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07123090-phase-2-sasanlimab-pd-1-mab-trial-for-advanced2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07082920-phase-1b-study-jnj-78278343-klk2-cd3-bispecific-and2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07005154-phase-2-asp5541-abiraterone-decanoate-cyp17-inhibitor-in-advanced2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07005128-phase-3-trial-of-tarlatamab-a-dll3-cd3-bispecific2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07121595-phase-ii-trial-of-carboplatin-a-platinum-based-dna2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07097363-phase-ii-trial-epcoritamab-bispecific-antibody-cd20-cd3-plus2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07082803-phase-1-trial-of-tln-121-a-talin-12025-08-29https://www.sagelyhealth.com/cancer-trials/nct07123454-phase-i-ii-trial-of-azd4512-a-cd22directed-antibody2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07089992-phase-2-pembrolizumab-pd-1-inhibitor-study-in-ultra2025-08-29https://www.sagelyhealth.com/cancer-trials/nct06901531-phase-3-zolbetuximab-cldn18-2-mab-trial-in-advanced2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07124117-phase-1-2-obi-902-trop-2-antibody-drug2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07124351-phase-1-trial-of-cytaluxtm-pafolacianine-folate-receptor-targeted2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07123103-phase-1-trial-of-xb371-topoisomerase-inhibitor2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07114601-phase-1a-b-study-of-ly4257496-a-grpr-targeted2025-08-29https://www.sagelyhealth.com/cancer-trials/nct07115043-phase-i-ii-trial-of-azd6750-cd8-guided-il2025-08-29https://www.sagelyhealth.com/cancer-trials/nct02777385-sequential-pembrolizumab-pd-1-tops-concurrent-for-4-yr2025-08-22https://www.sagelyhealth.com/cancer-trials/nct01898494-ecog-acrin-e3311-tos-reduced-dose-rt-yields-542025-08-22https://www.sagelyhealth.com/cancer-trials/nct03772899-fmt-anti-pd-1-delivers-65-orr-and-mpfs2025-08-22https://www.sagelyhealth.com/cancer-trials/nct04303780-sotorasib-kras-g12c-improves-cns-pfs-vs-docetaxel-in2025-08-22https://www.sagelyhealth.com/cancer-trials/nct05194982-bl-b01d1-egfrher3-adc-corr-5467-in-exon20-her22025-08-22https://www.sagelyhealth.com/cancer-trials/nct04404088-acalabrutinib-lenalidomide-rituximab-btk-imid-cd20-hits-92-cr2025-08-22https://www.sagelyhealth.com/cancer-trials/nct03679455-obinutuzumab-cd20-induction-maintenance-delivers-65-orr-in-relapsed2025-08-22https://www.sagelyhealth.com/cancer-trials/nct05664217-nktr-255-il-15r-agonist-lifts-6-mo-cr2025-08-22https://www.sagelyhealth.com/cancer-trials/nct07112053-phase-ii-stemvac-dna-vaccine-targeting-breast-cancer-stem2025-08-22https://www.sagelyhealth.com/cancer-trials/nct06982521-phase-3-trial-rly-2608-a-pi3k-alpha-inhibitor2025-08-22https://www.sagelyhealth.com/cancer-trials/nct07108998-phase-2-trial-epcoritamab-cd20-cd3-bispecific-antibody2025-08-22https://www.sagelyhealth.com/cancer-trials/nct07110233-phase-2-trial-of-therasphere-yttrium-90-microspheres-for2025-08-22https://www.sagelyhealth.com/cancer-trials/nct07111507-phase-2-tarlatamab-study-dll3-cd3-bispecific-antibody-in2025-08-22https://www.sagelyhealth.com/cancer-trials/nct07105059-phase-1b-teclistamab-bcma-cd3-bispecific-antibody-and-mezigdomide2025-08-22https://www.sagelyhealth.com/cancer-trials/nct07106762-phase-2-3-izalontamab-brengitecan-egfr-her3-bispecific-adc2025-08-22https://www.sagelyhealth.com/cancer-trials/nct07107750-phase-i-trial-of-ca-4948-irak4-flt3-inhibitor2025-08-22https://www.sagelyhealth.com/cancer-trials/nct06458712-phase-ia-b-study-of-dsb2455-a-parp1-inhibitor2025-08-22https://www.sagelyhealth.com/cancer-trials/nct04552886-doc1021-autologous-dc-vaccine-hits-88-12-mo-os2025-08-15https://www.sagelyhealth.com/cancer-trials/nct03617679-parp-inhibitor-rucaparib-extends-pfs-to-28-mo-in2025-08-15https://www.sagelyhealth.com/cancer-trials/nct03037385-pralsetinib-selective-ret-tki-ctdna-clearance-flags-12-mo2025-08-15https://www.sagelyhealth.com/cancer-trials/nct04767009-consolidative-srt-after-1l-chemo-io-yields-29-mo2025-08-15https://www.sagelyhealth.com/cancer-trials/nct04180176-ctdna-tumor-fraction-clearance-predicts-longer-rwpfs-os-in2025-08-15https://www.sagelyhealth.com/cancer-trials/avapritinib-kit-d816v-beats-midostaurin-cladribine-on-os-in2025-08-15https://www.sagelyhealth.com/cancer-trials/nct05025800-evorpacept-cd47-lenalidomide-rituximab-achieves-80-cr-in-r2025-08-15https://www.sagelyhealth.com/cancer-trials/nct01991873-panitumumab-egfr-maintenance-spatial-immune-markers-predict-benefit-in2025-08-15https://www.sagelyhealth.com/cancer-trials/selinexor-xpo1-yields-13-6-mo-mpfs-in-thymoma2025-08-15https://www.sagelyhealth.com/cancer-trials/tar-200-intravesical-gemcitabine-device-posts-82-cr-in2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07078604-phase-ii-stemvac-dna-vaccine-targeting-breast-cancer-stem2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07076485-phase-ii-hypofractionated-ebrt-fine-tuning-targeted-ionizing-radiation2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07090148-phase-1b-ptvg-hp-dna-vaccine-and-sasanlimab-pd2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07098338-phase-ii-trial-dato-dxd-trop2-directed-adc-in2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07098988-phase-2b-trial-of-visugromab-antigdf15-monoclonal-antibody-in2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06925295-phase-1-expansion-xemri-guided-sbrt-using-xenon-contrast2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07076121-phase-2-3-trial-of-bms-986504-a-selective2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07089940-phase-1-trial-of-omo-103-a-myc-inhibitor2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07076212-phase-2-nalirifox-trial-with-liposomal-irinotecan-topoisomerase-i2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07096362-phase-2-mfolfirinox-trial-with-irinotecan-topoisomerase-i-inhibition2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07076472-phase-1b-sonala-001-protoporphyrin-ix-ros-activator-with2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07087002-phase-1-trial-of-gpc2-car-t-cells-targeting2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07076498-phase-1-trial-of-m032-il-12-producing-hsv2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07031765-phase-1-champ1on-nivolumab-pd-1-inhibitor-for-pediatric2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07089758-phase-1-pilot-study-cerebral-open-flow-microperfusion-device2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07087860-phase-ii-therapeutic-plasma-exchange-enfortumab-vedotin-nectin-42025-08-15https://www.sagelyhealth.com/cancer-trials/nct07078838-phase-1b-tirzepatide-study-targets-insulin-fat-metabolism-and2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07082270-phase-i-trial-of-gb1211-oral-galectin-3-inhibitor2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07094685-phase-ii-trial-of-ivonescimab-a-pd-1-vegf2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06644781-phase-3-study-of-ifinatamab-deruxtecan-a-b7-h32025-08-15https://www.sagelyhealth.com/cancer-trials/nct07060014-phase-2-nalirifox-trial-liposomal-irinotecan-topoisomerase-i-inhibitor2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07092514-phase-ii-lenvatinib-trial-multikinase-inhibitor-for-radioactive-iodine2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07077083-phase-1-pilot-89zr-girentuximab-anti-caix-imaging-agent2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07075120-phase-1b-study-ipilimumab-ctla-4-mab-and-nivolumab2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07076186-phase-ii-doxorubicin-trabectedin-trial-dna-synthesis-and-tubulin2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07082868-phase-ib-trial-epcoritamab-cd20-cd3-bispecific-antibody-for2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07082439-phase-ii-pembrolizumab-pd-1-inhibitor-plus-odetiglucan-immune2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07085091-phase-1-alx2004-antibody-drug-conjugate-targeting-egfr-in2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07021898-phase-1-trial-of-eras-4001-a-pan-kras2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06894771-phase-1-study-of-mk-4700-investigational-immune-modulator2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06994806-phase-1-study-of-kqb168-an-investigational-anti-tumor2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06974110-phase-1-moma-341-study-novel-dna-damage-response2025-08-15https://www.sagelyhealth.com/cancer-trials/nct07090122-pilot-phase-rfa-ba-rt-for-metastatic-spine-lesions2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06892379-phase-i-trial-of-hs-20110-a-novel-antibody2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06708897-phase-1-ze50-0134-investigational-bcl2-inhibitor-in-relapsed2025-08-15https://www.sagelyhealth.com/cancer-trials/nct06994676-phase-1-study-of-cbx-250-an-investigational-cathepsin2025-08-15https://www.sagelyhealth.com/cancer-trials/nct03822351-durvalumab-oleclumab-cd73-or-monalizumab-nkg2a-lowers-pfs-hazard2025-08-01https://www.sagelyhealth.com/cancer-trials/nct03915951-encorafenib-binimetinib-braf-mek-delivers-75-orr-and-302025-08-01https://www.sagelyhealth.com/cancer-trials/nct02677324-finitecourse-venetoclax-bcl2-delivers-36-mo-median-pfs-in2025-08-01https://www.sagelyhealth.com/cancer-trials/ibrutinib-rituximab-btk-cd20-lifts-48mo-pfs-to-722025-08-01https://www.sagelyhealth.com/cancer-trials/nct03944941-avelumab-cetuximab-pdl1-egfr-halves-progression-risk-vs-avelumab2025-08-01https://www.sagelyhealth.com/cancer-trials/nct04464200-calibrated-cd191xx-car-t-achieves-75-cr-with-only2025-08-01https://www.sagelyhealth.com/cancer-trials/nct04972097-nanoknife-ire-yields-71-12mo-negative-biopsy-while-preserving2025-08-01https://www.sagelyhealth.com/cancer-trials/nct05343013-lonsurf-tas102-nudges-ctdna-clearance-to-36-and-extends2025-08-01https://www.sagelyhealth.com/cancer-trials/nct03783936-avelumab-trastuzumab-folfox-posts-61-early-response-and-82025-08-01https://www.sagelyhealth.com/cancer-trials/bhv1510-trop2topoix-adc-shrinks-tumors-in-6-6-patients2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06966453-phase-1b-2-disitamab-vedotin-adc-tubulin-inhibitor-in2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07069595-phase-ii-dato-dxd-adc-targeting-trop2-and-topoisomerase2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07063745-phase-2-3-trial-of-bms-986504-a-selective2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07073183-phase-i-cvhnlc-mrna-immunotherapy-plus-pembrolizumab-pd-12025-08-01https://www.sagelyhealth.com/cancer-trials/nct06732401-phase-iii-trial-durvalumab-with-azd6738-atr-inhibitor-in2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06780085-phase-2-raludotatug-deruxtecan-cdh6targeted-adc-with-an-enzymatically2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07047118-phase-ii-trial-of-jsb462-ar-inhibitor-with-177lu2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07070466-phase-ii-trial-of-ivonescimab-a-pd1-vegf-bispecific2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07069712-phase-ii-trial-azd0901-cldn18-2-adc-and-rilvegostomig2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06731478-phase-3-trial-of-trastuzumab-deruxtecan-a-her2-directed2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07073547-phase-1-gc012f-dual-car-t-cell-therapy-targeting2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07032714-phase-1-trial-mezigdomide-cereblon-e3-ligase-modulator-talquetamab2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06974786-phase-ii-trial-of-elranatamab-a-bcma-cd3-bispecific2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07062549-phase-1-study-of-111in-xyimsr-01-radiotracer-for2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07037004-phase-ii-trial-cbm588-microbiome-modulator-with-pembrolizumab-pd2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07062003-phase-1-mbrt-tungstenslit-collimator-enables-spatially-fractionated-minibeam2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06852222-phase-3-trial-bleximenib-menin-mll-inhibitor-for-acute2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06788756-phase-2-3-trial-of-l-annamycin-topoisomerase-ii2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07053020-phase-1b-2-cladribine-trial-dna-synthesis-inhibitor-in2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07052994-phase-ia-ib-revumenib-menin-mll-inhibitor-trial-in2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07008638-phase-i-ii-bortezomib-26s-proteasome-inhibitor-with-cpx2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06824168-phase-2-quizartinib-flt3-inhibitor-trial-in-aml-maintenance2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07060001-phase-1b-venetoclax-bcl-2-inhibitor-trial-comparing-hma2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07065552-phase-1-pre-operative-tirzepatide-study-dual-gip-glp2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07052695-phase-1b-mosunetuzumab-cd20-cd3-bispecific-mab-trial-in2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06915025-phase-3-trial-ip-imnn-001-a-firstinclass-peritoneal2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06682988-phase-2-mirvetuximab-soravtansine-adc-targeting-folr1-with-tubulin2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06698458-phase-1b-alpha-dart-diffusing-alpha-radiation-emitter-for2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06850623-phase-2-acoustic-cluster-therapy-ultrasound-triggered-microbubble-enhancer2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07033689-phase-1-study-of-suizenji-ultrasound-guided-hifu-ablation2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07052305-phase-1b-trial-of-nt-i7-a-long-acting2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06649812-phase-ii-venetoclax-bcl-2-inhibitor-trial-for-relapsed2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07030699-phase-1b-epcoritamab-bispecific-antibody-cd20-cd4-trial-in2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07044635-phase-2-brachytherapy-radiation-device-delivering-targeted-radiation-induced2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07063212-phase-ii-sacituzumab-govitecan-trop2-directed-adc-and-cetuximab2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07065630-phase-ii-medi5752-ctla-4-pd-1-bispecific-mab2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06532279-phase-ii-trial-of-bmx-001-a-manganese-superoxide2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07071961-phase-1b-regorafenib-and-lorigerlimab-in-colorectal-cancer-multi2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07039760-phase-1-study-asciminib-a-bcr-abl-inhibitor-with2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06818643-phase-1-2-mk-3120-trial-of-a-selective2025-08-01https://www.sagelyhealth.com/cancer-trials/nct04906434-phase-1-absk-011-a-novel-kinase-inhibitor-in2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06884618-phase-i-study-of-ro7673396-a-ras-pathway-inhibitor2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06847867-phase-2-momelotinib-trial-jak1-jak2-inhibitor-for-low2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07064122-phase-i-ii-study-of-azd2962-an-irak4-inhibitor2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06552416-phase-1-zedenoleucel-trial-multi-target-primed-allogeneic-t2025-08-01https://www.sagelyhealth.com/cancer-trials/nct06969430-phase-1-2-trial-of-debio-1562m-novel-inhibitor2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07032727-phase-1b-olutasidenib-idh1-inhibitor-trial-in-idh1-mutated2025-08-01https://www.sagelyhealth.com/cancer-trials/nct07052370-phase-i-blinatumomab-bispecific-cd19-directed-antibody-combined-with2025-08-01https://www.sagelyhealth.com/cancer-trials/nct03639948-biomarker-duo-stils-tnbc-dx-flags-91-pcr-with2025-07-25https://www.sagelyhealth.com/cancer-trials/nct03546829-gut-targeted-vancomycin-boosts-sbrt-survival-in-early-stage2025-07-25https://www.sagelyhealth.com/cancer-trials/nct04449874-divarasib-delivers-56-orr-and-14-mo-pfs-in2025-07-25https://www.sagelyhealth.com/cancer-trials/nct02519322-neoadjuvant-nivo-relatlimab-pd-1-lag-3-yields-802025-07-25https://www.sagelyhealth.com/cancer-trials/nct03767348-oncolytic-hsv1-rp1-plus-pd1-blockade-yields-33-orr2025-07-25https://www.sagelyhealth.com/cancer-trials/nct03564912-biweekly-capecitabine-oxaliplatin-capox-slashes-cytopenias-while-matching-3yr2025-07-25https://www.sagelyhealth.com/cancer-trials/nct05262491-egfrher3-bispecific-adc-logs-40-responses-in-pd1refractory-metastatic2025-07-25https://www.sagelyhealth.com/cancer-trials/regorafenib-benefit-survives-bias-checks-hr-0-71-in2025-07-25https://www.sagelyhealth.com/cancer-trials/avutometinib-defactinib-delivers-31-orr-44-in-krasmut-in2025-07-25https://www.sagelyhealth.com/cancer-trials/nct03326193-parp-vegf-duo-niraparib-bevacizumab-posts-61-month-os2025-07-25https://www.sagelyhealth.com/cancer-trials/brentuximab-vedotin-pembrolizumab-yields-88-pre-asct-cmr-in2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06966700-phase-3-sac-tmt-adc-trop2-directed-antibody-drug2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07053085-phase-ii-trastuzumab-her2-directed-mab-trial-combining-surgery2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06780098-phase-2-trial-of-raludotatug-deruxtecan-adc-targeting-cdh62025-07-25https://www.sagelyhealth.com/cancer-trials/nct07053007-phase-1-nk-102-umbilical-cord-blood-nk-cells2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07038915-phase-2-tiragolumab-tigit-mab-and-ivonescimab-pd-12025-07-25https://www.sagelyhealth.com/cancer-trials/nct06712355-phase-iii-bnt327-vegfa-directed-mab-trial-in-extensive2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07049055-phase-i-iia-trial-of-e-edv-d682-nanocells2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07043270-phase-2-trial-gemcitabine-ribonucleotide-reductase-inhibitor-and-nab2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07030283-phase-1-pilot-paclitaxel-tubulin-inhibitor-and-nalirifox-in2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06961006-phase-2-trial-v940-mrna-cancer-vaccine-pembrolizumab-pd2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07049276-phase-2-anti-pd-1-checkpoint-inhibitor-trial-comparing2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07060365-phase-i-ii-saruparib-parp1-inhibitor-trial2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07000084-phase-iii-trial-gemcitabine-dna-synthesis-inhibitor-plus-intravesical2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07048457-phase-ii-study-enfortumab-vedotin-nectin-4-adc-consolidative2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07043972-phase-ii-study-gemcitabine-ribonucleotide-reductase-inhibitor-and-carboplatin2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06668493-phase-1-2-trial-of-nadofaragene-firadenovec-ifn-alpha2b2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06990880-phase-1-2-study-of-gsk5458514-a-psma-targeting2025-07-25https://www.sagelyhealth.com/cancer-trials/nct05983198-phase-i-ii-trial-of-225ac-psma-r2-psma2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06991556-phase-ii-trial-of-jsb462-novel-androgen-receptor-antagonist2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06990542-phase-ii-tumor-focused-radiotherapy-image-guided-brachytherapy-radiation2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07054346-phase-1-pilot-225ac-psma-617-alpha-emitter-targeting2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07050836-phase-1b-definity-microbubble-ultrasound-contrast-agent-for-enhanced2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06860594-phase-i-trial-of-triapine-ribonucleotide-reductase-inhibitor-with2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07055477-phase-i-ccr4-car-t-cells-gene-therapy-targeting2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07049432-phase-i-n-803-study-of-il-15-agonist2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07047885-phase-i-ib-ropeginterferon-trial-targeting-interferon-a2b-protein2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07042438-phase-ii-trial-of-axicabtagene-ciloleucel-a-cd19-targeted2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07042919-phase-ib-ii-zanzalintinib-trial-cmet-vegfr-inhibitor-for2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07059494-phase-1-feasibility-trial-atezolizumab-pd-l1-mab-bevacizumab2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07044362-phase-1-trial-histosonics-histotripsy-ultrasound-cavitation-tissue-ablation2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07042685-phase-ii-trial-of-fruquintinib-vegfr-inhibitor-with-5fu2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07043608-phase-ii-zanzalintinib-cmet-vegfr-inhibitor-for-metastatic-clear2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07060261-phase-2-gdcontrast-gadolinium-agent-enhances-t1-relaxation-for2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07059611-phase-ii-rp2-hsv-1-oncolytic-virus-trial-with2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07043400-phase-3-trial-of-tislelizumab-pd-1-inhibitor-in2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07038278-phase-1-trial-of-5-ala-tumortargeted-fluorescent-imaging2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07049848-phase-ii-trial-atezolizumab-pd-l1-mab-doxorubicin-dna2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07050186-phase-ii-cemiplimab-pd-1-inhibitor-trial-in-incurable2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07040982-phase-i-asciminib-bcr-abl-inhibitor-study-in-post2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07053059-phase-2-study-of-obecabtagene-autoleucel-a-cd19-directed2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07059975-pilot-trial-venetoclax-bcl2-inhibitor-in-pediatric-aml-chemotherapy2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07060989-phase-1-2a-trial-of-nts071-a-tp53-y220c2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07038343-phase-1-2-avzo-1418-trial-of-investigational-tyrosine2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07057349-phase-1-18f-csb-321-radiolabeled-pet-imaging-agent2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07052760-phase-1-pilot-111in-abd147-dll3-targeting-imaging-agent2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06745024-phase-3-trial-radiation-therapy-dna-damaging-agent-for2025-07-25https://www.sagelyhealth.com/cancer-trials/nct06351527-phase-i-trial-of-icp-248-novel-b-cell2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07046078-phase-ii-flag-ida-trial-fludarabine-and-cytarabine-as2025-07-25https://www.sagelyhealth.com/cancer-trials/nct07008118-phase-1-inca035784-bispecific-mab-targeting-calrmut-and-cd32025-07-25https://www.sagelyhealth.com/cancer-trials/nct01817192-platinum-doublet-lifts-2-year-dfs-to-96-in2025-07-11https://www.sagelyhealth.com/cancer-trials/nct03875820-avutometinib-defactinib-raf-mek-clamp-fak-blocker-posts-422025-07-11https://www.sagelyhealth.com/cancer-trials/nct03200847-pembrolizumab-atra-mdsc-targeting-posts-55-5-year-os2025-07-11https://www.sagelyhealth.com/cancer-trials/nct04300140-gas6-axl-blocking-batiraxcept-cabozantinib-yields-43-orr-in2025-07-11https://www.sagelyhealth.com/cancer-trials/nct04787263-fresh-cd19-car-t-achieves-100-mrd-neg-cr2025-07-11https://www.sagelyhealth.com/cancer-trials/nct02101853-blinatumomab-cd19-bite-sees-28-attrition-after-toxic-uk2025-07-11https://www.sagelyhealth.com/cancer-trials/nct06568939-phase-2-study-of-telisotuzumab-vedotin-cmettargeted-adc-with2025-07-11https://www.sagelyhealth.com/cancer-trials/nct06439836-phase-1-trial-of-ca-4948-irak4-flt3-inhibitor2025-07-11https://www.sagelyhealth.com/cancer-trials/nct05827081-phase-iiib-study-ribociclib-cdk4-cdk6-inhibitor-in-hr2025-07-11https://www.sagelyhealth.com/cancer-trials/nct06654037-phase-1-abemaciclib-cdk4-cdk6-inhibitor-and-5-fluorouracil2025-07-11https://www.sagelyhealth.com/cancer-trials/nct06824701-phase-1b-trial-tazemetostat-ezh2-inhibitor-with-zanubrutinib-btk2025-07-11https://www.sagelyhealth.com/cancer-trials/nct06723236-phase-1-trial-of-mgc028-an-adam9-directed-topo2025-07-11https://www.sagelyhealth.com/cancer-trials/nct06311214-phase-ii-adc-match-sacituzumab-govitecan-trop2-adc-enfortumab2025-07-11https://www.sagelyhealth.com/cancer-trials/nct07042100-phase-1-sbo-154-trial-of-novel-muc1-adc2025-07-11https://www.sagelyhealth.com/cancer-trials/nct06514794-phase-2-wu-cart-007-cd7-targeted-car-t2025-07-11https://www.sagelyhealth.com/cancer-trials/brca-palb2-mutations-cut-real-world-pfs-to-112025-07-03https://www.sagelyhealth.com/cancer-trials/nct06072612-bria-imt-vaccine-pembrolizumab-shrinks-brain-mets-in-52025-07-03https://www.sagelyhealth.com/cancer-trials/nct03298087-6-mo-triple-ar-blockade-metastasis-directed-rt-yields2025-07-03https://www.sagelyhealth.com/cancer-trials/nct01130519-vegf-blocker-bevacizumab-egfr-tki-erlotinib-delivers-72-orr2025-07-03https://www.sagelyhealth.com/cancer-trials/nct04521231-subcutaneous-blinatumomab-achieves-77-cr-in-relapsed-refractory-b2025-07-03https://www.sagelyhealth.com/cancer-trials/nct04797767-ven-clag-m-nabs-65-cr-in-adverse-risk2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06790693-phase-3-inavolisib-pi3k-inhibitor-trial-in-advanced-breast2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07017673-phase-ii-ivonescimab-a-pd-1-vegf-bispecific-antibody2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06999798-phase-2-mayo-ultrasound-marker-enhancing-lymph-node-imaging2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07011654-phase-i-ii-trial-naxitamab-gd2-mab-sacituzumab-govitecan2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07016399-phase-ii-trial-of-darolutamide-an-androgen-receptor-inhibitor2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06926868-phase-2-3-trial-of-izalontamab-brengitecan-egfr-her32025-07-03https://www.sagelyhealth.com/cancer-trials/nct07017829-phase-ii-gt103-mab-targeting-complement-factor-h-with2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06773910-phase-2-trial-of-bms-986489-atigotatug-anti-fucosyl2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06991738-phase-1-2-trial-of-177lu-dota-eb-tate2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06580314-phase-iii-olaparib-parp-inhibitor-maintenance-in-ovarian-cancer2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06952660-phase-4-tivdak-tissue-factordirected-antibody-drug-conjugate-ocular2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07022470-phase-ii-investigational-hdr-brachytherapy-dose-adjusted-internal-radiotherapy2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07028853-phase-3-trial-of-mevrometostat-an-ezh2-inhibitor-with2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07025512-phase-1b-177lu-psma-617-psma-directed-beta-emitter2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06970847-phase-3-64cu-sar-bispsma-psma-targeted-imaging-agent2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07027124-phase-ii-darolutamide-androgen-receptor-inhibitor-in-prostate-cancer2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07025369-phase-2-trial-of-relugolix-a-gnrh-receptor-inhibitor2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06995677-phase-2-tyra-300-fgfr3-directed-mab-trial2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06833073-phase-2-study-v940-personalized-mrna-vaccine-for-patient2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06994299-phase-1-trial-tremelimumab-ctla-4-directed-mab-combined2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07001592-phase-1-vvdd-hil2-oncolytic-vaccinia-virus-with-il22025-07-03https://www.sagelyhealth.com/cancer-trials/nct07011550-phase-2-trial-bms-986340-a-ccr8-targeting-antibody2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06998342-phase-ii-pilot-scrt-hypofractionated-radiation-for-high-risk2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07025226-phase-1-trial-dasatinib-tyrosine-kinase-inhibitor-for-residual2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06885281-phase-ib-ii-zl-1310-dll3-targeted-topoisomerase-i2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07027748-phase-1-study-of-naxitamab-gd2-directed-monoclonal-antibody2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06943755-phase-2-3-zanzalintinib-trial-cmet-vegfr-inhibitor-in2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07007117-phase-1-trial-of-phox2b-pc-car-t-a2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06784752-phase-3-trial-of-177lu-lu-dota-tate-a2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07029776-phase-2-teclistamab-bispecific-bcma-cd3-antibody-trial-in2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07009899-phase-2-linvoseltamab-bcma-and-cd3-bispecific-antibody2025-07-03https://www.sagelyhealth.com/cancer-trials/nct05714839-phase-1-2-belantamab-mafodotin-a-bcma-targeted-tubulin2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07021989-phase-2-pembrolizumab-pd-1-inhibitor-with-gvd-consolidation2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07002216-phase-2-brentuximab-vedotin-adc-a-cd30-targeted-tubulin2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06765317-phase-1b-glofitamab-cd20-cd3-bispecific-mab-for-frontline2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06977711-phase-ib-loncastuximab-tesirine-anti-cd19-adc-and-roflumilast2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07001384-phase-i-alectinib-alk-kinase-inhibitor-plus-duvelisib-pi3k2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07013565-phase-2-nivolumab-checkpoint-blockade-in-relapsed-refractory-alk2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06978088-phase-2-lp-168-small-molecule-inhibitor-and-obinutuzumab2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06943872-phase-3-study-sonrotoclax-bcl2-inhibitor-with-anti-cd202025-07-03https://www.sagelyhealth.com/cancer-trials/nct07025564-phase-1-trial-of-miristen-a-cell-growth-molecule2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07011004-phase-1-trial-of-atezolizumab-pd-l1-mab-combined2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07014462-phase-1b-dexamethasone-glucocorticoid-plus-venetoclax-trial-in-treatment2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06983743-phase-1-study-of-eras-0015-a-ras-inhibitor2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06922591-phase-1-2-tng462-prmt5-inhibitor-trial-with-kras2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07023731-phase-1-2-trial-arv-806-kras-g12d-inhibitor2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06941272-phase-1-2-patritumab-deruxtecan-her3-directed-topoisomerase-i2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06620302-phase-i-ii-trial-dt2216-a-bclxl-degrader-combined2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07007559-phase-1b-2-evorpacept-trial-cd47-binding-ig-fc2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07027488-phase-1-ab821-trial-of-cd8-targeted-il-212025-07-03https://www.sagelyhealth.com/cancer-trials/nct07020117-phase-1b-225ac-ac-aky-1189-nectin-4-radiopharmaceutical2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06714617-phase-1-study-of-bl-m17d1-her2-directed-mab2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06777316-phase-1-2-trial-of-cgt4859-an-fgfr2-32025-07-03https://www.sagelyhealth.com/cancer-trials/nct07029217-phase-iii-rt-trial-vldrt-as-ionizing-radiation-for2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06998407-phase-1-2-trial-of-avzo-023-a-cdk42025-07-03https://www.sagelyhealth.com/cancer-trials/nct06960395-phase-1-vir-5525-egfr-directed-t-cell-engager2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07029399-phase-1-study-of-nkt5097-a-cdk2-cdk4-62025-07-03https://www.sagelyhealth.com/cancer-trials/nct07026981-phase-1-trial-of-ga-68-mtp220-targeted-pet2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07010692-phase-1-tirbanibulin-ointment-dna-synthesis-inhibitor-trial-for2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07020221-phase-1-2a-vs-7375-trial-kras-g12d-inhibitor2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06799533-phase-1-pf-08046031-anti-cd228-adc-trial-for2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06672185-phase-1-arc101-cldn6-directed-t-cell-receptor-engager2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06993844-phase-1-2-etx-636-pan-mutant-selective-pi3k2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07025538-phase-1-trial-of-ruxolitinib-a-jak1-inhibitor-for2025-07-03https://www.sagelyhealth.com/cancer-trials/nct06904482-phase-1-haplocord-transplant-unmodified-cord-blood-graft-for2025-07-03https://www.sagelyhealth.com/cancer-trials/nct07006025-phase-1-study-tetrahydrouridine-decitabine-dna-methyltransferase-and-cytidine2025-07-03https://www.sagelyhealth.com/cancer-trials/t-dxd-outscores-t-dm1-across-her2-copy-number2025-06-26https://www.sagelyhealth.com/cancer-trials/nct02684032-gedatolisib-pan-pi3k-mtor-triplet-hits-85-orr-in2025-06-26https://www.sagelyhealth.com/cancer-trials/rly-2608-mutant-selective-pi3k-inhibitor-achieves-31-orr2025-06-26https://www.sagelyhealth.com/cancer-trials/nct06245824-t-dxd-pyrotinib-hits-100-pr-in-phase-ib2025-06-26https://www.sagelyhealth.com/cancer-trials/nct04585750-rezatapopt-restores-mutant-p53-yields-38-orr-in-heavily2025-06-26https://www.sagelyhealth.com/cancer-trials/nct03820141-chemo-free-durvalumab-trastuzumab-pertuzumab-yields-49-pcr-682025-06-26https://www.sagelyhealth.com/cancer-trials/real-world-endocrine-resistant-hr-her2-mbc-progresses-in2025-06-26https://www.sagelyhealth.com/cancer-trials/nct02945579-five-fraction-ablative-rt-endocrine-therapy-achieves-53-pcr2025-06-26https://www.sagelyhealth.com/cancer-trials/nct03594396-olaparib-durvalumab-parp-pd-l1-achieve-70-pcr-early2025-06-26https://www.sagelyhealth.com/cancer-trials/nct03959891-ipatasertib-triplet-doubles-pfs-in-pi3k-akt-pten-mutant2025-06-26https://www.sagelyhealth.com/cancer-trials/palazestrant-ribociclib-shows-79-clinical-benefit-after-prior-cdk42025-06-26https://www.sagelyhealth.com/cancer-trials/zelenectide-pevedotin-nectin-4-btc-delivers-50-orr-in2025-06-26https://www.sagelyhealth.com/cancer-trials/nct04606446-kat6-inhibitor-pf-07248144-fulvestrant-posts-37-orr-and2025-06-26https://www.sagelyhealth.com/cancer-trials/nct05027139-zanidatamab-evorpacept-delivers-56-orr-in-centrally-confirmed-her22025-06-26https://www.sagelyhealth.com/cancer-trials/nct05230810-tucatinib-alpelisib-her2-tki-pi3k-nets-60-partial-responses2025-06-26https://www.sagelyhealth.com/cancer-trials/taxane-sc-pertuzumab-trastuzumab-scores-86-pcr-in-node2025-06-26https://www.sagelyhealth.com/cancer-trials/nct03328026-bria-imt-whole-cell-vaccine-plus-pd-1-blockade2025-06-26https://www.sagelyhealth.com/cancer-trials/nct05563220-elacestrant-oral-serd-everolimus-mtor-blockade-yields-81-242025-06-26https://www.sagelyhealth.com/cancer-trials/larotrectinib-delivers-53-orrand-83-in-secretory-subtypewith-732025-06-26https://www.sagelyhealth.com/cancer-trials/perioperative-pd-1-blockade-nivolumab-chemo-pushes-30-mo2025-06-26https://www.sagelyhealth.com/cancer-trials/riskreveal-14-gene-assay-guides-platinum-adjuvant-to-962025-06-26https://www.sagelyhealth.com/cancer-trials/nct03013998-revumenib-aza-ven-hits-88-orr-and-universal-mrd2025-06-26https://www.sagelyhealth.com/cancer-trials/nct03471260-idh-triplet-aza-dec-venetoclax-ivo-enas-delivers-922025-06-26https://www.sagelyhealth.com/cancer-trials/ulevostinag-sting-agonist-pembrolizumab-scores-50-orr-in-first2025-06-26https://www.sagelyhealth.com/cancer-trials/nivolumab-relatlimab-posts-52-4-year-os-in-first2025-06-26https://www.sagelyhealth.com/cancer-trials/nct02871219-obinutuzumab-lenalidomide-delivers-93-2-year-pfs-in-first2025-06-26https://www.sagelyhealth.com/cancer-trials/anlotinib-adds-4-months-pfs-to-stupp-in-newly2025-06-26https://www.sagelyhealth.com/cancer-trials/nct03336333-zanubrutinib-holds-a-72-5-year-pfs-in-del2025-06-26https://www.sagelyhealth.com/cancer-trials/nct07015853-phase-1b-study-of-axatilimab-csf1r-mab-in-metastatic2025-06-26https://www.sagelyhealth.com/cancer-trials/nct07020806-phase-1-trial-of-68ga-ga-dota-5g-somatostatin2025-06-26https://www.sagelyhealth.com/cancer-trials/nct04499053-phase-ii-durvalumab-pd-l1-inhibitor-with-tremelimumab-ctla2025-06-26https://www.sagelyhealth.com/cancer-trials/nct05098210-phase-i-neovax-personalized-neo-antigen-vaccine-targeting-patient2025-06-26https://www.sagelyhealth.com/cancer-trials/nct06439485-phase-i-ii-trial-of-pemigatinib-fgfr1-3-inhibitor2025-06-26https://www.sagelyhealth.com/cancer-trials/nct07015242-phase-1-trial-lisocabtagene-maraleucel-a-cd19-directed-car2025-06-26https://www.sagelyhealth.com/cancer-trials/nct06501911-phase-1-study-of-bicalutamide-an-androgen-receptor-inhibitor2025-06-26https://www.sagelyhealth.com/cancer-trials/nct06894511-phase-ii-trial-177lu-vipivotide-tetraxetan-psma-directed-beta2025-06-26https://www.sagelyhealth.com/cancer-trials/nct07014917-phase-ii-venetoclax-bcl2-inhibitor-plus-acalabrutinib-in-first2025-06-26https://www.sagelyhealth.com/cancer-trials/nct03081910-phase-1-cd5-car-28zeta-car-t-engineered-t2025-06-26https://www.sagelyhealth.com/cancer-trials/nct07020533-phase-1b-cmv-mva-triplex-vaccine-mva-based-cmv2025-06-26https://www.sagelyhealth.com/cancer-trials/nct04494425-t-dxd-her2-adc-nearly-doubles-pfs-over-chemo2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04886804-zongertinib-irreversible-her2-tki-posts-27-orr-with-zero2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04964934-camizestrant-switch-halves-progression-risk-in-emerging-esr1-mutant2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04191499-inavolisib-palbofulvestrant-adds-7-mo-os-benefit-in-pik3ca2025-06-20https://www.sagelyhealth.com/cancer-trials/nct03674112-fixed-dose-sc-pertuzumab-trastuzumab-delivers-94-3-year2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04408118-atezolizumab-paclitaxel-bevacizumab-triplet-hits-11-mo-pfs-in2025-06-20https://www.sagelyhealth.com/cancer-trials/nct05563220-elacestrant-everolimus-mtor-delivers-8-5-mo-pfs-after2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04260126-hpv16-targeted-vaccine-pds0101-pembrolizumab-pushes-1l-os-to2025-06-20https://www.sagelyhealth.com/cancer-trials/epcoritamab-cd20cd3-bispecific-subcutaneous-tops-chemoimmunotherapy-and-other-bispecifics2025-06-20https://www.sagelyhealth.com/cancer-trials/nct05579366-rinatabart-sesutecan-fr-adc-yields-50-orr-after-pd2025-06-20https://www.sagelyhealth.com/cancer-trials/nct03981796-dostarlimab-carbo-taxol-delays-next-therapy-by-11-mo2025-06-20https://www.sagelyhealth.com/cancer-trials/nct03539536-telisotuzumab-vedotin-c-met-adc-shows-100-orr-in2025-06-20https://www.sagelyhealth.com/cancer-trials/nct05029882-temab-a-abbv-400-monotherapy-hits-63-orr-in2025-06-20https://www.sagelyhealth.com/cancer-trials/nct05009329-glecirasib-hits-48-orr-and-8-2-month-pfs2025-06-20https://www.sagelyhealth.com/cancer-trials/nct01775072-mismatch-repair-gene-shapes-immune-checkpoint-blocker-outcomes-mlh12025-06-20https://www.sagelyhealth.com/cancer-trials/nct03504488-ror2-targeted-adc-ozuriftamab-achieves-80-response-and-52025-06-20https://www.sagelyhealth.com/cancer-trials/nct03767348-oncolytic-hsv-rp1-pd-1-blockade-nets-33-orr2025-06-20https://www.sagelyhealth.com/cancer-trials/nct01968109-nivolumab-relatlimab-shows-22-intracranial-response-in-pd-1refractory-22025-06-20https://www.sagelyhealth.com/cancer-trials/nct03319667-isatuximab-vrd-boosts-pet-mrd-double-negativity-and-delays2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04934475-isa-krd-consolidation-rivals-up-front-transplant-for-102025-06-20https://www.sagelyhealth.com/cancer-trials/nct05137054-linvoseltamab-bcmacd3-bortezomib-delivers-79-orr-and-6-mo2025-06-20https://www.sagelyhealth.com/cancer-trials/nct05379595-egfr-met-bsab-amivantamab-inflames-tumor-9-mo-pfs2025-06-20https://www.sagelyhealth.com/cancer-trials/nct03969004-cemiplimab-pd-1-boosts-2-year-dfs-to-872025-06-20https://www.sagelyhealth.com/cancer-trials/nct05176483-zanzalintinib-vegfr-met-nivolumab-yields-63-orr-in-front2025-06-20https://www.sagelyhealth.com/cancer-trials/nct03277924-epirubicin-ifosfamide-nivolumab-hits-69-orr-in-first-line2025-06-20https://www.sagelyhealth.com/cancer-trials/nct03929666-zanidatamab-her2-bispecific-chemo-drives-76-orr-and-362025-06-20https://www.sagelyhealth.com/cancer-trials/nct06472076-phase-3-trial-belrestotug-tigit-mab-plus-dostarlimab-pd2025-06-20https://www.sagelyhealth.com/cancer-trials/nct05676931-phase-ii-trial-of-zimberelimab-a-pd-1-inhibitor2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06424067-phase-ii-trial-of-fingolimod-a-sphingosine1phosphate-receptor-modulator2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04412616-phase-1-trial-of-zz06-an-egfr-mab-in2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06597721-phase-1-study-of-adce-t02-a-tissue-factor2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06999187-phase-1a-1b-study-of-dr-0202-a-dectin2025-06-20https://www.sagelyhealth.com/cancer-trials/nct05685602-phase-i-trial-of-emavusertib-irak4-flt3-inhibitor-with2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06730100-phase-2-trial-of-cbx-12-a-topoisomerase-i2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06532006-phase-iii-hlx22-her2-targeted-mab-trial-in-first2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06952504-phase-3-sacituzumab-tirumotecan-trop2-directed-adc-for-endometrial2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06819007-phase-3-trial-trastuzumab-deruxtecan-her2-directed-adc-with2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06811116-phase-i-ii-trial-sapanisertib-mtorc1-2-inhibitor-and2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06309225-phase-2-trial-of-cisplatin-a-dna-crosslinker-in2025-06-20https://www.sagelyhealth.com/cancer-trials/nct07003542-phase-2-trial-of-sitagliptin-as-a-dpp-42025-06-20https://www.sagelyhealth.com/cancer-trials/nct06450106-phase-1-study-of-stm-416p-a-resiquimod-tlr72025-06-20https://www.sagelyhealth.com/cancer-trials/nct07007273-phase-ii-trial-of-pembrolizumab-pd1-inhibitor-in-advanced2025-06-20https://www.sagelyhealth.com/cancer-trials/nct06179511-phase-i-ii-azd9829-cd123-directed-mab-topo1-inhibitor2025-06-20https://www.sagelyhealth.com/cancer-trials/nct04389632-sigvotatug-vedotin-ib6-adc-pembrolizumab-hits-57-orr-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04526691-datopotamab-deruxtecan-trop2-adc-pembrolizumab-delivers-5556-orr-and2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04932525-ctdna-sequencing-flags-keap1-stk11-notch-as-frequent-drivers2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04395677-taletrectinib-hits-89-orr-and-45-6-month-pfs2025-06-13https://www.sagelyhealth.com/cancer-trials/lorlatinib-depth-of-response-tracks-with-75-5-year2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04988295-amivantamab-carbo-paclitaxel-halves-risk-of-progression-after-osimertinibregardless2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04613596-adagrasib-pembrolizumab-posts-44-orr-and-26-month-dor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04956640-olomorasib-pembrolizumab-delivers-70-orr-and-80-6-mo2025-06-13https://www.sagelyhealth.com/cancer-trials/teliso-v-ctdna-study-finds-100-orr-in-kras2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04623775-relatlimab-lag-3-nivolumab-platinum-chemo-expands-lag-32025-06-13https://www.sagelyhealth.com/cancer-trials/nct05740566-tarlatamab-cd3dll3-t-cell-engager-lifts-median-os-to2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05990738-obrixtamig-bi-764532-topotecan-doubles-typical-second-line-response2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04892342-esg401-trop2-directed-adc-hits-83-orr-first-line2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04191499-inavolisib-adds-7-months-os-atop-palbo-fulvestrant-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct01817452-12-week-dual-her2-paclitaxel-delivers-97-5-yr2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05143229-alpelisib-sacituzumab-govitecan-yields-36-orr-50-in-tnbc2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04567420-ctdna-surveillance-pinpoints-relapse-risk-in-high-risk-er2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05474378-b7-h3-car-t-infusions-via-dual-ommaya-reservoirs2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03405792-adjuvant-ttfields-pembrolizumab-temozolomide-lifts-mpfs-to-12-mo2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05660369-carv3-team-e-dual-egfr-car-t-shows-02025-06-13https://www.sagelyhealth.com/cancer-trials/nct04607421-first-line-encorafenib-cetuximab-mfolfox6-doubles-survival-to-302025-06-13https://www.sagelyhealth.com/cancer-trials/nct04440735-dsp107-cd474-1bb-atezolizumab-doubles-survival-and-controls-disease2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03929666-zanidatamab-chemo-posts-76-orr-and-36-5-mo2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04704934-trastuzumab-deruxtecan-tops-ramucirumab-paclitaxel-for-2l-her2-positive2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04589234-oral-salmonella-il2-bacteria-systemic-folfirinox-triples-median-pfs2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04543071-motixafortide-cxcr4i-cemiplimab-pd-1-with-gem-nab-paclitaxel2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05832892-surufatinib-vegfr-fgfr-csf-1r-tki-kn046-pd-l12025-06-13https://www.sagelyhealth.com/cancer-trials/nct05669482-avutometinib-raf-mek-clamp-defactinib-fak-i-with-gem2025-06-13https://www.sagelyhealth.com/cancer-trials/adaptive-folfirinoxgem-nab-paclitaxel-plus-losartan-drives-88100-r02025-06-13https://www.sagelyhealth.com/cancer-trials/nct04936178-nb003-broad-spectrum-kit-inhibitor-delivers-43-orr-and2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03430843-notch1-mutant-esophageal-squamous-cell-carcinoma-escc-achievesgets-182025-06-13https://www.sagelyhealth.com/cancer-trials/nct05775159-rilvegostomig-pd-1-tigit-bispecific-gemcitabine-cisplatin-lifts-mpfs2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04338269-cabozantinib-alone-matches-cabo-atezolizumab-after-1l-io-combos2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05536141-casdatifan-hif-2-cabozantinib-logs-41-orr-in-previously2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04752722-detalimogene-voraplasmid-eg-70-non-viral-il-12-rig2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04561362-zelenectide-pevedotin-nectin-4-btc-pembrolizumab-delivers-65-orr2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05682443-gotistobart-ph-sensitive-anti-ctla-4-177lu-psma-6172025-06-13https://www.sagelyhealth.com/cancer-trials/nct06400472-ly4170156-exatecan-linker-fr-adc-delivers-55-orr-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06234423-cusp06-cdh6-targeted-exatecan-adc-shows-36-orr-502025-06-13https://www.sagelyhealth.com/cancer-trials/nct05296512-pembrolizumab-lenvatinib-pd-1-vegfr-met-fgfr-tki-hits2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03981796-dostarlimab-carboplatin-paclitaxel-stretches-time-to-next-therapy-by2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03933735-etentamig-bcmacd3-bispecific-hits-66-orr-with-half-the2025-06-13https://www.sagelyhealth.com/cancer-trials/daratumumab-carfilzomib-lenalidomide-dex-beats-krd-alone-for-deep2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05623020-elranatamab-daratumumab-lenalidomide-logs-92-confirmed-orr-in-transplant2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05652335-jnj-5322-trispecific-bcma-gprc5d-cd3-antibody-delivers-1002025-06-13https://www.sagelyhealth.com/cancer-trials/nct03328078-emavusertib-irak4i-ibrutinib-achieves-4-6-deep-responses-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04989803-kite-363-dual-target-cd19-cd20-car-t-hits2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03646123-brentuximab-vedotin-nivolumab-clears-ctdna-in-100-of-early2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05883449-acimtamig-allonk-delivers-86-orr-and-55-cr-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04925479-asciminib-stamp-bcr-abl1-pediatric-formulation-hits-64-672025-06-13https://www.sagelyhealth.com/cancer-trials/nct05384587-asc2escalate-asciminib-stamp-inhibitor-clears-bcr-abl1-1-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04984356-cd7-directed-allogeneic-car-t-wu-cart-007-delivers2025-06-13https://www.sagelyhealth.com/cancer-trials/nct02072148-tors-based-risk-adapted-de-escalation-sustains-97-52025-06-13https://www.sagelyhealth.com/cancer-trials/nct04722523-cemiplimab-platinum-docetaxel-cetuximab-delivers-31-pcr-97-12025-06-13https://www.sagelyhealth.com/cancer-trials/nct04472429-retifanlimab-carboplatin-paclitaxel-cuts-risk-of-progression-37-across2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04728633-high-dose-bcnu-chemoembolization-yields-93-disease-control-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05022901-melphalan-hepatic-delivery-system-achieves-46-orr-in-first2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04940299-tocilizumab-ipilimumab-nivolumab-links-lower-early-grade-3-iraes2025-06-13https://www.sagelyhealth.com/cancer-trials/nct01968109-nivolumab-relatlimab-shows-22-intracranial-response-in-pd-1refractory2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03504488-ozuriftamab-vedotin-shrinks-tumors-in-4-out-of-52025-06-13https://www.sagelyhealth.com/cancer-trials/nct03767348-rp1-vsv-gm-csf-nivolumab-shrinks-97-of-injected2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03798106-durvalumab-pd-l1-doxorubicin-boosts-pfs-to-8-22025-06-13https://www.sagelyhealth.com/cancer-trials/nct04675710-pembrolizumab-dabrafenib-trametinib-drives-97-r0-r1-resections-and2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05265091-kl590586-ret-targeted-tki-yields-63-orr-and-782025-06-13https://www.sagelyhealth.com/cancer-trials/nct05428969-bexmarilimab-clever-1-macrophage-checkpoint-azacitidine-logs-80-orr2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06108479-phase-1b-df6215-trial-il-2-variant-immune-modulator2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06906900-phase-i-trial-novottf-200melectromagnetic-therapy-for-refractory-spinal2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06771219-phase-1-study-of-slv-154-small-molecule-inhibitor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06764771-phase-1-1b-trial-of-bms-986488-undefined-moa2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05932862-phase-i-trial-of-xl309-a-usp1-brca-hrd2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03190941-phase-1-2-study-of-anti-kras-g12v-mtcr2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06244992-phase-1-2a-ptt-936-trial-of-alpk1-activator2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04956640-phase-1-2-study-of-ly3537982-a-kras-g12c2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06545331-phase-1-fih-xb010-a-5t4-targeted-tubulin-inhibitor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04665206-phase-1-vt3989-transcription-factor-inhibitor-trial2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06975293-phase-1b-2-trial-of-stc-15-a-mettl32025-06-13https://www.sagelyhealth.com/cancer-trials/nct06997029-phase-1-trial-of-bms-986500-undisclosed-target-inhibitor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03454035-phase-i-trial-of-ulixertinib-an-erk1-2-inhibitor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06974734-phase-1-pf-08046037-tlr7-agonist-adc-study-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03602157-phase-i-atlcar-cd30-ccr4-cart-cells-targeting-cd302025-06-13https://www.sagelyhealth.com/cancer-trials/nct04157985-phase-2-mdx-1105-pd-l1-mab-trial2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06910657-phase-i-idov-immune-oncolytic-virus-trial-in-advanced2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06616766-phase-1-2-study-of-yh42946-egfr-and-her22025-06-13https://www.sagelyhealth.com/cancer-trials/nct06500481-phase-iii-pcsi-proton-beam-therapy-for-precise-cns2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06624059-phase-ii-alectinib-alk-kinase-inhibitor-trial-in-resectable2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06162572-phase-1b-2-trial-cemiplimab-pd-1-inhibitor-with2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06996782-phase-ib-ii-trial-of-ab248-plus-rilvegostomig-a2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06731907-phase-2-trial-patritumab-deruxtecan-a-her3-directed-antibody2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06616584-phase-ii-iii-trial-of-cemiplimab-pd-1-inhibitor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06979661-phase-2-port-modulator-portight-a-ctdna-guided-adjuvant2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06881784-phase-3-rmc-6236-pan-kras-inhibitor-in-ras2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06745323-phase-2-tarlatamab-trial-dll3-and-cd3-directed-bispecific2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06884254-phase-3-eg1206a-her2-mab-vs-perjeta-neoadjuvant-breast2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06997081-phase-2-trial-elranatamab-a-bcma-cd3-bispecific-mab2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06988488-phase-1b-2a-study-of-mezigdomide-cereblon-e3-ligase2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06993675-phase-2-trial-of-talquetamab-a-gprc5d-x-cd32025-06-13https://www.sagelyhealth.com/cancer-trials/nct06638502-phase-1b-hrx215-mkk4-inhibitor-trial-for-post-hepatectomy2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06699836-phase-2-leronlimab-a-ccr5-directed-mab-in-relapsed2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06919666-phase-ib-ii-trial-of-nt219-an-irs1-22025-06-13https://www.sagelyhealth.com/cancer-trials/nct06997094-phase-i-decitabine-dna-methyltransferase-inhibitor-trial-in-surgically2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06373380-phase-1-pilot-hb-200-hpv16-e6-e7-mrna2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06902623-phase-ii-trial-of-reduced-dose-radiotherapy-in-hpv2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06984861-phase-2-cetuximab-egfr-directed-mab-in-de-escalated2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06997068-phase-ii-trial-erlotinib-egfr-inhibitor-in-triple-oral2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06991101-phase-2-trial-of-ruxolitinib-jak1-inhibitor-in-combination2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05353530-phase-i-8r-70car-t-cells-il-8-receptor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06995872-phase-i-trial-of-rhil-15-immune-agonist-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06153238-phase-1-study-of-gme751-pd-l1-pd-l22025-06-13https://www.sagelyhealth.com/cancer-trials/nct06995053-phase-2-ct-sbrt-image-guided-precision-radiotherapy-for2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04606914-phase-ii-mirvetuximab-soravtansine-adc-folr1-directed-tubulin-inhibitor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06222593-phase-i-ii-trial-of-bicalutamide-an-androgen-receptor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06968195-phase-1-rpcar01-car-t-cells-targeting-gpc3-in2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06980077-phase-ii-ivonescimab-pd-1-vegf-targeted-bispecific-antibody2025-06-13https://www.sagelyhealth.com/cancer-trials/nct04577755-phase-ii-study-of-pomalidomide-thalidomide-derivative-vascular-inhibitor2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06968988-phase-i-trial-zanzalintinib-cmet-vegfr-inhibitor-with-checkpoint2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06989112-phase-iii-t-dxd-a-her2-directed-adc-with2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03269669-phase-ii-obinutuzumab-cd20-targeted-mab-trial-in-relapsed2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05370430-phase-1-baffr-car-t-cells-baff-r-directed2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06967610-phase-ii-pirtobrutinib-btk-inhibitor-trial-in-relapsed-cll2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06846671-phase-3-study-of-bgb-16673-a-btk-protein2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06634394-phase-1b-2-apvo436-bispecific-anti-cd123-cd3-antibody2025-06-13https://www.sagelyhealth.com/cancer-trials/nct03007147-phase-3-trial-imatinib-mesylate-a-bcr-abl-c2025-06-13https://www.sagelyhealth.com/cancer-trials/nct06542250-phase-i-ii-trial-of-azd5492-trispecific-t-cell2025-06-13https://www.sagelyhealth.com/cancer-trials/nct05829226-phase-1-trial-of-lyt-200-a-galectin-92025-06-13https://www.sagelyhealth.com/cancer-trials/nct06661915-phase-2-astx727-trial-cytidine-deaminase-inhibition-in-accelerated2025-06-13https://www.sagelyhealth.com/cancer-trials/precision-strikes-kras-g12d-ret-trk-therapies-post-record2025-06-07https://www.sagelyhealth.com/cancer-trials/frontier-pipeline-dll3-trispecifics-psma-radioligands-b7-h3-adcsand2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02752685-pembro-lead-in-lifts-orr-to-47-and-extends2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02779855-oncolytic-hsv-tvec-taxane-ac-regimen-yields-46-pcr2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02276443-ultrasound-tvr-50-at-week-6-pinpoints-94-of2025-06-07https://www.sagelyhealth.com/cancer-trials/h-e-based-gene-expression-signature-stratifies-pcr-82025-06-07https://www.sagelyhealth.com/cancer-trials/nct03616886-anti-cd73-oleclumab-fails-but-ctdna-wins-in-first2025-06-07https://www.sagelyhealth.com/cancer-trials/high-grade-neutropenia-marks-palbociclib-benefit-in-early-hr2025-06-07https://www.sagelyhealth.com/cancer-trials/nct03565835-abiraterone-without-ongoing-gnrh-holds-testosterone-down-and-delivers2025-06-07https://www.sagelyhealth.com/cancer-trials/nct01436968-hsv-thymidine-kinase-gene-therapy-can-2409-valacyclovir-cuts2025-06-07https://www.sagelyhealth.com/cancer-trials/high-psma-pet-tumor-volume-halves-5-year-pfs2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02952534-methylation-based-tumor-fraction-ctdna-beats-psa-for-predicting2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02975934-rucaparib-boosts-pfs-across-germline-and-somatic-brca-mut2025-06-07https://www.sagelyhealth.com/cancer-trials/nct03436654-short-course-adt-apalutamide-abiraterone-with-sbrt-yields-852025-06-07https://www.sagelyhealth.com/cancer-trials/nct02650401-entrectinib-nets-69-orr-in-children-with-ros1-fusion2025-06-07https://www.sagelyhealth.com/cancer-trials/nct01876511-pembrolizumab-clears-tumors-in-58-of-msi-h-cancers2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06500676-gfh375-kras-g12d-inhibitor-delivers-38-orr-52-in2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02091141-ctdna-drop-50-by-cycle-3-flags-long-term2025-06-07https://www.sagelyhealth.com/cancer-trials/nct03037385-pralsetinib-ret-inhibitor-shrinks-diverse-tumors-46-orr-112025-06-07https://www.sagelyhealth.com/cancer-trials/nct04886804-oral-her2-selective-tki-zongertinib-logs-71-orr-and2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06040541-zoldonrasib-rmc-9805-hits-61-orr-in-kras-g12dmutant2025-06-07https://www.sagelyhealth.com/cancer-trials/nct05067283-mk-1084-kras-g12c-inhibitor-pembrolizumab-drives-74-orr2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02486718-atezolizumab-pd-l1-mab-halves-5-year-recurrence-mortality2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02122913-larotrectinib-delivers-69-orr-and-22-mo-pfs-in2025-06-07https://www.sagelyhealth.com/cancer-trials/nct05249426-sirp-blocker-bi-765063-pd-1-ezabenlimab-cetuximab-drives2025-06-07https://www.sagelyhealth.com/cancer-trials/nct03765918-pembrolizumab-pd-1-boosts-peri-operative-efs-in-resectable2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02675829-t-dm1-hits-88-response-in-her2-amplified-salivary2025-06-07https://www.sagelyhealth.com/cancer-trials/nct03504488-ror2-adc-ozuriftamab-vedotin-posts-36-orr-in-pd2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02224781-nivolumab-ipilimumab-first-doubles-5-year-os-vs-dabrafenib2025-06-07https://www.sagelyhealth.com/cancer-trials/one-time-til-therapy-lifileucel-delivers-31-orr-with2025-06-07https://www.sagelyhealth.com/cancer-trials/nct01616303-ca125-targeted-oregovomab-added-to-carboplatin-paclitaxel-hits-102025-06-07https://www.sagelyhealth.com/cancer-trials/nct03393884-il-12-gene-therapy-imnn-001-adds-13-month2025-06-07https://www.sagelyhealth.com/cancer-trials/nct01803152-dendritic-cell-vaccine-shows-durable-control-in-20-of2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02912572-anti-pd-l1-avelumab-vegfr-tki-axitinib-delivers-402025-06-07https://www.sagelyhealth.com/cancer-trials/nct06283719-trispecific-dll3-t-cell-engager-zg006-delivers-67-orr2025-06-07https://www.sagelyhealth.com/cancer-trials/nct02576431-larotrectinib-delivers-79-orr-and-71-six-year-os2025-06-07https://www.sagelyhealth.com/cancer-trials/nct03575013-avelumab-docetaxel-scores-52-orr-in-platinum-refractory-or2025-06-07https://www.sagelyhealth.com/cancer-trials/senti-202-logic-gated-cd33-flt3-car-nk-cells2025-06-07https://www.sagelyhealth.com/cancer-trials/nct04871282-varegacestat-secretase-inhibitor-shrinks-desmoid-tumors-in-4678-of2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06952010-phase-1-study-of-xb628-targeting-nkg2a-and-pd2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06858813-phase-1-fih-study-of-abbv-324-undisclosed-adc2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06710756-phase-i-iia-fap-targeted-alpha-particle-therapy-in2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06894745-pilot-pet-imaging-study-of-89zr-dfo-starpeg-for2025-06-07https://www.sagelyhealth.com/cancer-trials/nct04305795-asp-1929-photoimmunotherapy-with-anti-pd1-in-advanced-egfr2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06857006-phase-ii-trial-of-optimal-margins-in-brain-metastases2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06984523-phase-ii-trial-of-vmat-csi-in-leptomeningeal-metastasis2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06745908-phase-3-trial-of-n-803-tislelizumab-docetaxel-in2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06892548-phase-ib-ii-trial-of-bnt324-b7-h3-adc2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06898957-phase-1b-study-of-tarlatamab-dll3-cd3-yl201-b72025-06-07https://www.sagelyhealth.com/cancer-trials/nct06925737-phase-3-study-of-ifinatamab-deruxtecan-b7-h3-adc2025-06-07https://www.sagelyhealth.com/cancer-trials/nct05558241-micro-us-vs-mri-in-active-surveillance-for-detecting2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06972628-trial-of-177lu-psma-617-pluvicto-in-psma-positive2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06984562-phase-i-trial-of-adaptive-radiation-therapy-for-pancreatic2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06981806-phase-1-trial-of-cosibelimab-and-balixafortide-targeting-pd2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06926920-phase-1-2-trial-of-sacituzumab-govitecan-in-trop22025-06-07https://www.sagelyhealth.com/cancer-trials/nct06923527-phase-ii-ctdna-guided-elacestrant-trial-in-er-her22025-06-07https://www.sagelyhealth.com/cancer-trials/nct06964958-laser-phase-2-trial-of-177lu-psma-617-in2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06894979-phase-1-trial-of-azd1390-atm-inhibitor-with-radiation2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06461988-phase-ii-study-of-talquetamab-gprc5d-cd3-bispecific-in2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06680752-phase-1-2-trial-of-ard103-cll-1-car2025-06-07https://www.sagelyhealth.com/cancer-trials/nct06986174-phase-2-trial-of-pacritinib-for-r-r-waldenstrom2025-06-07https://www.sagelyhealth.com/cancer-trials/nct04082572-pembrolizumab-pd-1-neoadjuvant-delivers-80-3-yr-efs2025-05-30https://www.sagelyhealth.com/cancer-trials/bms-986504-prmt5-mta-inhibitor-posts-23-orr-and2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05415072-dyp688-adc-delivers-direct-gq-11-inhibition-with-a2025-05-30https://www.sagelyhealth.com/cancer-trials/larotrectinib-trk-inhibitor-achieves-77-response-in-treatment-naive2025-05-30https://www.sagelyhealth.com/cancer-trials/alectinib-shines-on-alk-alterations-in-advanced-solid-tumors2025-05-30https://www.sagelyhealth.com/cancer-trials/zl-1310-a-dll3-targeted-adc-achieves-a-682025-05-30https://www.sagelyhealth.com/cancer-trials/zg006-ignites-tcell-response-in-refractory-sclc-by-targeting2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05680922-dll3-targeted-lb2102-car-t-demonstrates-dose-dependent-expansion2025-05-30https://www.sagelyhealth.com/cancer-trials/nct04429087-obrixtamig-dll3-cd3-engager-achieves-40-orr-in-dll32025-05-30https://www.sagelyhealth.com/cancer-trials/nct03779191-alectinib-bevacizumab-a-dual-targeted-strike-but-cautionary-safety2025-05-30https://www.sagelyhealth.com/cancer-trials/nct04194203-atezolizumab-antipd-l1-combo-in-non-sq-nsclc-pfs2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05099172-bay-2927088-achieves-59-orr-in-advanced-her2-mutant2025-05-30https://www.sagelyhealth.com/cancer-trials/zipalertinib-shows-sustained-egfr-exon-20-inhibition-yielding-similar2025-05-30https://www.sagelyhealth.com/cancer-trials/afatinib-shines-against-chemo-in-uncommon-egfr-mutant-nsclc2025-05-30https://www.sagelyhealth.com/cancer-trials/sacituzumab-tirumotecan-trop2-adc-delivers-a-35-7-orr2025-05-30https://www.sagelyhealth.com/cancer-trials/pdl1v-adc-plus-pembrolizumab-achieves-50-orr-in-pd2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06525220-petosemtamab-pembrolizumab-dual-egfr-lgr5-targeting-yields-60-orr2025-05-30https://www.sagelyhealth.com/cancer-trials/ficerafusp-alfa-egfr-tgf-pembrolizumab-achieves-64-orr-in2025-05-30https://www.sagelyhealth.com/cancer-trials/pembrolizumab-pd-1-inhibitor-in-neoadjuvant-adjuvant-setting-extends2025-05-30https://www.sagelyhealth.com/cancer-trials/pf-07248144-a-firstinclass-kat6-inhibitor-achieves-optimal-52025-05-30https://www.sagelyhealth.com/cancer-trials/durvalumab-gemcis-boosts-3-year-survival-in-advanced-biliary2025-05-30https://www.sagelyhealth.com/cancer-trials/nct03673501-ripretinib-switch-control-kit-pdgfra-tki-matches-sunitinib-on2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05914116-db-1311-bnt324-b7-h3-adc-logs-28-responses2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05521412-tb-161-psma-i-t-auger-rlt-achieves-702025-05-30https://www.sagelyhealth.com/cancer-trials/nct02985021-rucaparib-parp-inhibitor-maintenance-after-platinum-induction-hits-172025-05-30https://www.sagelyhealth.com/cancer-trials/olaparib-abiraterone-parp-1-2-inhibitor-slashes-rpfs-risk2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05067283-mk-1084-kras-g12c-inhibitor-plus-cetuximab-drives-502025-05-30https://www.sagelyhealth.com/cancer-trials/nct03674424-avelumab-anti-pd-l1-plus-ddmvac-nets-58-pcr2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06973564-phase-1-2a-trial-of-jab-23e73-in-advanced2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06573294-phase-1-trial-of-gen1057-targeting-fap-alpha-and2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05513027-augmented-pet-ct-enhances-malignant-lesion-detection-in-carcinoma2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06841055-phase-ii-trial-of-vegfa-targeted-bnt327-with-docetaxel2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05198830-phase-2-trial-in-stage-iii-nsclc-targeting-dna2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06827236-phase-1-2-trial-of-bnt323-bnt327-in-advanced2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05673200-phase-i-study-targeting-dna-methyltransferases-in-metastatic-triple2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06966388-feasibility-pilot-of-topical-azelaic-acid-in-breast-cancer2025-05-30https://www.sagelyhealth.com/cancer-trials/nct05366179-phase-i-trial-of-car-t-cells-targeting-b72025-05-30https://www.sagelyhealth.com/cancer-trials/nct05781321-phase-ii-trial-in-glioblastoma-accelerated-rt-with-temozolomide2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06907485-feasibility-of-5-ala-for-fluorescence-guided-surgery-in2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06670105-phase-2-trial-of-glofitamab-cd20-cd3-bispecific-in2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06971614-phase-ii-trial-of-herpes-virus-t3011-injection-il122025-05-30https://www.sagelyhealth.com/cancer-trials/nct06696768-phase-i-trial-of-ca-4948-irak4-flt3-inhibitor2025-05-30https://www.sagelyhealth.com/cancer-trials/nct04171622-phase-ii-study-of-lenvatinib-pembrolizumab-pd-1-in2025-05-30https://www.sagelyhealth.com/cancer-trials/nct04972942-phase-i-daratumumab-cd38-immunotherapy-in-high-risk-t2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06317662-phase-2-study-of-blinatumomab-cd19-targeted-and-venetoclax2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06835387-phase-ii-nalirifox-in-advanced-unresectable-small-bowel-tumors2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06320990-pilot-study-of-tamoxifen-estrogen-receptor-inhibitor-in-pre2025-05-30https://www.sagelyhealth.com/cancer-trials/nct06554158-phase-ii-de-escalation-trial-for-hpv-p16-oropharyngeal2025-05-30https://www.sagelyhealth.com/cancer-trials/cemiplimab-boosts-survival-in-nsclc-patients-with-brain-metastases2025-05-22https://www.sagelyhealth.com/cancer-trials/alectinib-plus-bevacizumab-yields-impressive-12-month-pfs-and2025-05-22https://www.sagelyhealth.com/cancer-trials/impower151-in-metastatic-nsqnsclc-atezolizumab-combo-falls-short-on2025-05-22https://www.sagelyhealth.com/cancer-trials/nivolumab-plus-low-dose-ipilimumab-shows-promise-in-hypermutated2025-05-22https://www.sagelyhealth.com/cancer-trials/nct04082572-pembrolizumab-erases-ctdna-in-median-2-cycles-boosting-32025-05-22https://www.sagelyhealth.com/cancer-trials/fusion-of-dose-dense-docetaxel-and-radium-223-delivers2025-05-22https://www.sagelyhealth.com/cancer-trials/faz053-monotherapy-shines-in-rare-sarcomas-despite-combination-setbacks2025-05-22https://www.sagelyhealth.com/cancer-trials/daratumumab-enhanced-regimen-elevates-outcomes-in-older-ndmm-patients2025-05-22https://www.sagelyhealth.com/cancer-trials/high-baseline-wbc-identifies-high-risk-patients-in-ph2025-05-22https://www.sagelyhealth.com/cancer-trials/tap-and-cps-scores-show-high-concordance-in-predicting2025-05-22https://www.sagelyhealth.com/cancer-trials/durvalumab-plus-gemcis-delivers-sustained-survival-benefit-in-advanced2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06902311-h-assist-ultra-hypo-fractionated-wbi-with-sib-for2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06963905-phase-ib-randomized-open-label-trial-of-sacituzumab-govitecan2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06756932-phase-1-study-bgb-21447-combination-therapy-in-hr2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06671912-lotam-a-randomized-phase-iii-clinical-trial-of-low2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06959537-phase-ib-ii-study-low-dose-cyclophosphamide-with-axatilimab2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06961955-fast-november-a-phase-ii-randomized-trial-of-a2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06960707-prospective-randomized-trial-of-two-versus-one-week-accelerated2025-05-22https://www.sagelyhealth.com/cancer-trials/nct04674306-phase-i-trial-adjuvant-alpha-lactalbumin-vaccine-in-high2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06907615-phase-ii-trial-of-hlx43-anti-pd-l1-adc2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06800339-a-phase-i-single-arm-single-institution-study-evaluating2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06841874-expanded-access-program-of-taletrectinib-in-advanced-ros1-nsclc2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06767514-phase-3-trial-of-ivonescimab-vs-pembrolizumab-in-high2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06782932-a-pilot-study-comparing-neoadjuvant-and-adjuvant-gvax-vs2025-05-22https://www.sagelyhealth.com/cancer-trials/nct04005690-a-window-of-opportunity-strategy-for-targeted-pathway-inhibition2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06904378-phase-i-ii-clinical-trial-of-ontegimod-and-gemcitabine2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06661902-burn-study-buffered-lidocaine-in-reducing-pain-from-prostate2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06904313-evaluation-of-ultralow-dose-pet-imaging-for-detecting-psma2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06906471-a-single-arm-blinded-fluorescent-psma-histopathology-trial-of2025-05-22https://www.sagelyhealth.com/cancer-trials/nct03701581-4-aminopyridine-treatment-for-nerve-injury-resulting-from-radical2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06961357-phase-i-ii-clinical-trial-of-cd40l-augmented-tumor2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06771544-metronomic-cyclophosphamide-with-pembrolizumab-in-checkpoint-inhibitor-refractory-me2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06390956-a-phase-ii-study-of-pirtobrutinib-in-combination-with2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06796998-phase-ii-trial-of-epcoritamab-in-patients-with-newly2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06964009-a-phase-1b-study-of-bcl-xl-degrader-dt22162025-05-22https://www.sagelyhealth.com/cancer-trials/nct05887609-phase-ii-trial-mirvetuximab-soravtansine-olaparib-maintenance-in-recurrent2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06906341-phase-2-study-of-relacorilant-combo-in-advanced-ovarian2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06963346-hero-trial-phase-i-study-investigating-intravesical-hdac-inhibition2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06637423-phase-1-2-study-of-intravesical-sacituzumab-tirumotecan-in2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06964737-phase-i-trial-of-anti-garp-car-t-in2025-05-22https://www.sagelyhealth.com/cancer-trials/nct05762419-feasibility-study-using-fus-with-oral-etoposide-in-pediatric2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06805305-randomized-study-of-doc1021-dendritic-cell-immunotherapy-in-combination2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06959511-neoadjuvant-treatment-with-zanzalintinib-for-advanced-thyroid-cancer2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06959641-phase-2-open-label-study-of-xl092-as-first2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06961084-comparison-of-i-124-pet-ct-to-i-1232025-05-22https://www.sagelyhealth.com/cancer-trials/nct06622005-phase-1-trial-sx-682-combination-with-standard-of2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06832865-phase-2-study-of-elranatamab-plus-isatuximab-in-relapsed2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06912087-phase-i-study-zanzalintinib-with-pembrolizumab-and-cetuximab-in2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06819228-window-trial-of-fluorescently-labeled-panitumumab-in-head-and2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06784947-a-phase-ii-trial-of-tiragolumab-in-combination-with2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06789757-phase-ii-study-of-atezolizumab-bevacizumab-and-memantine-in2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06852820-a-pilot-study-of-68ga-psma-11-pet-directed2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06902246-regorafenib-and-yttrium-90-radioembolization-for-unresectable-hcc2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06957327-phase-1b-2-study-of-eras-601-shp2-inhibitor2025-05-22https://www.sagelyhealth.com/cancer-trials/nct04191304-phase-iii-trial-of-benralizumab-in-hypereosinophilic-syndrome2025-05-22https://www.sagelyhealth.com/cancer-trials/nct03541720-18f-fluorodopamine-pet-studies-of-neuroblastoma-and-pheochromocytoma2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06770855-phase-ii-study-of-total-mpdt-in-metastatic-clear2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06898970-an-open-label-multicenter-phase-2-study-with-safety2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06586515-phase-1a-1b-trial-of-ly3962673-in-kras-g12d2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06619587-phase-i-ii-trial-gdc-7035-in-kras-g12d2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06911008-phase-i-study-mti-301-in-advanced-metastatic-refractory2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06959706-phase-1-study-of-tgw101-in-advanced-solid-tumors2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06750185-phase-i-study-bnt317-in-advanced-solid-tumors2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06833008-phase-i-ii-study-of-ipn01195-in-advanced-solid2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06963281-phase-1-study-of-ibi3020-in-advanced-solid-tumors2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06770764-phase-i-1b-study-odc-il2-in-advanced-solid2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06788990-multicenter-phase-2-3-study-of-ficerafusp-alfa-with2025-05-22https://www.sagelyhealth.com/cancer-trials/nct04852328-non-randomized-phase-2-trial-of-three-schedules-of2025-05-22https://www.sagelyhealth.com/cancer-trials/nct05010005-phase-i-multicenter-study-of-ruxolitinib-and-duvelisib-in2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06957431-a-phase-i-trial-of-zanzalintinib-combined-with-eribulin2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06828588-pilot-study-of-68ga-ga-aby-025-imaging-in2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06959550-phase-ii-study-of-anti-pd-1-vegf-bispecific2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06760819-phase-2-basket-study-evaluating-bay2927088-in-her2-activated2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06914999-assessment-of-radiation-induced-vascular-complications-in-h-n2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06764875-a-randomized-phase-iii-study-of-rilvegostomig-in-combination2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06956690-phase-1-2-trial-of-env-501-in-advanced2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06548061-single-center-observational-study-using-spinal-laser-interstitial-thermal2025-05-22https://www.sagelyhealth.com/cancer-trials/nct06802315-phase-ii-study-of-im-tmi-in-high-risk2025-05-22https://www.sagelyhealth.com/cancer-trials/nct05714072-phase-i-study-of-ruxolitinib-plus-abemaciclib-for-patients2025-05-22https://www.sagelyhealth.com/cancer-trials/nonoperative-management-of-early-stage-dmmr-tumors-offers-organ2025-05-13https://www.sagelyhealth.com/cancer-trials/next-generation-kras-g12c-inhibitor-d3s-001-demonstrates-robust2025-05-13https://www.sagelyhealth.com/cancer-trials/zongertinib-delivers-robust-efficacy-in-previously-treated-her2-mutant2025-05-13https://www.sagelyhealth.com/cancer-trials/induction-chemotherapy-enhances-survival-in-locally-advanced-cervical-cancer2025-05-13https://www.sagelyhealth.com/cancer-trials/trastuzumab-deruxtecan-enhances-quality-of-life-in-her2-low2025-05-13https://www.sagelyhealth.com/cancer-trials/breast-tumor-bed-biopsy-falls-short-of-sufficient-pcr2025-05-13https://www.sagelyhealth.com/cancer-trials/chemotherapy-free-triplet-regimen-shows-promise-in-pre-treated2025-05-13https://www.sagelyhealth.com/cancer-trials/elective-nodal-radiotherapy-outperforms-mdt-in-oligorecurrent-nodal-prostate2025-05-13https://www.sagelyhealth.com/cancer-trials/enzalutamide-plus-adt-shows-prognostic-benefit-tied-to-psa2025-05-13https://www.sagelyhealth.com/cancer-trials/effective-chemo-free-therapy-brentuximab-vedotin-plus-nivolumab-yields2025-05-13https://www.sagelyhealth.com/cancer-trials/isb-2001-a-novel-trispecific-antibody-shows-robust-activity2025-05-13https://www.sagelyhealth.com/cancer-trials/lynch-like-msi-h-endometrial-cancer-exhibits-superior-outcomes2025-05-13https://www.sagelyhealth.com/cancer-trials/dual-her2-targeting-zanidatamab-shows-promise-in-pre-treated2025-05-13https://www.sagelyhealth.com/cancer-trials/cetuximab-plus-folfiri-delivers-superior-outcomes-in-chinese-mcrc2025-05-13https://www.sagelyhealth.com/cancer-trials/atezolizumab-combined-with-personalized-neoantigen-vaccine-shows-feasibility-in2025-05-13https://www.sagelyhealth.com/cancer-trials/nivolumab-plus-ipilimumab-as-first-line-therapy-improves-survival2025-05-13https://www.sagelyhealth.com/cancer-trials/high-dose-palifermin-shows-promise-in-preventing-acute-gvhd2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06946797-phase-2-trial-subcutaneous-nivolumab-with-ipilimumab-and-chemotherapy2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06918132-phase-ii-study-neoadjuvant-dual-checkpoint-blockade-in-resectable2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06905197-phase-1-study-dose-escalation-of-dzd6008-in-egfr2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06902272-phase-2-study-ctdna-guided-neoadjuvant-and-adjuvant-pembrolizumab2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06946680-phase-i-study-safety-and-feasibility-of-il-82025-05-13https://www.sagelyhealth.com/cancer-trials/nct06917885-phase-ib-study-evaluating-cue-102-in-recurrent-glioblastoma2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06934889-phase-ib-trial-abbv-637-abbv-155-with-eras2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06514898-matchpoint-combined-immunotherapy-for-relapsed-progressive-medulloblastoma2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06949410-phase-i-trial-her2-directed-peptide-vaccine-in-locally2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06954831-phase-2-trial-ultra-hypofractionated-whole-breast-irradiation-with2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06953882-phase-ii-adjuvant-trial-evaluating-chemotherapy-omission-in-er2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06922318-phase-ii-study-sequential-batzen-and-zenza-therapy-in2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06610825-phase-ii-trial-evaluating-enhertu-in-her2-mcrpc2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06952803-phase-iii-study-adjuvant-saruparib-with-rt-adt-in2025-05-13https://www.sagelyhealth.com/cancer-trials/nct04840472-pilot-evaluating-111in-panitumumab-for-nodal-staging-in-head2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06915038-circulating-tumor-hpv-dna-driven-adjuvant-treatment-deintensification-after2025-05-13https://www.sagelyhealth.com/cancer-trials/nct05816785-pilot-window-study-imatinib-combined-with-cetuximab-in-head2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06948552-phase-ii-study-5-alaenhanced-fluorescence-for-upper-tract2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06948955-expanded-access-bezuclastinib-with-sunitinib-in-advanced-gist2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06926634-zanzalintinib-maintenance-in-high-grade-neuroendocrine-neoplasms2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06947083-phase-ii-study-of-elranatamab-as-maintenance-therapy-post2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06592638-phase-1-dose-escalation-study-of-zg006-in-small2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06948786-promote-fl-pirtobrutinib-and-mosunetuzumab-to-enhance-treatment-efficacy2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06919939-phase-2-study-epcoritamab-and-loncastuximab-tesirine-in-relapsed2025-05-13https://www.sagelyhealth.com/cancer-trials/nct05400109-phase-1-study-evaluating-uf-kure19-car-t-cells2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06921785-phase-iii-study-rilvegostomig-combinations-in-first-line-advanced2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06501625-phase-1b-2-study-ivosidenib-durvalumab-gemcitabine-cisplatin-in2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06673017-phase-ib-study-ptm-101-as-an-adjunct-to2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06932757-phase-2-trial-adjuvant-quisinostat-in-high-risk-uveal2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06863311-randomized-phase-ii-trial-of-xl092-in-combination-with2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06555133-phase-ii-pilot-study-y-90-capecitabine-atezolizumab-in2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06797999-phase-1-2-study-adce-d01-in-advanced-soft2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06953089-phase-ii-trial-db-1311-combinations-in-advanced-metastatic2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06895564-pilot-study-proton-sbrt-for-complex-spinal-metastases2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06915753-first-in-human-study-tyra-430-in-fgfr-driven2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06840886-phase-1a-1b-study-of-phst001-in-advanced-relapsed2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06915727-phase-iii-trial-pafolacianine-for-localization-of-pediatric-extracranial2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06910761-phase-ii-trial-photon-vmat-craniospinal-irradiation-for-leptomeningeal2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06803680-phase-1-study-bgb-b455-in-cldn6-positive-advanced2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06715124-phase-1-trial-of-qtx3544-in-kras-g12v-advanced2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06921928-phase-i-ii-study-azd4360-in-cldn18-2-positive2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06914128-phase-i-study-bay-3713372-in-mtap-deleted-solid2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06930352-frontline-ziftomenib-in-npm1-mutated-or-kmt2a-rearranged-aml2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06916767-phase-i-study-baff-car-t-cells-lmy-9202025-05-13https://www.sagelyhealth.com/cancer-trials/nct06928662-sequential-decitabine-with-flag-ida-and-ric-hct-for2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06934382-phase-1-study-allogeneic-anti-cd7-car-t-beam2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06950034-phase-1-study-stx-0712-in-advanced-hematologic-malignancies2025-05-13https://www.sagelyhealth.com/cancer-trials/nct06834282-phase-1-1b-study-of-cer-1236-in-relapsed2025-05-13https://www.sagelyhealth.com/cancer-trials/perioperative-ctc-changes-predict-early-relapse-in-resectable-nsclc2025-05-07https://www.sagelyhealth.com/cancer-trials/divarasib-plus-migoprotafib-a-dual-target-strategy-showing-encouraging2025-05-07https://www.sagelyhealth.com/cancer-trials/trop-2-expression-uncoupled-from-efficacy-in-sg-pembrolizumab2025-05-07https://www.sagelyhealth.com/cancer-trials/d3s-001-breaks-through-resistance-in-kras-g12c-inhibitor2025-05-07https://www.sagelyhealth.com/cancer-trials/daraxonrasib-shows-promise-in-nsclc-early-ctdna-clearance-linked2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06943664-phase-ii-trial-combines-photoimmunotherapy-with-anti-pd1-in2025-05-07https://www.sagelyhealth.com/cancer-trials/kn-b10-emerges-as-a-strong-contender-in-first2025-05-07https://www.sagelyhealth.com/cancer-trials/tolinapant-and-radiation-combine-to-offer-a-platinum-free2025-05-07https://www.sagelyhealth.com/cancer-trials/penpulimab-plus-chemotherapy-significantly-prolongs-pfs-in-global-npc2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06064097-phase-ii-chemoimmunotherapy-combining-nivolumab-with-standard-chemo-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06727565-phase-2-platform-study-of-novel-combination-therapies-in2025-05-07https://www.sagelyhealth.com/cancer-trials/evorpacept-plus-r2-achieves-remarkable-complete-response-rates-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct05888493-phase-iii-trial-compares-tisagenlecleucel-versus-standard-therapy-in2025-05-07https://www.sagelyhealth.com/cancer-trials/enzalutamide-plus-venetoclax-shows-early-signals-of-activity-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06945315-phase-iii-rct-evaluates-ralp-with-safe-nerve-preservation2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06004661-open-label-study-on-lutetium-177-vipivotide-tetraxetan-safety2025-05-07https://www.sagelyhealth.com/cancer-trials/fgfr-inhibition-shuts-down-tumor-growth-in-sdhd-gist2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06655246-phase-1a-1b-study-combines-menin-inhibition-with-imatinib2025-05-07https://www.sagelyhealth.com/cancer-trials/falcon-final-os-analysis-fulvestrant-and-anastrozole-deliver-comparable2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06829199-phase-2-umbrella-study-evaluates-boserolimab-with-standard-neoadjuvant2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06841354-phase-3-trial-evaluates-sacituzumab-tirumotecan-alone-and-with2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06827613-phase-1b-2-study-combines-invikafusp-alfa-with-sacituzumab2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06878248-phase-1-dose-escalation-study-combines-clbr001-with-abbv2025-05-07https://www.sagelyhealth.com/cancer-trials/nct04420754-icam-1-car-t-therapy-aic100-yields-promising-responses2025-05-07https://www.sagelyhealth.com/cancer-trials/emb-01-delivers-dual-egfr-cmet-targeting-with-promising2025-05-07https://www.sagelyhealth.com/cancer-trials/high-mir-494-expression-predicts-poorer-outcomes-and-alters2025-05-07https://www.sagelyhealth.com/cancer-trials/tegavivint-targets-catenin-in-ahcc-with-promising-safety-and2025-05-07https://www.sagelyhealth.com/cancer-trials/cm24-combo-yields-survival-benefit-in-pancreatic-cancer-patients2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06941857-phase-ii-study-combines-nc410-folfirinox-and-immune-modulators2025-05-07https://www.sagelyhealth.com/cancer-trials/nct04158635-phase-i-study-evaluates-bosentan-with-gemcitabine-and-nab2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06929286-compare-it-trial-evaluates-intravesical-nadofaragene-firadenovec-vs-best2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06488365-cytophone-liquid-biopsy-aims-for-early-detection-of-metastatic2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06940739-phase-1-2-trial-of-iov-3001-plus-lifileucel2025-05-07https://www.sagelyhealth.com/cancer-trials/nct05478837-phase-i-kind-t-cell-study-targets-h3-3k27m2025-05-07https://www.sagelyhealth.com/cancer-trials/nct05512208-phase-ii-durafak-trial-combines-dual-raf-mek-and2025-05-07https://www.sagelyhealth.com/cancer-trials/nct05512208-preoperative-hypofractionated-radiotherapy-trial-targets-soft-tissue-sarcoma2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06401330-risk-adapted-treatment-trial-for-unilateral-favorable-histology-wilms2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06940518-phase-ii-study-of-ivonescimab-in-advanced-clear-cell2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06937866-indiana-university-trials-maintenance-zanzalintinib-with-oral-etoposide-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06888921-adaptive-trial-evaluates-com701-maintenance-in-relapsed-platinum-sensitive2025-05-07https://www.sagelyhealth.com/cancer-trials/nct03675893-resolve-trial-evaluates-multi-agent-targeted-combinations-in-recurrent2025-05-07https://www.sagelyhealth.com/cancer-trials/triple-ddr-assault-art0380-and-low-dose-irinotecan-yield2025-05-07https://www.sagelyhealth.com/cancer-trials/kva12123-a-novel-anti-vista-antibody-shows-promising-safety2025-05-07https://www.sagelyhealth.com/cancer-trials/fmt-enhances-immunotherapy-response-while-influencing-toxicity-profiles-in2025-05-07https://www.sagelyhealth.com/cancer-trials/first-in-human-wrn-inhibitor-ro7589831-shows-promise-in2025-05-07https://www.sagelyhealth.com/cancer-trials/ank-101-anchored-il-12-conjugate-elicits-local-immune2025-05-07https://www.sagelyhealth.com/cancer-trials/amg-404-a-new-pd-1-inhibitor-advances-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06941480-dll3-targeting-theranostic-agent-explored-in-high-grade-neuroendocrine2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06915454-intraoperative-pet-ct-enhances-margin-visualization-in-solid-tumor2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06917079-phase-1a-1b-trial-of-bbo-11818-in-advanced2025-05-07https://www.sagelyhealth.com/cancer-trials/nct04198766-phase-1-2-trial-evaluates-inbrx-106-with-pembrolizumab2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06074705-first-in-human-study-of-ds-1471a-in-advanced2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06906887-pulso-trial-evaluating-pulsed-low-dose-rate-radiation-for2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06487624-phase-1-study-evaluates-hcb301-in-advanced-solid-tumors2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06922825-pilot-study-evaluates-68ga-fapi-46-pet-ct-for2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06939283-phase-1b-2-study-evaluates-wtx-330-dosing-regimens2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06943521-phase-i-ii-study-explores-mt-4561-in-advanced2025-05-07https://www.sagelyhealth.com/cancer-trials/nct03919292-phase-1-2-trial-evaluates-neratinib-plus-valproic-acid2025-05-07https://www.sagelyhealth.com/cancer-trials/nct05184816-phase-1a-1b-trial-investigates-intrathecal-deferoxamine-for-leptomeningeal2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06940180-perioperative-chemoimmunotherapy-with-toripalimab-for-sinonasal-cancer2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06228326-phase-1-2-trial-assesses-inhaled-oncolytic-virus-kb7072025-05-07https://www.sagelyhealth.com/cancer-trials/nct06939036-phase-i-ii-study-of-225ac-sso110-combined-with2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06751329-phase-i-ii-trial-evaluates-dm002-in-advanced-solid2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06937970-phase-1-trial-investigates-mrtx1719-in-mtap-deleted-advanced2025-05-07https://www.sagelyhealth.com/cancer-trials/incb057643-rebalances-bone-marrow-in-mpns-by-shifting-megakaryopoiesis2025-05-07https://www.sagelyhealth.com/cancer-trials/tp-0903-shows-early-signs-of-activity-in-heavily2025-05-07https://www.sagelyhealth.com/cancer-trials/novel-immunotherapy-combo-yields-high-response-rates-in-non2025-05-07https://www.sagelyhealth.com/cancer-trials/senti-202s-dual-targeting-car-nk-cell-therapy-shows2025-05-07https://www.sagelyhealth.com/cancer-trials/nct03579875-tcr-depleted-pbsc-transplantation-in-inherited-bone-marrow-failure2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06627751-phase-ii-mezikd-combines-novel-agents-in-relapsed-refractory2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06940297-phase-ii-dasatinib-quercetin-with-car-t-therapy-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06630806-first-in-human-phase-i-study-of-sar446523-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct04155749-phase-i-master-protocol-evaluates-bcma-directed-car-t2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06938867-phase-1b-2a-study-evaluates-snipr001-with-levofloxacin-in2025-05-07https://www.sagelyhealth.com/cancer-trials/nct03850574-phase-1-2-study-of-tuspetinib-hm43239-in-aml2025-05-07https://www.sagelyhealth.com/cancer-trials/nct05233618-phase-i-post-transplant-maintenance-with-tagraxofusp-in-cd1232025-05-07https://www.sagelyhealth.com/cancer-trials/nct06577441-phase-ii-myelomatch-trial-examines-astx727-enasidenib-in-higher2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06846606-phase-1-study-of-autx-703-in-relapsed-refractory2025-05-07https://www.sagelyhealth.com/cancer-trials/nct03504644-phase-ib-ii-venetoclax-plus-vincristine-in-relapsed-refractory2025-05-07https://www.sagelyhealth.com/cancer-trials/nct06876649-master-protocol-to-evaluate-the-long-term-safety-of2025-05-07